var title_f37_2_37920="Fluocinolone: Pediatric drug information";
var content_f37_2_37920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/32/3587?source=see_link\">",
"       Fluocinolone (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29938?source=see_link\">",
"       Fluocinolone (otic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/49/12052?source=see_link\">",
"       Fluocinolone (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13310 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37920=[""].join("\n");
var outline_f37_2_37920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/32/3587?source=related_link\">",
"      Fluocinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29938?source=related_link\">",
"      Fluocinolone (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/49/12052?source=related_link\">",
"      Fluocinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_2_37921="K pneum liver abscess";
var content_f37_2_37921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver abscess with K. pneumoniae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographic film shows abnormal gas accumulation in the right upper abdomen (A). CT of the abdomen shows a huge gas-forming liver abscess (B). Blood and drained liver pus yielded K. pneumoniae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37921=[""].join("\n");
var outline_f37_2_37921=null;
var title_f37_2_37922="Hiatus hernia";
var content_f37_2_37922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hiatus hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of a hiatus hernia seen from the stomach during retroflexion of the endoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37922=[""].join("\n");
var outline_f37_2_37922=null;
var title_f37_2_37923="Papaverine: Drug information";
var content_f37_2_37923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Papaverine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/20/7492?source=see_link\">",
"    see \"Papaverine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/61/39891?source=see_link\">",
"    see \"Papaverine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Labeled uses have fallen out of favor; safer and more effective alternatives are available. The manufacturer&rsquo;s labeling recommends the following dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arterial spasm:",
"     </b>",
"     I.M., I.V.: 30-120 mg; may repeat dose every 3 hours; if cardiac extrasystole occurs during use, may administer 2 doses 10 minutes apart",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 30 mg/mL (2 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapid I.V. administration may result in arrhythmias and fatal apnea; administer no faster than over 1-2 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F206377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Iohexol 64.7%, iopamidol 61%, iothalamate sodium 60%, phentolamine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ioxaglate meglumine 39.3%, ioxaglate sodium 19.6%.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Various vascular spasms associated with smooth muscle spasms as in myocardial infarction, angina, peripheral and pulmonary embolism, peripheral vascular disease; cerebral angiospastic states; visceral spasms (ureteral, biliary, and GI colic).",
"     <b>",
"      Note:",
"     </b>",
"     Labeled uses have fallen out of favor; safer and more effective alternatives are available.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15244587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of vasospasm during harvesting mammary arteries for coronary artery bypass graft surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7280343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Papaverine may be confused with pamidronate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (with rapid I.V. use), flushing, mild hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, malaise, sedation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, anorexia, constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cirrhosis, hepatic hypersensitivity, hepatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea (with rapid I.V. use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with complete AV block",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: May (in large doses or with rapid infusion) depress AV and intraventricular cardiac conduction leading to serious arrhythmias (eg, premature beats, paroxysmal tachycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis: May cause hepatic hypersensitivity; discontinue use if GI symptoms, jaundice, eosinophilia, or abnormal LFTs occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not indicated for treatment of impotence by intracorporeal injection; persistent priapism may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F206343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F206342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Papaverine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (2 mL): $3.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15070778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Papaverini (ID);",
"     </li>",
"     <li>",
"      Papaverinum Hydrochloricum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Smooth muscle spasmolytic producing a generalized smooth muscle relaxation including: vasodilatation, gastrointestinal sphincter relaxation, bronchiolar muscle relaxation, and potentially a depressed myocardium (with large doses); muscle relaxation may occur due to inhibition or cyclic nucleotide phosphodiesterase, increasing cyclic AMP; muscle relaxation is unrelated to nerve innervation; papaverine increases cerebral blood flow in normal subjects; oxygen uptake is unaltered",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Girard DS, Sutton JP, Williams TH, et al, &ldquo;Papaverine Delivery to the Internal Mammary Artery Pedicle Effectively Treats Spasm,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2004, 78(4):1295-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/2/37923/abstract-text/15464488/pubmed\" id=\"15464488\" target=\"_blank\">",
"        15464488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heulitt MJ, Farrington EA, O'Shea TM, et al, &ldquo;Double-Blind, Randomized, Controlled Trial of Papaverine-Containing Infusions to Prevent Failure of Arterial Catheters in Pediatric Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1993, 21(6):825-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/2/37923/abstract-text/8504648/pubmed\" id=\"8504648\" target=\"_blank\">",
"        8504648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ilan Y and Gemer O, &ldquo;Papaverine-Induced Coma,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1988, 33(6):651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/2/37923/abstract-text/3366170/pubmed\" id=\"3366170\" target=\"_blank\">",
"        3366170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jahr JS, Kang B, Paxtor CG, et al, &ldquo;Hemodynamic Responses to Papaverine: Do Nitric Oxide, Cyclic GMP, or Calcium Mediate the Vasodilitation?&rdquo;",
"      <i>",
"       Am J Therapeut",
"      </i>",
"      , 1995, 2(4):258-64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yavuz S, Celkan A, Goncu T, et al, &ldquo;Effect of Papaverine Applications on Blood Flow of the Internal Mammary Artery,&rdquo;",
"      <i>",
"       Ann Thorac Cardiovasc Surg",
"      </i>",
"      , 2001, 7(2):84-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/2/37923/abstract-text/11398777/pubmed\" id=\"11398777\" target=\"_blank\">",
"        11398777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9739 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37923=[""].join("\n");
var outline_f37_2_37923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206372\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206358\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206359\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206334\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206320\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206337\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206377\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206336\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15244587\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7280343\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206370\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206340\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206324\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299820\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206353\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206331\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801078\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206362\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206343\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206342\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15070778\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038718\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206323\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206339\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9739|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/20/7492?source=related_link\">",
"      Papaverine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/61/39891?source=related_link\">",
"      Papaverine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_2_37924="Pediatric hip fracture classification";
var content_f37_2_37924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delbet classification of hip fractures in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Delbet classification of hip fractures in children. I: transepiphyseal with (IB) or without (IA) dislocation from the acetabulum; II: transcervical; III: cervicotrochanteric; and IV: intertrochanteric.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McCarthy J, Noonan K. Fractures and traumatic dislocations of the hip in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37924=[""].join("\n");
var outline_f37_2_37924=null;
var title_f37_2_37925="Treatment of cat scratch disease";
var content_f37_2_37925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cat scratch disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     David H Spach, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37925/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/2/37925/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cat scratch disease (CSD) is an infectious disease characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bartonella (formerly Rochalimaea) henselae is the etiologic agent in most cases of CSD.",
"   </p>",
"   <p>",
"    The treatment of CSD will be reviewed here. The microbiology, epidemiology, and clinical features of CSD, Bartonella endocarditis, and other Bartonella infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36583?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Bartonella quintana infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/56/26503?source=see_link\">",
"     \"Bartonellosis: Oroya fever and verruga peruana\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with typical CSD have gradual resolution of symptoms, even without specific antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/3\">",
"     3",
"    </a>",
"    ]. In five to 14 percent of individuals, the organisms disseminate and infect the liver, spleen, eye, or central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients with disseminated disease can have life-threatening complications.",
"   </p>",
"   <p>",
"    In vitro susceptibility testing often does not correlate with a clinical response and should not be considered in the choice of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/3\">",
"     3",
"    </a>",
"    ]. The literature on the use of antibiotics in CSD primarily derives from case reports and small series. There is one prospective, randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lymphadenitis studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized prospective placebo-controlled trial of 29 immunocompetent patients (including children and adults) with typical cat scratch disease examined the effectiveness of a five-day course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day one and 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on the subsequent 4 days for patients weighing less than 45.5 kg and 500 mg on day 1, followed by 250 mg on the next four days for those weighing at least 45.5 kg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/6\">",
"       6",
"      </a>",
"      ]. Seven of 14 patients who received azithromycin had an 80 percent or more decrease in lymph node volume during a 30 day follow-up period compared with only one of seven placebo recipients. This trial provides the most convincing data in favor of antibiotic treatment.",
"     </li>",
"     <li>",
"      The largest therapeutic trial was an uncontrolled retrospective study of 268 persons with CSD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/7\">",
"       7",
"      </a>",
"      ]. The mean duration of illness was 14.5 weeks for 66 patients without treatment, 14.5 weeks for 113 patients treated with antibiotics thought to be ineffective, and 2.8 weeks for 89 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In one small nonrandomized series, five adults with CSD and painful lymphadenitis received oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and had rapid clinical improvement without relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another small series, four patients (three children) with localized CSD received therapy with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      for 5 to 10 days, and all had 50 percent reduction in lymph node size by day 5 and complete resolution of lymphadenopathy within 14 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hepatosplenic disease",
"    </span>",
"   </p>",
"   <p>",
"    Hepatosplenic disease in patients with CSD is uncommon as compared to localized disease and is due to systemic dissemination of the organism. Hepatosplenic CSD should not be confused with peliosis hepatis which is caused by either B. henselae or B. quintana and is most often diagnosed in HIV-infected individuals, although other immunocompromised individuals, such as cancer patients and solid organ transplant recipients, have also developed this manifestation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report described three patients with CSD who responded to intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      ; two of the patients had extensive hepatic involvement and one had regional lymphadenopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nineteen children (aged 2 to 11) who had hepatosplenic CSD appeared to respond well to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , either given alone or in combination with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/11\">",
"       11",
"      </a>",
"      ]. These patients most often received rifampin at a dose of 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 14 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuroretinitis studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective case series of seven consecutive patients with B. henselae neuroretinitis evaluated the outcome of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg PO twice daily) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (300 mg PO twice daily) for four to six weeks compared to historic controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/12\">",
"       12",
"      </a>",
"      ]. Antibiotic therapy appeared to promote the resolution of retinitis. However, a case report described prompt resolution of B. henselae-associated neuroretinitis in a patient who received no antimicrobial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/13\">",
"       13",
"      </a>",
"      ]. Thus, optimal therapy for neuroretinitis remains unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the available data, we make the following treatment regimen recommendations according to the clinical disease setting. A Jarisch-Herxheimer reaction can occur after the first several doses of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lymphadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some experts would suggest not treating typical CSD in immunocompetent patients with mild to moderate illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37925/abstract/3\">",
"     3",
"    </a>",
"    ], we suggest a five-day course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (500 mg on day one, followed by 250 mg for four days for patients weighing more than 45.5 kg; or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day one, followed by 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for four days for those weighing less than 45.5 kg [100 lbs]).",
"   </p>",
"   <p>",
"    In patients intolerant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , we suggest one of the following alternative regimens for a seven- to ten-day course:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      divided in two doses for those weighing less than 45.5 kg; or 500 mg twice daily for patients weighing more than 45.5 kg)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      (in children, 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours, maximum dose 600 mg daily; in adults, 300 mg twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (in children,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, sulfamethoxazole 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, in two divided doses; in adults, one double strength tablet twice a day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (for patients &gt;17 years of age, 500 mg twice a day).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatosplenic disease and prolonged fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest treatment in children should consist of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    as a single agent for 10 to 14 days. However, given the concern for rapid development of rifampin resistance, we along with some experts recommend adding a second agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (loading dose 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    then 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours dosed based upon normal renal function and adjusted with monitoring) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (dosed as above) for the entire 10 to 14 day course. As long as the patient improves, there is no need to repeat the imaging studies of the liver or spleen to document resolution of the lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuroretinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for neuroretinitis is unknown. Based upon limited data, we would suggest in adults,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 mg orally twice daily) for four to six weeks in conjunction with close monitoring by an ophthalmologist. For children &le;8 years of age, we suggest rifampin (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, maximum dose 600 mg daily) plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day one, followed by 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for four days for those weighing less than 45.5 kg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, sulfamethoxazole 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, in two divided doses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about optimal therapy for neurologic manifestations of B. henselae infection. In severe cases, we suggest therapy with a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    for 10 to 14 days.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is an alternative to doxycycline, but more experience exists with using doxycycline to treat central nervous system infections caused by other pathogens and we prefer treatment with this agent. In children &le;8 years of age, azithromycin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (dosed as above) should be substituted for doxycycline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of suspected or proven Bartonella endocarditis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/40/35457?source=see_link\">",
"       \"Patient information: Cat scratch disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cat scratch disease (CSD) is an infectious disease characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bartonella (formerly Rochalimaea) henselae is the etiologic agent in most cases of CSD. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with typical CSD have gradual resolution of symptoms, even without specific antibiotic therapy, but in five to 14 percent of individuals, the organisms disseminate and infect the liver, spleen, eye, or central nervous system. Patients with disseminated disease can have life-threatening complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although some experts would suggest not treating typical CSD in immunocompetent patients with mild to moderate illness, we suggest treatment of all patients with antimicrobial agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The preferred antibiotic for treatment is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      since this agent is the only one studied in a randomized controlled study. The typical dose is a five-day course (500 mg on day one, followed by 250 mg for four days for patients weighing more than 45.5 kg; or 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day one, followed by 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for four days for those weighing less than 45.5 kg [100 lbs]). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lymphadenitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other regimens that appear effective in patients with mild to moderate illness who are intolerant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 mg twice daily for patients weighing more than 45.5 kg; or 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      divided in two doses for those weighing less than 45.5 kg)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      (in adults, 300 mg twice daily; in children, 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours, maximum dose 600 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (in adults, one double strength tablet twice a day; in children,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, sulfamethoxazole 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, in two divided doses)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (for patients &gt;17 years of age, 500 mg twice a day).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Lymphadenitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment of all patients with hepatosplenic or disseminated disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Acceptable treatment regimens include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (in adults, 300 mg twice daily; in children, 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours, maximum dose 600 mg daily) plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (loading dose 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      then 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 8 hours dosed based upon normal renal function and adjusted with monitoring) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (dosed as above). The usual duration of treatment is 10 to 14 days. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hepatosplenic disease and prolonged fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment of all patients with neuroretinitis or neurologic disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An acceptable treatment regimen in adults is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice daily) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (300 mg orally twice daily). In children &le;8 years of age,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (dosed as above) should substitute for doxycycline. The usual duration of treatment is four to six weeks for neuroretinitis and 10 to 14 days for other neurologic disease. Neuroretinitis should be managed in conjunction with close monitoring by an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neuroretinitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Neurologic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/1\">",
"      Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/2\">",
"      Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/3\">",
"      Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/4\">",
"      Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 1985; 139:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/5\">",
"      Margileth AM. Cat scratch disease. Adv Pediatr Infect Dis 1993; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/6\">",
"      Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/7\">",
"      Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/8\">",
"      Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA 1991; 265:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/9\">",
"      Chia JK, Nakata MM, Lami JL, et al. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 1998; 26:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/10\">",
"      Bogue CW, Wise JD, Gray GF, Edwards KM. Antibiotic therapy for cat-scratch disease? JAMA 1989; 262:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/11\">",
"      Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/12\">",
"      Reed JB, Scales DK, Wong MT, et al. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology 1998; 105:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/13\">",
"      Rosen BS, Barry CJ, Nicoll AM, Constable IJ. Conservative management of documented neuroretinitis in cat scratch disease associated with Bartonella henselae infection. Aust N Z J Ophthalmol 1999; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/14\">",
"      Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37925/abstract/15\">",
"      Koehler JE, Duncan LM. Case records of the Massachusetts General Hospital. Case 30-2005. A 56-year-old man with fever and axillary lymphadenopathy. N Engl J Med 2005; 353:1387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5530 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37925=[""].join("\n");
var outline_f37_2_37925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lymphadenitis studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hepatosplenic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuroretinitis studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTIMICROBIAL REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatosplenic disease and prolonged fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuroretinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/56/26503?source=related_link\">",
"      Bartonellosis: Oroya fever and verruga peruana",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36583?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Bartonella quintana infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=related_link\">",
"      Endocarditis caused by Bartonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=related_link\">",
"      Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/40/35457?source=related_link\">",
"      Patient information: Cat scratch disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_2_37926="Neural pathways in syncope";
var content_f37_2_37926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Pathways in neurally mediated syncope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the specific syndromes, the suspected peripheral receptors (triggers), the afferent neural pathways, and the efferent pathways responsible for the clincial manifestations of bradycardia and hypotension in specific syncopal syndromes.",
"    <div class=\"footnotes\">",
"     NTS: nucleus tractus solitarius; V, VII, VIII, IX,and X: cranial nerves.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37926=[""].join("\n");
var outline_f37_2_37926=null;
var title_f37_2_37927="Adrenal blood supply";
var content_f37_2_37927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Adrenal blood supply",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing showing the inferior vena cava, the aorta, the renal veins and arteries, and the relationship of these structures with the adrenal glands. Note the arterial and venous supply of the left adrenal gland. Only the vein of the right adrenal gland is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uflacker, R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37927=[""].join("\n");
var outline_f37_2_37927=null;
var title_f37_2_37928="Juvenile colonic polyp Light";
var content_f37_2_37928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile colonic polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 405px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGVAQMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCZbKFVK+REAeSNv61KLSHAxDHke1XhH8vTPrSrHtJ459a2ehxpFL7KgYFok+uKmW2jHPlJz7VZSIcLn3qykPQjIpoqxRWCNRkRIce3SkijUvjyk59q01gB6DP9aFgA4AwfSizKsiqsKgZ2LnpQIlxgopHbir3k5IG3kCniH5uBzTCxTECg/dH+FIkQkVgigDsxHFaBhyDkc1KsXyjOMVcYg0ZiQf31UjsQOfrUhgGTkDPb2q9IqxxeZMyxx4+85xWDf+LNCsiA935pPH7kbv1qnZblQpSm7RVzR8hQeBxinCJdvOPauN1D4iWUZA022klYfe3nFZVz8QdSlwsFtFArLncvNYutFHfTyvET15bep6MYcD3pPLHJxyeleZxeOtXjILbZAV/iXg+9X7Lx5qEzuk0VvvKEx+5HakqiuOWV10r2X3nebACOPyo8klhj64rktN+INsUC6xZS28p7xfMuPWtiXxf4ejWMm+ZlfoVQkfSmpruYTwdaDs4mn5W4YHU9zUbRnB45z0rBn+IXh2E43XTgdSIiAtST+OfDiwpMb4kN0UIciq5o23M3hqq+yzUaHkjHJ9KPJ4BIBJFZlr408OXIXbqIiLNtCyKQc10YiEiI0bK6EZDKcj86enQzcGt0Z3kgjp0ORmh4uMnr3NXtm5juB29PrTGhJIK8Acc0rNE2KHlE9AOec00wqfSr5j4HHHah4QvQc4prUTRn+UclhxUflsATt571oMnzANz7UGMckjOOBVvsTYzGjy3IGBURgRS3yj61pSQ7QfQ96jEQHTn69and2AoNCu3aVx9KrSQz/bCS0f2TZ93Hzb/X6Vq+UeeMnrmmlNx561pa5mZZiyeBRVxoMsfmNFTZ9gsbQTgjJ/CnRxFVAzux/Ee9W9nOcDFORMZ469qytbY1RXEXzA7cn+QqZY85OQQKmWPjA7damWIICcdetLluUV0UA52nPpTkjycAdKthA3GDSrFtCj06Voo6AV44gQT09zUvlNuAHX2qprmt6VolqbjU7uNATgKpBbP0ridb+JFsbyO20hWexdD513j5lPbaKTlGOhtTw9So9Edb4p1WPw5oVxqU8Rm8rpFuAL/TNec3fxbu7hf+JXou2ORcI8jZKN3Ncxq13fardsl/ePfBQfLJOFx2JHrVe2spEXC4GSCSp4rF1JN2R7dDKYKKlUd/627EWp6prWtyF9RvZJyG3GJW2j8hVqKwY245SMnnb/jU1kBCZokWJtp3+bjB+lOEwlTZCNr5yzMKV7no06Ead9LWKzWLuiGNULITuP8Ae+lXZkiitEFsP9YvzqagSaXUpYbLTo2luS2FK8An1pNW0vUtHvooNQTdPnLKKbpTcW0OGIoxqRjLX+v89TQmkku7AoqRngDb/EmOlZNvGyqYXg/0h+jD+Yq3KrMQ8KtHIvUeo96sN5hYlwBGiZj9QfrUXb3OuVFQ+Hb8L+Rmi3eNnWSYDjgHofaj7OzXSwgr5aDcqhRWhO+6OAzLG5kBG5RnH1qsWaJggGX6A55FRKMd3sOPMrRi7y2+XcrX1rnln35OABj9ay7vS7SO3NwyYERK7Ae+etaGozIj+UwUSsNqqpySawbyK4ikdZXdowApXHJNWou7tsctapBRXMuZ/f8AeaMVjHKA08MWxBu54JFamj3k9rHK9hfXFo8fZn3L+RpmnRLNFGLiQldvK7f0pdQtxGEiKYA+bA67fekr2ui6tGm/ijodj4d+IxLXMfiJI444Iwyyxfec+mDXWaX4q0DVIEmt9Qij3kAJMdpz6c14UxiuZyQjZU/IGHQetWL+2gBBnSJlPRlHT61XtZRSueU8rpVm3B27H0RtDpvUo6HoUYEfmKayZA+XjvXkfwqnvovEbRW90RpqJmdJmyoB9M9K9fmlhhiLzTRRITgM7AA/SuiL5kpHi4jDuhUdN7oheIKfu8U3YAOnerSbJo98UqSoRwyMCPrTxD8oPPHpzmtEmzmasZ7opJDHmoGQB+n41oPHj3zULgE4A/GkKxW8vB9OO1RPH83CjaB361bKSMcFCfQ+oqMRuWAZSc8D2rZeRmyr5J9KKu+UT0IA9Miir5TMuo+WA2nGfzq2keMnP1FLDGp+ZAwGeMjFWIlz64PauM6EiBY8nI4PenxDP3TuGetTrGMjA4rE8YeKNP8ACdgLjUSZJ5OIrZPvv/gKNEuZmkYuT5UtTXlkitrZ57qWKGCMZaWQ4UCuC8Q/FPTNOnmt9HtjqUsQ/wBaD+7z9a848S+JNW8X3eL6RoNOxhbOL7jD0Y9zWLFbxYQRDlm+RVPI+orCVdt8sdLHuYfKPdVSr12RBm71DUriaYuzTMZCvULnt9Ku2eY84ONvG0DG3n0p1vG+fJLhXGWLZzgVYEjm5VfJEkSrwSKy5lLRHs0sJ7D33+f4fIljESQFssJC3BA6irCoYoy7AeWwGSvODVeGQYUIuBkjY3ar1rdlYZI3QRxL1z3NO6vc6oQtFR7vbvb+unQhA8oRMiCRAcM3T8cVR8trie43P5dsCeF4BPqaXUbhrqCCO2aRDLMFCn+LNd3rmg2Gl6TNaQWpe6gtxJNdF/4yOgXsK6qMHK7PKxlenCUadrM4nwzqT6StzDJEHkD745AdrhRz8tW7ya+1XU/t90wcuuUjDfMP/r4rOtbN57m2Q4uJtu9c8bR7+taVqinUvJlgNswKxhwcZyRyK0lFySXQwockJ88tyxI8EFspilK+ZxIHOTxUElvKZfOkl3W68qccY9K9D+I+gaHovhMzQWirdybUSTOWY/3q4D7URFtmjZ7QgAjp+VYVFyvXoeng68MTTvFWvor/ANf8MUGURO4hbAYZB3daWSNDvmf5G4+Unp70k0YZwVGU3jaeu0+lTTK+84VJA/3hu7CsZxlF77s6Kc6dRPR+4n8/W227RR0XRrjVvEcE1rG7wxNuYKP4Rzmtjxi0P261s4rPyJpJDKwP3sds/hWRaavc6I8z2c8tvFN8uE6iql7rwub1JrqRmuVP/Hwwy2PcV0qaUOU8idK1XmvZG9Jttodtugd1GHYjIOe4HtUUKtezkOrKSpLSDhR9ait3lFojMRK8ikiTH8vSnzhorWJnaS3jn64PDt9KyT1d+h21F7icdnp5/wBakaxQRblSRZCfukjBYiqkwiiZhcFGlPI9Dx3omuB5Mb+Ts52ZPXP94Vn3JknlNrGGEkuApxk5JxSs2tCOeMJarRdP8z0H4ZaPYv4W1G7vwHluZ9mC+FKL/wDqrB8b67/wkupfZ4FEekWR8uELzvI7iuk8TSW/hfwZ9kgObvyFhCr/AHmALH86880mxZDEXJEOAQc8A+9a1W0lCJ5OEpRqVXWmrrUsWpu7RXXStQuLXI2NEzYBHoKfD4j8V6TtEOoyyQAjCt82B6Veu2SZNzxqHY4I9P8AaFZ+zZC7mYs0bA8Hg5NYJtPTU9KthaNSKco8rfb/ACZ6Z4b+JOmazNBZ3UM1peSDaHkXCO3tTfG/jV9BvLewsLRbi7njLb2Pypg46V5re+dFb+YAzNERMhK4MbDnitHx1efbJNB1IBAbm2O9x/e7/rW/tJOL1PIqZfCnVgujIL7XfEF+fMuNb8t8ZCQjatZT3+vTSYfWrt2AztVucVNbC3+x/ukDluG3cbG9qmgt1eZYixjUDIcN1PsaxjzS6npSw2HglaH4mWNQvVGH1q83DriQ0VoN4e8xi8UqBCcgMcGir97+rHN9Vj2X4/5H0/tJ69PWl24RnOFRRkueAPrWH4w8XaR4Ttc38vnXZ/1dpCQXb6+leLeLfG+r+J4/KeZtPsf+fWMkFvqetaVaqhpueVhcFUrvsjvPiJ8RrSx09rLwxdibVGbaZoxlY/x9a8dk8+/uDc6tLPc3UzYLu2cfQVJHZxxRxJHsVR8zhP51aa3BDLGdxm6ZyNvvXNKblr1PoMLl6pJ31X/A/r/IXT2aK5t0MxERypQjjFIbOaONwqISx4YHBwKGt4re0AJd2Bw7Ht61KilcKjHyv4XbqRUuKUm0ejTcnSjGfR276NW0v2/AhQsJVYJsQptZjzmrsBRl3RhpCq8AcfnVaPJnmEshJY7VUD5frVlBHHbZZChVsYJxu96hvldmu2xvRjzL3ZJ6SeuiX3dyaG0vrm5jijgMs8nEKqP1NRXdhc6ZcSQaghjuV+bBORmuh+Hus2mneKRdXspFts2bj/D7034ka5Y6hrDTafGZEKiMHqW963aXLpq2ccZyVZ30gtb9n2RzsdzGs8JaDc8MgdSvb0zXTeNvF1rqemS2em2ssNzekfaZGPLkDhR7VxQimt4ri4llRJByo56dql0p3LrLct5jqeAB/Kuh/uYWPOX+3V7tWV930JPD17cafrNnEylkcrG4I5HNdb400ua+FvPYsyTKzJvA4U54z+Fcknlya5AUmKTeaodX7EsOn4V6xbxrE2oQMGKzAAbfvJ23YNdFC86bUjmxSjRmuR33/r9Tz/XPEV7q9vZ2OqTeadOAjwOM+hp9ws9/bI1pbIkVuMSbf7vY1N420I6IbW4BhYuR+9U5Einsfes97yaytp7NVZFcBsZxkdq55x1cXsz0MNOMI88NGtvv/MqNGZpGlVvLOD8h6nHQiku5UhtoxKG6fMQOhpZrlo7NH8tZJN4RF/ic+1Y+tSXECEXSyRzytxGBnj2965eSpUac1ojvqV8PhaclRd5SSv5dfvuXdNMWpGc3SObWEYCnoT61QttD2XM08RIgcHywwzkd67bRdKSHwteTuuYxGohyMbnOMk/qKxBdw+SLa0ZpHf8Ads2CFj9SDXfGMYpJnhV06j527u5DoTyjTEj35jhJMak1cuXjlmjtbhXljCbtmNoV/XPpT7LT7eGDyY8tLGCUGcZHoaqavfXCJDDOqBydiKBgD+tcihaUm9Uz1KtV+xpwSs4p3frsZ95Id/lJGWTqR6f7tbHgK0F1qU+ozlWtrRdzZ6licKPrkg1zaQz/AGhbePc88vGR6Z7V6TpVtbaTELIYEFon2i6fH+tlI+VfwyPyrWlBOV9kjgr1Zclt2zkfH9xPe37JIwRoQAUzyxPLfrUaNttYYkgbAO0uxwCazpHN/rVxI2Q2S7NnI3HnjNa1nAyxvwGuGG5ctkNj2obu2KnFxVo/1YZGFlvNr/JnhCOVb2qO+D24aMqro7Bio4O3NTGa3iVzc3EYjj4JxyrdsVmx36SzATThsDCLINp/P/GptGzXcuVWcWru7WyJL3UCba6iWVgrDG314p1wxl8B6LI8jB4bpo07gg5p8ttF9meLfFuyTGyEEciqEcqL4W+wysTNDd7sd1BB5xVNWRz8znKz8v8AglyCJY4d5iyWBbDng/SprVFhUXEpMkS/NsXqnvVOxnXUrI2ch2Swthmzk47ECrttG1q8Yw23nYjfxD39jSdormOuipVpKO3n+ZSufEKpO6x2ylAeNx5oqjf2llLeSv5ph3NnYBkLRVc77nE4zvpb8DduJX1K7e+ucfaHyrTNz+FRIm0kSorc4356CrcdsigoHMav85J55+lSyRJKkofHlKOT7+org5uV6n08cM5RSjo+1v6t/kUUtcqEO1QoJ3D17ZpYSyN5ZfzXVcnIwAfatG3DmSKJgoDcEnv6c0y4HkySqwXzAe3Ye9atuOyIhQjJJ3/pfgUrXOxhcKZgeQE9feppGM0Ku0QUICqZP3j2BoEe+YSWgkiOAMnvSy5chijHqGJ5B98dqSWzfUUublcI6pf1v/WoT2MawsqzFJmGd+Oh9BTLSO7ttPxqTi6kT5kkRRgD0PvVuFROoikYcchW6/8A16Jk3RhY/MjCn50HQj2rBrnl7zV1/W52Qh7GLlTUrNPfZt91s7d/wIbJInY/xSsCzM4AAGOmKs+EtGm1e8kmScQwEHfKRkIg9Pc1WjiikAPmeWfmVXxnfnt/Sui+Gs8Nrfto99uEd4pUZOeO1d1DWV2jxMbeNHli9tfw/Nam/f8AgFW0NZBGVeIEp82WcerCvPEiGk6hLLGh2yptRW52gdTXuouY7Gwee9kRDt8ksxwqoOhHvXjWunfNDcRBljeVgFb+JfSuqolZnl4OdSW/f89DEs5Yl1aO5uAGAkV946YBr27REc+IQ0MfmvLF5i7jkFSP/r14VqaPayBYotsTfMCRwfau70XxJPb+GhbWnmHVCNn2of8ALGI9h71nhq3NF21TR25lhOV8r0knr2Nb4oaebHw6kDlPMZ2mwOcfN2rhpPMuxCxALSLy/Ur7Grmv3H2bTbiaW5nmDpsQytu+Y1i6XPeXEUMGmwO9w/Acj5R6k0qylK6W48FKlRa9rqvz1Nbw1o66hqtzI90E+yRBQzLkLnoB71nbzqvipWUErAhAzyCc4ya67T7WDw1oMl3PLvU7juPWaY/3R3A4rjNFnl0qOS/u8PHdyHywgznv17VootJKXzMJ1ISqXSsr6HZXN3AdGS1w6pG2+Zc8celcfbIbu6aW3kEUMkpaNSPlIzy1aHiLUTB9ltbYRefeDCsnIQ//AKqda2QtFywxGFKlv4WPessRW9mrnZg8EsVV9mtuvkQzTxyySNuYPF8odeFkPrWVqsjfbIWvFZ7rgbAc5+lW5LqfUvNggjUQh9q3B+6g/wBn/GpYLK20pftE5EjCQfvnbKsfXFTGDcb7dR16l6vKndbX6F/w5pd3BdfbJ4g+oSnFtEBwo9T7DrU3ie7XTNOaytpkmldy8rg5Mkh649h/SptR8Xy3qS2qTWil0wPsw2D05b+lcPDHIt6ZoQ0207fMccD1IrRzSVonE6cvier/AK6lzRbdkDtKod2z8o5JPdhW0lh5k6mzlAlQA+6D3p2iRv8AaBFYKWueu5h931/CreyS2u57IDFzKMyFTwg+tYSn7qcVdbHfRwrg7VHyta/j1/Tucrr9m0aliquYXE4C87h61sarqXgzxFZwXz3H9l6htCyxsM5IGCQPSrN3pxuI2kS3kPlpsfa2MKP51ysHh2CEzS3MiSy7sRRsMgA+ppylyRs9EcUqVWvVvS1er/4P9dRupz+G4k8rS0ujKDkXLMQCfZRxUEMU2qxK20R3Uef3hBHmD3FdVp1mLJJ5LzT0iESAhSv3qt6JBNeW0l7cwSrA0gYMo4GP4R6UR96SurXLnh3GDbknbt1ueZi8ntdRRrZRHcwk5LjGfUe9dlDrVpqmhzXo3Qy2w2yW/Ug/X0NO8W6NcX8l1JDbKzMAYweHB9qq+HNJe38OalZatbNbTTnduP3gR0FaJNM5qanTqWTundjf7Z0x8NDGixkcBhkiinweCJZIUdJ7faRxubBoo98EqnWKOqu7JYYWaBg8gbAQ+lJLbQxsnmlY1C5lfptpZIniDnkkgPG27qDWT4g0q/1C4RYttwVXEsOcfj71zpe89NT6atPlpKSd+3d/MkkvtOTMcd8ZV6eWiZIPrmmwy20jNG6nGOGlXBY1WtpTZQ209xaQxy2TfLKBxIufukeorsvGfi7w34g0GG3s4hda06qENvAUEfTljTdCnJNvc89ZlXpzjF7fel95hWUvlI8E8cjSryu4cD0qUoIY2lkX7/yhcZqtFObC3nluCX8lQgd+hamtqGoR2IaWCO6tphueMfeU+1ChpZbo7HXV7y0T3t/TJkLzxEMEYYwTjBX8aFjBYox3Lj73X8KZbzKIA0CboX52A8j61Fq98ltNDCQQ5Xeqp1H1rknTlU922vzsenSrUsOvaOSs+lkmElvGgZmIUD/VED/Vn39qZY6smkaxBd3CskYIxIOcN6/Q0+2v4pcw3EbRyn5lVhywovgA4feoh27WQpkMP6Vth6s4vknujgzDB061N18O9Huv6/I9RuWtvEuitJaPlJlDKeyOOgPpXmOo6Xc2N5NLcyTS+WceVIOYPp6ioLeTVfDVxJcaNK89mih2ReVUHqD7CvQrDVtK8aeHdzT28OswL5nlk4EuOoB759K9FSjNanzKhKjLl6fijhkgju4ES5jJjVGJLHAPGQc0zw9IbXRvOnfbEpIHHBXPGfWo5bxksr2FIXmRJBvUdY1Jxj8657V9QnkCx2zO8cXzFBzs544FTRjGgrR6nVja7xUlOpo0rPzaNXxDNLqFrN5zC1s4yBHCRh5Sf4vpXbQXei6Z4O03zLqPETH7VEBiaZh91fZetcfJs/sYX2qRSzTlQQvQtntWp/wiNrolgl3fTiW9uAJY7d8koD0yelOnJyuycRRUJxUexm+K9an1KE3l3PGFVdlvbL92Idse9c1Y62bPRfs7Kk5IbYH6qT6Vb8UTogh3WkUUsnBZjz9cdqpaVaWy30ct1Bm3Yn7v30OOGx6ZpNuMnY5ZJ1Gor3bGp4fgCxQ3csjPduMNvOdo9hXQWNhLrl5DpyShINx8xScbh3x71zdxcLHN/ooLSc5IOFUf3ias2l7ewQLb2cUUlzcMVE+SdnqxxWEUp1OaXTY9h1Xh8L7Gnu/if6ep1fiPUrXw/ph0zS7eBY5E2xxryQvcs3rXC7v7TvY4L+7ECcFCDlM+grq7Hwgt5ZTSTpLeshzLcO+C2OoT1rO1Pwpp0sckmnvLC6fdUnge1dMqc3r+B5jvFWMvVbK2hvYo9OfegH73ByP8mr7B0UIyiNSgIUD9KyNJmSHzIZ1laUnbGP4SfQ1r+dElsRcRyySgEb1PCmuOpJyl2R6uDhBU3JJyk9PJFi2vjZH7RYp+9I2byceWfc1U/t2VrhJXgMy8q8qNl2Prn0FR3V0k2jqjKryo4bao/h75rs/CV/4amsbO2ji09ZCc3JvcggnupyOK0gk9HocuIm4vmTv5WMfSNVXUpZolk8kMCoWQ4ZavQaatu+RMqp286LO71Gc1j/EKHQotTuRocpltlIMci/K2/uB6itnwZeXUmiJLfCG6eNTujcfOF9adlJq+vmKFWUYuMNLlu6Z5kBns1kCYLBhhdvYg1hwC5a5Vo7mf7S1ztNgVxEYsEhh+lddNFbyxRjy2+zsvzF32jB7AetNhsBbW8vzb9vK5HIX0zWvKnYyu11sZlrZy3V3LKj5RMIyNxub/AGat3VtcQvcx3FpEJJmCsCc4x6n3qKLTwsOY5ioBLmM/3TUssFtarJMsk4YgMvO7I9TV7CjC6HmGztz5UxdZF4KqMgfjRU8N9FPEsizRKGHR8Z/GimndaL8hP2idm/zOevI5UMUNwPs8jAfePFP068XT7lpBve6QFHU9GB6MKlurSSdzHOzZJyATnj15rPWNyoTzE3bivmMcZXFcuvM3bU9eStTSvp+pHPMl5IXkhY8naGxhfWqpM8V00mYYIivz7EAJA7D3qzcyxjMG8F0GRk8N+NO2eakZeJXdjkYb5fxrGVSNJ2fU0WEniUmrJrsn+Nlv6kaB5SfORZkI+X+7t7Z96ryTf2dKIS2A67Ymb7oPoasCNvMuVkBRNuCiklV9MVRtpJjcsbqCO5s0UIElONv+1nrmlTTUuaL0FXq+4qU0+bZ/8H+rjEuFtNQtZ7c7VmbZNCOefWtbWNPt7maOWCQxXicRk8gj0NRqLWGP9xDsnZtyrIMj86hKFplkR/345P8AdzTlLllroa0aanScV7y7dguIJVtbSO4iRJ4ZMpPu+Y56g+1a7W6iJGLh0BywxjJ71R1KWG3w92NzTAAein2p7TWslsvm3DlEP45rOdVTT318jqoYV4d8t0mnd3f5l0CNYCySmJwR8o+6ynsa5ubR7K4uWe3822u4zu3Jwn1reRYAQFlaVic4xUdxKNxVEBDMN2KwpTlBNI7sZhaWJtKpbTfv6Kxm6VbX1hqUy300DW8sWMp1lp6Wtil+RYbLaSVMmMZJ4/vZ/OtFLOR1lkhjiMqqdjMxwtRWcCJKXmAkkK/6wL1OK7JVH1PKoYKN1GK69d7eQxozf2E+yUuz/dLDjI9KyNVm1G8eS61O6DXClYUAB2L6ZrchC2+1URhjkEnj/wCtUe1JleG5gzFKdzAHjPY1UJ2M8Xg1P1tYxfCmg3GreKp4tOibUykIZw3IRvcnpVbULeHRr1lu0eN45NsiRnO8Z5XNbQ1PUrDw+ul6D/xL7VpC1xcxj9/P7FuoArItbaOfXGXc88cGC3mcksa1Xvy908dxeHpOE4630ZW1FrnUJ7m9t9OW3tMALBk8KO5/nWr4Ph8yG4umO1ZCIhjuO5q1ZpHe6xqRYsbMoIxtOBnvj3qhp0q+HNRuNHvciyP7yGdupB7cVvGCi1K+hzRk3Lml1f8Amei6hdHTrSO1EUvlRgGMrxtHr+NZF3HH5xBkR4HxIccFT71kXvim0iQRz3sk8YXb5aDOR25rn3vNU1kPBpVpJHZSHaWI5k9s1pOrd2jqJKEOt2QXl/aPrdxeRN/ooyojA4J6ZrtbbU7YWFt9gNiCFzOs5HIrB8KabaG4uY7mMQ3C/KI5R8uOh+prqbjwxo0dwiCASXGPuAcMPWueEJ/Eup0e0Sj7Of4M5a/NnJfTTaeheAj51HY+3qKqfYIXhK+QhY8bgOT9K0ta0gaKGubIMFRgJ485CKf4gf6U+J0W23JKsuWzG/SueqpwZ6WE9lXi4zWq/rczTo0XkB4EeUE/KM4IrrNIs7uy0mCWxtXmkLgSsSAUX0q/YWul3djwJVZfnaRD91vQe1aurLexabatp4R55m+bYflUY6sKuMeVN/kY1eVzUY6eu33iLareSJMFMYX53TqsjdB/kUke6a8ldIpHKD5sHgn0xQZD9hj+YExnDGP9SB061NCsiNHGqmTeC6lDjA9TWyOOSSZmLays7RO4aaQFki6Mw9KfGrf6wMVgHG6TGIz3HvVqIvBrkOpCDzr1IzFFz8qj+8aW4Y28MRuUV4ZgQUAz+nrTipdRSlFOyOevbOEXcu15wM/wqMfhRVpmjjYqYpHI/iLkZoquZB7KT1sUDcTG1YXwTzZX3B16qPf2rnrp0vLyYwxM6ltsa989yRWjeLMLYqWBMgHmEnp7iuy+B/h231HXWvLlA4s135YcMx4Fc/LeaimehUq8lGVWa0XbrtYwLnwfe2OhRXepwiJzwkLH53Q98fWsQpFp5DMGEj/KIicD619V31q9zLKTDBKojOPMXkNjjaa+W/Funy2usSR3Ux8wu28k8Kuexp1aemhy4DH+0TctGu3n+n+Y/SrPWru5uBo1s1yI03SPt3L/APXpGjubVZG1GFViY/vRswwPbj0r0n4RT3Fl4Aujo8fnak9zsO7sOx/Kuk1qbw94htJItaiNrfRDa00acq31p+w5oaXIWZyhXalG9n6/ejw6Rkm8iONpJ7c/6sjqp+vpTryH7JAkt1Ko5xg8KfQfWtTWbA6BeobdDd6fJ/qpIfmy3uO2a6Pwx4Ml1VIdS1JQpQktBK37pV7Ensa5YUarqKF/dW7fU9atjMNHDyqyXvyeiXTz+/8AyMjQvCDanEL7X5ZI7IrhIYxljzxt/wAam8baZpOm6RHsjFvcZ5+f5gM8MT2NXfEnjfS9IE9jpU4uL1MKZVGFx02p6D3ry+/ug+tGfUFmubaQbhH6H+tdqcIx5KaPElUqVJurXe76/r6GxLqtmgjit7lBKwCuw6Bu/NWBcrbFchJZGGQYzn8zWfb6zdf2bLb6R4ejnS4BQzzJk49j61R0tL/SYTJLZuYyTuCnkH6dq5qmGU9dT18NnE6TUFa33/0zobidxGpjkUzScbcYApEnc7QvAVtrjrgVl22oQ3wdJGzI/wAqp/Evsa1bKCOC1aKWX97HyqN/GfSso0+iR6P15VfeUrrr3QTIRvkR24YAAjhq1NB0fUNdvXgtYlVFP7yUn5E+prMaWeYtGIiDIBkY5Ue1e5+CLPSrPSbaPTyfK++DKfmlbuTW1Ond67I48xx3sIc8Fds8Y17TJNBvJtPu3RrlBlHXoQehNcbHJcaddvA9u8t1c5ETLyrk9ya9s+PGmWtrplvrcQA1JpBCDnlk+nfrXk1n9qWxkkit47kONjox5U9QynsaqPLTm1sjz51qmPowlvL0/r8DoPD1kuk6dGbuGOaMkiYucbD6/XNYN9ZT67qBNoiLZQ5jjuHOBIe4H5Vl6jqc7W5tyTHFGR58pbLOf7prrrDTPFfinS4rfRtGFhpwAAuXOzp3FdSkp6bo8+pUUVyrQ4SJzb3bxvaAQiTYw6k464r0fRdUspNKWWBkUW5+dNoBqzZfCOY4fUNdtPO6bV+fn6+tVNW+E99C7XFjdR30XeJG2sfapgp002he2hNqLf6foN1eTTJNLnupdkEi/OjK+ST2rmNK8WXcUBV0mupgfvICMCm6LYWsWq3EWo27QalE4WG3nGFVM8nHc13NqsEVyLWXT5FkY5DRjIC+tNXnrsVJvWz0+84O91261a3ki8k2tmT+/lbl39hV6wkDpCnlJ9nC4VN2Hx6/Wuo1axtYgqWiEylsurDcFHrXK67NZXMksNrb/aLpFx+7HCN67qidO695mtCtKi7x1ua1pd3emq+8IoUjjHbsDXUrPaRpGYJlaW4GAX5AOOi15rp2oG2tvs18zpMTuVpBxn0Jrasb1rV0JxgLvZCPlz/s+lZxly7nbKKrO8HqjtVjQeXChAdAXKAcZ7irdtbJPC880rwoynKHqvsK83l1qddWkuLB5POYg8H5fy71rpN4r1C3llt4UhJOSxGA/sBWsat3axz1aDik1Jfkdo0SxQFhKiF0zGGH3kHSsvV7lbe1ndv30qNncgwIz2x61gNo3jCWBnjksgAAPLM4DK3oPT6VTn0nxlHBK9zp73UM33jG24ZH+FU5vqmcySk7XX4DLm5vzO5ea3DE5+fr+NFczJdahC7RyWRLqcEyfe/GiseaPc6ff/kZ0lzbh45EeUFlAAjB4+tdj8JPEUPh+41O3vZFjEsBMeBkbxyBXIWkTP5gkYrK4BwACNvqKpX/ANksmimtZ/PWTg9iB0zUX95tLbQ6akYypKNR6S1+5/nc+ofBevReJdCiu4yBcA7Z4geYznGfxrxr4v20Vvq9whUfY5B5i7vvBs8n865jwl4kv9Nu3vNLZvPkIhMKk4dc4/OvQfjRNpU1hpXmRsuqPB+8XP8Aq1x/F75rRSvG551PDLD4lKL92V7eR5lo+oa7oq3R0i4AeZQVJcLx6DNdJpfxI1WHGnazZ28+5RmaZOc+u4cE1y6ss2n2UcmWG3aHXqpHTNTNcNB/rSpYYwCAcenWuaNd8/KezPLIype2b37q500vxFt4v3I0q2nnGdoC9T6msi/1PXPGNrFLfXn2Gx3GKO0tDgOfcj8qxho8t7pz3bT7bp3wUUAfJ9a77wd4YuNNEP2lEMRH7uMsMrkZ3Gu2KnN2meXONKkudWRylt4TsbC+inwWdBhoZefm7Guglj+yLHHqKedvG8M0Y+Un+HpXXwWFlBcebd4L7toY8gntVXxJte3lib5NgGBwSfcV0xiktDljVTdktziri6+xwpDFFsxzg8bc9KXTNXntpmvY0j2qu2eN1zuFVNU1PTrJxZy+bLNNjDbSSararqlvqNgdPskeO4PBZVIY+5zWMppN3Ov2bktPuMjXJtPm8VRzQxR6fb3C/vEDAgN25rpFjGneWDhp0AZd3O4f/qrhdX8M3EOlpNaqbja+45OW+p/+tW3oV3eS2ksl+zOoCohkGHwB29uK46sPaW6dTvy3EPCzlCUL3/rc1Li5X968D4SRxle+SeQPavdPD6obuxS4hVEe0RY1UcI2K8Dtwj6jbiTYUmmRnOfuc19HXBTQLS51e/lj+zJH+7zwBxxV0tLtnNmlXnUaaWrvb8EeM/GC8GqeLpkluf8AQ9PZbeNB/e7n9a5LT7O517UItC8PIPtl05YFjxGo6s35Gl1Rprlta1C5QC2kYukgBxKfUZr1j4K+GYdN8LpqqgtqeqgO0jjBSIfwj6kUQhz7/M5KuIlg4Wg/JMn8KfDXQdGcXUrnVtRjGJJpV/dhh/dXvz3rtbbT12h55ppjkkKflUD0wMcVqRRrCoVEAT2GKaFJHJ47fStud2sjxHJyd2zLi0eGB5GtlWIt93HOCe9JLYJFHiFVBYjOe7etaq+4zSSqSuM7ffripdST1Yjj9d8NWniKzmi1y0jlCn91crhZYz9a4S8+H/iW0k8rQdaiu4WU4iuvkkPsGNexzRho3CsEZuAeufes65smeFXXO5WDLk/NkelDfNua060qfws+X9Vu79HmtdTmmimjYxNCg+6Qecn0rqfBz20lhthtYZnCZjJ4VsdTmq3xjtj/AMJtJEmY2u1jlYDtxzmtfS7ZdO0aJowoNx8iY/5ZoP8AGnQT5m2eq6l4J+RDq1rayx+fF5ZjlO2VcZCfjXE3SfYLmSCIk2T8IS3II5/Ku8127tVsLa2tFjUF98g/ix/UV5xqsp1DWJJo2zBENoTpn1oxNuVmuGm3KL6/odX4E09Z72SaZM28aiR/z6V2WpPA+nlL2QQLcPhJC+GjX0WuJ8NeIIdPEkfAEkXlSK3HHUEZq3Le6EttC11d3NzIMnBxwc/56Vph6sYRauTi8PUnPmtp5E2qW0Olxtb6XFcXl7KATJIWAAH8/rV7R4dUjdb0ajJpRjAkkcE+WW/ugHr+FYNx4qluZlt9HtHkmf7sm0kqv+FVzo+uaq4e9mkMROAoOB+VU8Qre6r/AJGEME5u0ml+J2eqeO9Ikv5mn01Z5SfmlVQA5x1xRXGf8IhB/wAtGdX7gv0/WisPbVOyOxYBJbP7yfycnEl4Yiv3REuTj0rQ0vw3NqbiPTtNnmGMl2UgY7k5r6Tt/DOiQ8ppVtknJJUHFbEcaQxCOKNEjAwFUYFLlu9Wc8s3pRX7mnZvq2eB2nh1fCmmG7muLePVm4jQrlYF/vH1PavMNVv59QvrgvNLc3JbB3jIcj+L2r6i8Z+G7XVbBybUySBTnacMw6gD8a4VPBfhjR9LfVL9rwkKC9u2QzN/dNVOnzJcuwqGPUk3P4m+iPMfD6m0S0wjR3ssg2o6gxle/XvUeoC3N/DJtElsZDjJxz2yK2vF2rvf6hpi+VbQ2scmUtohgqvoT3rEvYnuWnNygiaZ9ysBwn41hN+zkl2Paw8ZVqcjrNJ8O31w1vJcxwwWu4SFg4JIHbHvXT394uyRkjD54YqMOg6V5TpF8LZnW7uiksXCbTjK+tdLeakps4mSRxeD/XODxsxwfrXZCopRu+p5tbCty0eiOheMG0W4WeNdrgGKVuSv94D1rNlni82V0Y/Z5TtWSVsMCfT2rIFxbYN7NchkAyZWbOAK4/V9Ul1K7byYpJLbkoh/i96cqij8yYUEt2a+tRwXOsxQWhaY2o/fSIeAx6AGkmtzCYfmZ3ceXF6yN7n0rC0uK4mnSDTo5m2r5kyrwFPZfeuy0rTL271CGOeMQ5X5mY52ju3tWDpOo/eR2UcTCEHKD1Mm40+NIzFqF5M5X5SLfKgZ7A1Y8P2efEmiWOqXBfS55SmZMB4xyeT+FdLq+o6bAFsYkRLWE9cbpJiK5Mqx1R9SS2kvJ8HFsvAiTrg++K1cI2ta5yuc+bmUuXz/AK6nY/FSDw/aXNnZaAkSzIf3kyHKhc9PrVbSjHf3VonjHVLh9HiTcIIyWVgOgOK4rxDOk81rfPEyaY8ZURoOY5PcVmWuqtozwSWV68kTON0bjK+/FYKnrzM3deNKHsG29N+uvU674t+KLHxDHbaboFuIdJtyIw+3azfQDtXv+jxLAlpBG/7iCzjQRAdDgHOa+YL63llmivRGipHIrbV+6Uzkmvp/Rr+0v7K11OybzbO5iVQynhCBjH6VrBOzv1PExkXFJdEapySvPTqT3qCZTLDtRmTnJwOSPSrBGQNo4B6UYOCACM1L3scJCOgyMe1GBjgcmn/NtzzleKYo+ZicYH86TQyrNOguI4c5dj0x0qcr8wOfxqIKguWeRVVzwD6j2qXbnjt6VL7IZ438UvD0K+IH1ya/WMqURo5F4C46g965u31JFijtEaFvL4UlhyK7342pNceHZFIikgidWKEYbHfmvDNRtbeFi0CPtcBiAMYB7ZqnU9k7dz2MLSdajzJXt/VzV8QajaRakb+eRXmaPy4YI+n14rEsZI48iUo7El3Pp7Va0nRY7jMkyvGrf6uJRlz9TXUWHhK2YeWUjj3DOwt85NJU51fI6o8tB87sU9HtbXURGZbIMGOIznGfrVu9s9H0/wA6O/mhN0egQDAx2rH1K6lsQYPM2l8hAoxgDjB9+OtTaVoaahbOk4Vnkj8x5XOce2acYu7gkbOacVORraT44tbK3aC2sfMmHAlSMAY7AGtvSdd03UZvPimCsiESRn17VjafocFlYefI3+jxLgLCeD7k1k+JbNLNYtU0aMK8ihmjbkPjqMVtKnUgrvU5Y1oSfKdRckSXDutqHUnIbcOaKyLLWtKvLSK4uJRDK6gtHj7p9KKz5l3O1JtXX5n0npnibTr60SbeIy/GV+ZSfQGuV8c/FXT/AA1MlvZQLfXAfZPubaIj/WvEtPvdV0HUFWG5axvEzKrhsxyKfr34qHVrea6tzqF0Fe4QlnYnmQn096PiTaVrHlrK4RlfmuvQ7JfjFrV558omskhV8lNn8OeBnNWNS+Ieo6pBNbyNbW6Sp867ckj2PavP7TQzqaRyzyrGrdQBjb7VSvdJW3EyW7hpHyuQSQw9PasfbWSVj0llyj73KiK5UXfiFxaTFdiD52OcHsR7VoW66pO7W4miF5jJNwPkfH901U0ayfyUuEk2zIvl7BzjHavQ7XSEudCsz4gtjDP5u2JoT85B6E+1bxpKfQ5VVnSWsmrnEXFq0pSOe2lUhPnYrkZ9QfSq6WptXCXckv2N/uoD8rGu+1uNvD9w6XyQTG5UFJR/AOgrAuLuG1jf7fEDb/djQDJLnuKxqU1BWTselQn7V88rO/U5y4tYreKaWMMqlcGFug+lWPByNdideI36K46AemKLj97KkRlO5l+TcMbec4NZsAvrDVTOFJjb5pApxj6UsPVjGd5EZjhqjhH2SuutjvZZDblUhhBjAG94x8xPpWXe339kQTG4mkNzM2YoM/eHv/hVez8U3jofJsC05BXkZQn1qja6RqGqanJc3ZZ7pGzt7ZHYegFdc5qVuXVnnU4VI9LGrm9tLVbt7BmX7+E+aViR1I9KcsMml+HZZ5mZbi7YnI6jdzz6HHFdrDYq1hB5sRW8SMl5lPTjv+FcrrUMVzpUcQmHmSSHAk7KOc/pV8qim0EpOo0uiY7RtEjOk3V/Id0sEXyK/T6Y9a5d4RFp006xok19ICkRXIjHqPetaaS5n2xlVihZQCofIf346fjUsmm3Exm3FVMY3bkORt74rCrU52lHY7qOHUYOUt+nr/X5nM6bb6rdW4MEge33MPJPC49SfWuq8B+NZPB928ASS40m44mtpOsZzyVqz8OdRsNF+26XfIpju22s7c5B7+1SeMfCwigkuYFWUcqsiHnHXB/xrSMFKClA8upTabhPfs/yPbdJ1mzvLOG5025SWwfktn5oz6MK1w4dQwcbTwCO9fK2j32o+HoUm0278mdxloS+Vx7iuq0j4q6laT28Osx5Dt9+DkH/AOtSupb6HHUwlknF7/1Y+giQPlB/+vUDgAkMOBzuridN8f6bdqwEq7s/MGO0g1pXXi3TmUqsy8gdHHWl7O7ujB0KkdGi3d6PJLrNvqcN7KHjJBgY/uyvetgspY8/jXHS+ObG2iHntGoBxgOOaw9Y+JljBCRBPEsh/iB3fgAKTh3Y/YVX0KXxn1OKPTZrYuWeQgKMfKO/515Rp0a3uqxjadsYBAY4LHtWxrOuf2vfNPeLMLKH5kRxlpGPUn/CsiXUEtWjuI5QUxjYRzjtj0rCck6ifRHv4Wj7Ghyydmz0jRrO2tER7xBJeTS+WAD29Ks3LR2VtPPJGVlO5ju/QAdq4q08fWrRxb4Q0sbjaWHAb1NVtS8S3Go3UxQSXDFsgdFJ+vpXd9YhbQ4Pq8pSu2rGR4raO4ntorVX88AyHB4I6mt/wy5uoVMO6HdFtVQNyn1BrES1UFZ7pi88uWIA4Ht+VaXhGaWBTkA2zuyoFPzYzyD+NYUZ81RtHbXoSpwV+p1sUEs8djbwRRxxhj5qg8HHt3rC8XMDeQxW6CJMHYo756k1fF9t+aAOzucFD1UjuKyPGQMapLM5jjSAnIPzV2VWnE82knGdzzmGUbPniLtk5YDrzRXQaRZTTabBIkkaqy5Abr1orxmj26WGk4J36HVtaRXU80cha5QYVWzxu/2TVaHwwLyLF7NcpDE+FiL7cn15rd0uwl1AxW1g8UZVTIxPf6Ad6x7m3maZYrm4lkMLkgHOWb0PoK1cUktDs5eaTUtep0FnYwRWwS3Jm8rggkZqz/Z8CxTYVWEi5LcZBrK064e2ubiKJRGjqCfMGVBzzg1om6ljtJYjFEwVg4MZxhf6k1StbVEzk29Gc7e6TZvLFNamazvD/q2/hPue3NW9O8QanYWrRtulMZxuyGx9M81euNMS8to/s8jyEnKIzEBT/hVGeHZMXjmglAG1vKGAG75qJVJU1eIUsLCvO09O/X8O5Hqutz61dxPOkg2YVy6j7o7AVV1GKwvIYjcM8hgYsqK2D+NIYD5jPHIWOeSTxiqmUXcxUtIflHGAKwlXnKTud8MFTp01EuXbxXdobdAArgYXAyuPQ1Ws4VVJTcuFjLfImeQvqc0u6KOBTKNqE8Y7H3qeHSbi+BmTZb2p/il5Z/oPSrjz11ZK5lU9nhJ+028kxLBhA3n28nmCJ84IwCvtWlpeqfYHuX3InnfNtlP8P19azBptv5kLNq/Gdm3YAMelNvtLGlQma4xeWwbIycFf8a6aUHT1SPNxFdVnZ/ib0/i6K40+eMTGSZuGRFPzL6ZrHe3u7+4jkvIvIOAI4zxtXHAxUlsunQpGyXSozndt2D5R1wama9guWW5j8yV1bG4nOOetTVqOfmupvhMMo6y0fTTqV9WgMUMMMMyRiUkeWOrH69qjaO8sItsYWaMIG8sEhwvfBPBrf0u4sbvXDNfiMw8KEIwA2OtP8W3cN0BZrJGLkjZHIgwAD6ewrVUoOHMc9fE1oVOVK1jnNQt7TVtPS/iiLx7PLQIcOj9ifbNPsvEmo2Ph65sZrUzxAg7888ener5A02I2lrb70CDa3r6msS/eXbv+Z53OyKNOAB1NTCb2juicThkn7Rv4lfyv/XzNj4baNb6haX15qURMsiswHoO3XtXM3uxdSNsqIcSKCc8Jnrii1m1m2vYYId9pDO3lh5DhQCeefTvVvxDYQ6Trr6baTJqbwxh2uIDlfm5P41bmuVKxwtK9t9v6X5kuq+GrXT4BdtcbwDtZmbG4+oxWaYhbQ7pI5DkYEpJ2896W7DSI/mytKsADCCTjaP61Yu/EEV1YJY+S0ShfvOMBlqZKOulitL6vUQaPo32EzPevNcscCLccn3+lUF0I6SzXc0a3MR/1Rz/qz711HhDTI3kk1C5t1uGKfKgwoPYD6d6p+Lbh49PuWCxJuG0RgnGfatJUly3tYyi7v0KbDTbiOzgtriVbpsvO55H+6BW/peg2riNZWSKY8mIDLMvvnpXI+GbVhp4chZLhnHPoPSvQdJsLy6WSYGCORB5ZMrBST6e9GGgrXaNsXVbSexzut+HoBM89k9usxA8vGCD6hhXPsWaOZVRo54/kkjHG0+o9q09eYaWQbciZxKVKg8n1IrOvIHhtGv7jJnuJNqqpOFJHGazrKN9Nx4eU43vt1IhqrwRJbyK+Orbl9KVL94S9zbRZspCN5Vhw3cj0rptHtUazSWeNpM8Y2gnOOprB1iw+wOL21RNu795B0jlB/kal4eUEpRZt9b5m41Nbdun53LzeJXRoIoVkVtwXeyYwPTOO9P8AH5ku7ITruWKIqj56Op/u1mADVbJxCx24wqH+HHbPqKp3sOrXaRWouEfToPlYk5bNT9YbTUmKrgpu0qcbp9vM7nS4VbTrc+bHFlB8jKMiiuamBaQku3QDlvaiuV4hX3/E+gjh5qK906bTb6SxlQWpHnRcmRUAA9wfWrVqVinuJ7iYtdFt53ctz61R0/SoNQiiN3dSwedkwtGuVBHTfVDTGUJM8jLJcligw2A3OME+la3qQ5XPrsZuVCrKapLWO/8Akbl3qkDXUUNy0cUbLuVCMBj61ctLcSXHlXIDRFcqCMDGOufWqcNhZ219DNqsUF3GoAlUDd5YP933Fbii3gvBCJA0MnzxytyAvYfWrhv7zMK2sfdVrFW3txp8W24m9fL9SPTNcjNdGS8li062MgB/esOEU9s10niIiJyEuEllZuMHO0fTsazfBccEzaktzH9rnSbDJ0GPXHejkjUmqfYxlXqYeDrPdlS2lScFAjQSoMssnr7GqivLNNjamzHIz1961teht7XXVtYnDRqhYoeccdKzY2j2BFQpkk4A7VzVoqDsejhK88RFO/6EwghF7ZxTuht5WAeMnGff866e8jiZRHdOqqjZVi2MjtXGahmaJdsfGeCeox3FW9H8PX/iW9itYXlu+mZZGwkQ966MNiVFOKjds8/NcE5y9o5JRS6l27vNPtmaCws/tdw5yI1Xdg1t2vgTX9aS3m1+WOyhLBo7aPlwPUjtXo3hHwXY+HW3Jma6C7fPYcZ9V9K6cQ29tNGzMTK/BJ5LV0u7+L7kfN1MXGDtR+9/1ocLafDnR4CoFrJLMOTJI2d34Vj+KvAVtaadc3umQtBPAhkcxnO8fSvXWGQATzmmzRiaCWJ1DrJGyEHpgjFF01ytaGMMZWjNVOZ3Pk7R/EGn3zsp/d3Cg85wHNb1nJbiwjkaEP5rgIX5Zz/dB7CvPfG3h+88HeMJrK4CKTIZoSvKlCeBn6V2VjeyiXSZWCNbyH5CB9w1jRbi1B6JHv08R9ZhOpNXkv16lu4XV45pomFvsYH5VOdo9KzNRaSaCSO9hlgmgI2zqOPavUvDy2NxaT2N5biSblmO3mRfUH1FM1Lw9YeT5tvLLARwEzuz74rvdG+qOGWISbhO55REJtQUG51FbwW43tbxnA+oq14Fu7GFLzesUMnmk7ZB29K6PWPA1wsPmWqRm7QGaORPlbjnn1+led72vb1WtLGN75s+cr8ISOpx71zyTpyuxXTXuaryNq5ltr3xVsTAttu0HGVY9h+FdXr3h+1js5Bh5YY9quJOpz/EvtXDtO11EBp9u4mtfndVHyof7tSX/iDVTpSx+YfJUAMzHKj6fSmppJ3KveWr/wCCUYtZudIVLOFftLFjsjVvmVfQ1JNbazeyLPeiEo4+WIfwfX3rb8FaArg3spfdw1xMg3EqTgKB2rtTHHpcF159nDFasuI0zlnz0/GrjSc4+89DBS5Wl+B5Vp0lyk832VNuwjzIG4wfUGpdW1W7ldRlJp2+VVJ3ED+lF8iy6u8sDnyOFbaecgdK2vDWiR35eZ5YrdM7pXz0XsB9axhGTlyJnTNtU+Y5u2sdQv5RcXMqpMeMjnAHYCtPUtK1WOJgpkkLrlY5UwWI54r0LNjbaZeR2tqlk0Lf62U5Ew7baym1HZaXCXU5eJgCrSdUxzxW3sYrqctNuWljG8MazG2n7XZllxtMZOGRuhzWX4quopdPj02wm8yQMZHJPT6ms241S3aa78uzWWSVupHOMdfrVW1M8MbzmJRCnzFCcFvqKwnWbhyx1OqNOLn+8e+5v6Pbm001CCS0nzMxHAz2xVz7PJMszIgi34DOOB+FXdI2arZW93CSpxkpTDC1xlGnTyypVkIxg+ue1cco6XZ9LS5dFDbSxkNZmNihAkI/iLnmiqMviGK2laGMzTLGdokVMhvoaKjXsZOvhutRf18jprS+vbG3nt7SVRbN0DD7oPXFR21ukMIjiYYzkE/zq/4j0S60PXJ9JviHZWzG448xOzD261CsQRTwqhed39KxqyqOyn0PTwMcPKLq0V8Wv3kt3fqIliLruZcF8ctg+lWHunDKWlLSBR+ArLMiFgViJA7kdqq6vO9uBIGGJMKqdwPeqU5t3JrezgvInfWLW11SQeS085OBg8KT6epqyiSDVoXid9Hlx8/2hSA/pmuy+H3hu30/TF1CVIbjU7g74y67hCvb/gRqt49095EtbnU4nDuxWQ5B3ehrujh5Rjz317HzdXMI1ajotXW1zjrqOS3v5ZTN587/ACu45/Cpnia2hSSRs7hwQMZqvE1yLRLq5tnW1ZjG06jhiOgrQsIZ9d1q1sLJBNK6bVjP8Pq59gK5Jpt26s9ShWhShfRJC6Pp8+t6xZ2Vmn7yY7c/3V7k+1e+6VotnoVlDp2nRKABmSXu7etQ+DvCdl4Xt9ttie9cYluj/F7L7V0QX5s7eRzXTQh7NeZ8tm+ZvGTtDSC/HzKjJmFUkDEdMA9DT1SQsfNKkj7pA6CpmDByAflz+VNypOe/vWl2eSh2DnkjJ/WlOCMA54qGZysZIG5l5x0zUF9qEOn2DXl1IscIXcWb+VUk3sO2p5r8eLHTLzRoZL63Rmj4WRR84PsfSvL9K0t5vD0dqZhHKSHtnY4AP9010ni7Xf8AhK9cUySPFpdvzkDJP4VSXVrVWjhsIGNv/wA9JF/PFTK0pXPpcDT9hT5ZaN+fQkTXktbqCG9drbU4cEqThXA64PvXXJrWl6hLGJ5FtXY42yH5V+p6c1xGuT6ZLbb7+a2fJ+Q53OPbA5rnW0WwvY1ntZJ5bad9pKPwn1B5rpVeUfMyr4dT0W/rqegeNPFNvoUavp19beecr9lgcSFiRjOR0FcP4f0DUykGpaa0R1DeWMBOfMz2A9a2dK8LafpF7BPaWpadT1uB97jqM11c89trIt4YrGLTbyDO65jfaJfZeaznJzkpMinQcI2Z5mrat4cfUxLbB5p2MsgC4C57H0qjpFpc3VpKz2SspyfnORg/yr0bWtOS+0aYxl55/LaG4Dtyp7McdRXntvPd6fjT728htQ68TMcgj1xUpr7W3QKsfZv3Xp1JtJ1+60u3lw0kcSr5MrRyD5ueODUmlpqviK9SOO8S3Gdu3dlnB9T0HFTeH9L0+41x9P1CYW8TDMUj87v9r05PrTNS0vTYLwCD7TFIpKsYnGW9Ce35VrFSaTZjL3W0VNYtTol0thHJvyxAKnO1u5B796ZDejSk+WQvBL9wqwD57giqn9nNc67AVnkENsu6TzDnce2DWtqmnymxjvJLfYksvkRSbeh71zSk1N8q1O+jTcqPPJ8qW3n30KFz4qEkCRLHNLIM4Epwq+9UJY9Qv7mF7kFY5D8vPAHtXcWekWCaZI0piTYmxBjLzE9B7VykksFrdOsUjqIGwmTuwMdOPetJ05KymzmVSO/Y2YdDazgxAsPmxoXKty8i1gy6fJNPbRCUg3JJY5+6v+eK6pNbd7YPBYt9pCZEpIyRis7QbZbyT7bqNzHbyzMdgkIAAHGK2qpKNokUY+1naX9f8OblhZva2CwQxFIlUAMp4+ue9ZPi6QQ+Hpo0ZELIA204Yk+laeleI9Pvb86JaSOlzDlGVxw2Ou2svxbag6lp11eWkk9lGSJooOWUdiB3rksraHt1a16clDtbT7vwKumJCmn26x3MIQIMAgZorjrzSJJ7uWWxhuVtmYmMNkED3FFWpxWlvxPG9tX6Q/r7j6W+Otrm50u8iC+YD5IYdcHtXm8lq7WqvIdvzdB3r0747J5Gm6dczHahuFjBBwCff0ryW91r7DYZa3G0tkbzkZ7ba5sRGPO/NHp5JiZRwivtFu/poWJt8crRlh5mBgegrn9ZEsd7DuXGfmIPoDzzXVeHvCuv+JcXywpp1ocf6TdnHPqBXU3vwjvr5Y3fVo5WQfLuhG1vxqYUpJXsPG5pQqJw5vzLvhrWLRtOgSFhG5UeUFOSSKyPiHdWwsZES/FzfmUSeSGzsA6rj3rn9V8B+JdF1BmtkmRohvVrVvMX69qwIrAWN09/qaSu0pP+kFTsLe57GuqeJk1ax5dHDUpVOdTVn5/0zu/AbJr3h2/0edGikhPmxxseDnoR+NanwOS0jXxDJKgbXInEBbpiLOMj8a5Twvrlto/iOCe7VorS4Q2zy7v9UW+6/v1rc1WVvBHjGy1m0iZrK7Qw3iA8EdQw/DBpRaajN9NGPFxlepQWz1X9fie6wKI40i3cBcAjpUjEFcDkD9az9E1G11G1iltZVZWQEAHtir4PscDim48rszwWmhrHA9D3pjNuOTjIonkSJC8hAA7muB8V+OrLS18u1fzrgt8ypyT9apR67I0p05VHyxV2dJ4i1yy0vTZprqRfKA5Abk/SvFPFHiRtfmEcQmSxT5Uyx+c+4qjrGp3OuXDS38iKUP7uIcKoJ9O5pgngFuhjZVmt23MXHD8dDUe0Unyp6fme9QwKw0eeWsvyNXSrK202S2e/RmjcZlXJAPpj2p3iKa21G4jXTLf7PGnCojcE+prJ1DWrvxGttawWM88seFjSJPT/AD1rp9O+HGtXsiTapcRadb4BMKjL/wD1q6VUVrRRy1Gk71HqcRqfh+9vLqOaGLTrN1BUzOc4/AV1Pw38Ppp+ppaztDcBwZTngM/09K6F/hdGbc+VqlwshbgsOD+tcTrVjrvgHVrW+upGuI1kyk5PbuPpipm38TRND2PM+R6s9c1+xstS05mvpRAIBkzjC+WMV5BZO4klt0Rp7ISlkMhw788FPSu41e+Tx1ZJaaaHigAE1xI/CZxwB61mXHh/V7eyjuLdLa7itx80MbfvAPVa55vmfNHY9OhD2K5KvXo+g2dLh442hKiSJcFY1JLg9mHc15t4j8OC+vzMsbBmPMb5/rXpWjaldWV7DcaQ6CYx8NKuQnqH96r3UE7TmW+ljurhj5jsighCeuPaqvfUzqU41G6U9lt3PPL61tbkqw81GgXa8jnBPH3VArLtbKe9DtYJc7QdrFzyOewr0ufQrSZHjMiJHuMpOOSTU1pa2ljfxxwrJHOse9WAyH9/rWknZ9jKOG5tZO/kc1beG5dP09oriOaOcr5qpKcbh6n2rNez1O90+TGoO88SLOLUr8gT+8p6Z/Wuv177dqDu97PPNOkexpDwSn09q8+n1G+gj/sy1nlfTzJsWXHKt3UGs1aL1R0V+b2UUpL0JNMkvLm4ntbp3WWI/MuOSp6H2q/4bttPlvBHcfu41LCRmPzFuw+hqO1024h+1LO0sf2hQrSyH5xjsDWHrvnwTiQXG6RVA82JAqsR2PvUwxKUrbir4KpSoKpNfO522vXcEenvFbiMzucRLH1Ttt981laHYWi6I8uqgy3Yk2tGxH7sfQ9MGsDSr+OG6a6ZHvrkAbkLbdh9quSpJqGos/kNHLIQTE7nLj0962libvmsc9LDcySUtyTwnocc/id79rhvssUjMo6M3pz713klwZ7iVCyrKvRV4wvrmsFV1XTLcfatBuo7UruJxjavYg1R8WnyfDqz2Ux3yMqyuD86p/hWSdkehSVOjTbjst7HUq+4AxSQbO27k0V49DPMIlCS3ZXsVlOKKLvsYLM4ef8AXyPoj9prxFZ/2PaeH45EkuHkW4nwc7VXkD61B8JvATC3sdT8QobzUZU86C2lGY7VOzMP73HFeVaHBe+JPFsFteZnuJpVLyy85A/pX15ZWiWdusUZG4KAzY64FOnBSvUfyPDrSeHgqUHvv5+v6CxafAsDpOiytJ/rGb+P/wCtUpUIFSIbVHHHYU8HPGc/yqKcb4XQSMjEYDDqDVyucSdyCaRYQ8owGUZ3dSK5LXrOazX+07eCG4ikGb2x25inU9Wx2auvCkDBO5gOWx1qGcFYXLMNv3vmHGPSs79y4ycXoeT+LvBVnd6Cmo6BZO0DruMMB3BVPfHbBzXn4hv79oLPUNV87Tbf7kbfeBxjGe3pX0NZaLbvpSxRyT2Z3l4pIW5XP6Ee1eKa5YTaN4nvLbU0Xz0bcrqPllUn7361FT3NVse/l04Yt+yqPVbd7diPQtb1Pw9PjTT5tmpwIXb7p9q7KL4sOI2+0WUqyKD0GQT9a4q8e3gV5CVFufvbuNvvTdB8O3viiAXksv8AZ+jRE7GZT5k/qVHp71UZVF7sdTTFUcL8dRW/Uta98RdW1FJY4swxyHhickD2rmrKO7vpS0aSSNJxtVdxc+tev6D4J8Ppa5XTpZ2U5864Ocn6V2elGFAsMNnDEq8ZWMAUOjOX8R/I41mFKirYeJ5f4f8AhrJOUn8Q3EkCyYMdtH/rMf7XpXYL4F0GyZfL02OYA8NMd2TXWYIl+WMjB5Zv4qinnW2hkkeNpFj52Ly34VrCEY6JHBVxtaq7uQy0sBYwkafa20APIWFNp/OhLreXWcFWHD7uM1atrkTW0cxBQPyo6HH+NZPiFZo7X7Sp4BAwo5/GtIavlOa93qWzdJIoZTgDgfSuT8T2s+tWGo2eq2NutlHGWt7hXyXb0K9q2Y5XeON8AdhnjNcJ8UPEzWES6VYEvdy/6zn7q+9aSiktWa0U5TViL4DajHKNS0O6QMYzldwwSPSvWWsLd0xHEiADAIHSvm/wfeahpRmutGsZ7rym81rtOoPcY7jrXu3gbxXb+KtHe5hIFzC22dFGMH1x2rmS0OvFqcWpqXa/qc94q0NrK8k1GxjjZ2GLiAcbx/eHvXLrp8U6uEuHF5J1ijGcH0A7mvW9VshdwEOmSVIbb1+leI3AfS9TlilEkMsEhTfGfm3diKlo7sFXVSm02+ZG2NK1nTdLhfVLZ/sq8Suy/Oc9D9Pap751ayh+ztJK6EHA4O30+lc/Dq0t1Ekl5fzXCocnc3Ct2B9a2oYN1s0jfMzryo52jrWyj0CMnZOW9zjPFHiONr46fc3HkPJ/y1RceT2GfasazMbWttoGrRxW1zAzSC4LbVmz0bdSeJdAim+1azPqIhjQYlTYd0uDwq1W1HxK2p2MMeoaSIViUKhUhmUdunNTFtPUmq903ZdP6/zLepRG1le3bUpNS3rkNG+R9KiayhM8WBGUx8u/kg46VgT+Q93Fa2Nz5dswyZN3LHuK2NG8KR6jqkcJuGZjyPMY8Ducd6qD5vhRz1ZSUrPoZOr21ndxSQ2EAe6c4Jh/5Z+5PpWlJcXMcVrp3k/ar2OMATb9u0D3rafw9poeWLTrhw6ZDoEK7iO3NYWnCS08TLDc/wCkRyRnYXPzD2/CidJ8y5tF5Do1FCL5V7zt/X/BOrTx54rexWykEdxbxL5akDLgehPeue06/g8xopoT5jgqYX43DvivQfDKW48POG+R0clyRyR25rm/E9kt7CJJ4UV3BxIow/8Ask+9XUwrsmma0ca4S5baGbH4Q0x0DfY503c7VmwB+lFc3DqVykYWWGaZ14Mgb71FcntEuh3KOHkr8v4f8A7v4XXaf8LEsWucOCcLGOijtX1D1kJHX+lfMWnJbaF8U7UxIqRrN5ZyckFvavpuKQPErqQQwyCK6Ixahbs2j5/MNakZb3Q8/LycL61AE2SSMzblboKdKd0GAN7HkZ9aZ5hO1mHOOR6GofmcaAn2OelBUN8p+6Rhh1/Ck3E9cAVFN9rE0BtjGYv+Wu7rj2rNqxaXMyixNrrlvbJKyxTxnYn8Kkc1wfxut0W60a7kA3sGibHcDJ6/Wut8aSfYbe01dWwbGTey93Q8EVxvxxumm0TQ721y9nIWlDgAgEqSBSrawud2XNxxEGjh/C2if8JNc3F3fB10PTm3SIvJuJByEr2nQBHqdjFe/YzBZypiKJhtKY7Y7CsL4X6L9k8JaWGZTbSs11IuOWcngn8DXfFgzZH59APwqo+5FJGeLryrVXJsiCrHEIuFj27R9KjsLSGzg8qANs3E5Jyc1M3PDYIpEcL8p/CqVzkuSnPA29epqKZQfn/jXoakJ7np6elQysShAwD2zTjuJkM0jzWoeKMM6tuVBxk1T1+dRYotzKkJcgtk4AxWhErKiqSGbGcgYAryH41XTzXdjEzOsSthh0DVafLrY1oU3Umol/xP41t7GL7Poai6vM7fMJ+RK4A6fcz/AGjUNSmMc04K+afm5PQY64qWxikvIo1tcQwuSgAUbyR3+nvU9/4WlWNppHnjbI+eOXepPqQTWkozmrnqUVTpOyGeHPF1vpuj/wBnX9nPBPbuSRCOJjjjNdZ8EFuZNS1e+8vyLSbLOmMZJ5A+tcDpk7oZZLkoZUzEy+vo2TXqfwpu1R59PDKfNTzx65HX69ax5pS36FYmlGFFuLvc9BnkTYFL4kfoueTXhXxUsbiHXr9rVmVgolC553Ht+le2XdpHLNHPg+ehypBPNeX+NbOTXfFOoW9lBJNOCqhlP3cdaUo32OTBNXavpbU8/wDB80F1bTyapIkMSDccgkMw7Aetdba6hFJIVtSyh495kY/eA7YFcndw2umnyooHN3GTmF/u57kmqtvLDJicSzBZD8yqQDGR6e1TCU+a2lj1Z+zpU1e7m9+iXl/wTT1rTrXXdMuYbUtazyEyKjnOWHp7Vxgi1ONop7qCN1Vcb0cZI+ldtBdDPmXhiDJzE+cEjrkVlawkOpI17pQTaW+4D0z1NW7J3W5nUp+1ipO5yN0LGW0lZYnF0pJRFUgg1q6d/aNpYWlzLOomI3eWT8yemCKm+zNFJmWRIXVdys2dsi9xnrVfXrxprY3kxt085gkccJ+bjuBUu6dzmjCnC95P7jVl8dXblzewJuVcecijcTj2rnYLuO8ke7nZopT/AKps8r7n60aZo17qmTEkm3IDRqM4+p6VdvfCuo2EjERuGAyNygqR6ZFOTqyXM9ghyqXKv0L1r4rWybaylmI2sCflJ9R61Fq/iO71L9xp1qVLEFZVyQh7nmqGnJbSACWDfOp2mI8FfU+lbMcyW2fscBfIIG3gD60nXqWtc6qeHhUfM3/mWrLQ7FbWISs5kx8xB6nvRTI0j2DfLKG7hRxRWXJc9VVYxVuUYr3k+pXGuXQ3XXmKyFlwWx6ivpPwZr8GraPbzwAGOcBkAPQgYI/Svn7V7qXT7ae7hgE3yAENypJ/pWl4S1jUPBs0Uuq+V/ZV3tmKI2TET/Gg9PUV005O7U9n+f8AwTwMwoQcUobo+kS3z7ONxGce1AH3sDp696zNN1i01GyhukmVoZgPLmX7r/jWg2BL15xjrwKJRtueLsxCXU5wCR096RtsigEHn5vQikDfMcH6+1QXciKoZztZeQQahLoO5U8SiGXSriOYAwmJt5P3QMV4hqup3mrfCeJYgjwaddSRRoDlphgnP0A/lXpvjrxNa6V4curiZQ004MEEJ6uT7V41a2Jh8MwWV7C5zK0xOcFWYH5f1qKui5WelgKUpS5ke5fDdEHgbR2RnMTw5O45INdMjeg6dDXC/B67Nx4IhgnBD2k7R4HYEkjNdyWBIGPoKascdaLhNxfQU8cA5FQ3EZmiMattJHB6FT61Ke+T+FJnK4Uc1S01MSlp0lx5JjvcJMh27uzj1q3LlkIxkmqGsR7o0dFYvF8wXPWn2dwbiPJYFhjIHb61rvqImtnPzK33lP514d8WNQN94rmjgmWWK2jGSORGe4r2W/k+ymScnhFJ2D+Kvn/U76LUdYv70RhLW4bywi8EqO+fWpqaJeZ35fFubl2TOm8K2yJZvMcYlXy1dumP6VY8VarbabZCOyeAzMNmxTkqMd64J7y8jtl+z3kkVugO5n4H/wBetDwt4L8QeMCLxwLPTAcfaJRgv/uj+ta/WE42gjWrTUJ81R/1+pgR3qLMiSqHkLEiFRvLk9Bj1rrtKn8T6eEvrDwrqKxJjDsPmX1A56V6Z4U8H6d4XeVLC1U3bLn7XN8zt9PStmXT5pLiOcXd3FIuNyh/lk+orGEOrepnVx7ekFojzm4+Ll/DZMl3od1ZTrkSXTwkqnviq/hjxLe6V9suoPKvft3zi56gf7Q/wr1Sa1H2ou8jTWroVe2kGVYGvCNb0m88M63rmgWfyWd8j3Ni5P3VI5VaJaO9ww1WM24OKVylqF8E1BiInvLidyQxwQc9eK526sNWdridLFl8lvn24/AYq9pt/p3hy3hku9IfU5pEy6tNwhzg4GODXQ6f8RPDForrpnhhY5ZOZDPJvzx0HFZe51djtqVqtR8qX9fM4nWJTf6dDGJJHvYFLNFjbxn7ufpVi0Wxhso7/QL7bIyYktZx8qN3GK6uSz8NeKLeW+0OOTStSAJe2dv3bN1+U+vtXG3WlwXUCui+XdDqyDBB9DVK8dd7kRi6jvbVb/8AAH3F/Fqb266grRFZljvEVuI0P8S+xrq4/DPhh91x9ivbeSyOSGctHIOxDehrgItNlt3uJZWklMibZM9l9a0dF8Q6vo1vDAjLd2G7KhhuaP2rWDSfvLQ5akpSleT1PSo2uC4XT7cJabQfLiGB+JqYTQW0ZF3LI0ag+fu756AeuK4qP4hTLE0cccTlm5Xys7T9aztW1PVdeaQfaIUMa8KvfvgelbTxMEtApUJTlpr6EPikwWV7b3EEbE3WVCLyzehxRZzysRBJM0cgG4q4wWHt9PSt7wPpippc2s6lF9su0O2AMc+Wvc4pPF8Md5oEl8kSxXMMo8krH5e71yK55UG4+0OqGIam49yOOeZo1K2kkgx95TwaKILKMwxlriRGKglVTgHFFTyeR6Sqt68z/r5CX5aVmkTE9s2VaMHjjuKriGWa2TEcjsisuGbcFAGcCunvtFUWcgh3b1k+RU6CM9296zrL7TCpsYIwYv4QxHJ789aTi4tpkTgqlmtzVsf7R8NeF9PvPD+uxXS3Tn7TpU3+rQ+uOore8M/FWKS4ex1Nxps5wkZf5oi317CuKTT3UB53a3AY7lI4HHGanudOht9Pm/cwXO+JnQvgYPf9aUZThqtjjng4zVnue0t4rgtbbz55ITGnzSSxyhkYetcQfF2veL9UksvA9vFLHET5l3dHESD2Pc1lfC/4d+Htd8N2+sX8t1ezOxEsCzERxMOiEZr2fSrOx0y0jt9PtY7WBBgRxrgfj61tzSlrt6Hjy5IXSR5BqXw28TSS/wBpanrdpe6kOUt5FOwk/wAK84FY0d/Fq9uvnRzRXNsTFcQDqrDv9K+gJjtZMoHJcAdOOetfPVz/AKV4x8Sy2aFoftO3K8ZPGRXPUVj1MsqynJwex1nwt1drPxfPp10VWyv0HlEHjzAOPxwK9hGQ55AHQ59a+erqGNrRIom8jVEcS22G/wBWR0z9a9Q8E+NovEESWWpBLbX4hiaEsAs+P4kPv6UU2mrIjM8PNVPa20Z25I7Y56ZpksfmxyRMfkkUq/rg+lRqWkd0ChSOQP4vxpXl2Mi8AnrntWlmeUMW3CWYtosiNV2ISeQPrWOJZbVlhZg23uBgke9bksqovUEn06VxHjLxTZ6RDJIdrXABVVP8R9BW1JW32GouTsjnvit4mkjtra2sSM3B2n5sMn4V5/8AJa6fu5eMnAjB5dvQD1qneXk+sam1zcQvLqE7AW8MYJJ9vb3NepeBfBkFpqMdzrl3Bd6v5JKWqDKW49uxasZXqS02R60JwwlKz1k+hX8B+AhKsOq+KQHTO+303OVT0L+/tXo2jO8rylojGkR8pVHCEdeBUpsN0kkgkb5gPlPTI71cTC8L2rSNo6I8mrUlUfM2IVO0rwWOefSoreIQqFV2ZM8Bj0qaQlF4xk9KhwhfzGB3duaERcGH3+MKR1FecfFiw87QbXWkQh9MnUsM8shOCM+nFd5c3HlxOsrjeOQAD0rM12Nbvwxf2siAmaBlx6k9Kpx90qnK00z5z1VY00y8D5gkDB13fxK3TH51wLsGOHfGP7vUV6Zptt9vRLe52zRzI0J39UZckVwes2D2F0ySDoSFIHUZrzasbSufQyTlSVtkQ2uovDFLEGIVgNxzhsVuWuu2t7KsTRNAxXb5inggdyPWuXKb3O8gMBz70kPySpIf4GzipjLldyHUnsdRq0E0rb4LgpcxgBHjOUI/umoZUkMMbMiRXLE+bHG2QTj71dLYrD4u04GwgWx1i2QkBP8AV3KDtz/FWBe2rIPsssTx3jNiPsd54CmuyEra7o5cRSVS7WjJLC4jlh+ytEsVwn3TjCy9/mrStVBCCR/s7ZyAo4f8aw5YprG+Ntf27xXcICyR4IYEj3roIzFfadA6LNFdxkouBlJaUn2NcLDmVp7ogtb3UNH1BhY3CqrMXwT8qg1NqF/qGtM8d9IfL3Btqcb/AH+lJDp729s0t6i/L8u5Tng1RvtUFvaShCRCOBxyPpUc8krdD0HSpr3pHQJcpsXes4YDBCoSKK5S38VayYUNuFMWPlyO1FUqj7C+s0f5n93/AATutM1tb7V991eG0UIWZkAKufTFWXubaKRjIrTPv8wsox8vYVjax4Sv9It0uY0EmSdrIPlOPas4DVtSjMVtbSiQhmkcZOOMc1U+aLtLcKVa8eaOq8jpbiOK5nBSSaMZ8wLM+SR6nnGKswSwbAsyea6ZIUH5X9wf6VymmXAMEAlzcvECkoY/MDnt7VpWd7DazTrJbH7NJglAfucdRURkovyZrJurFX3NnQW1Hwva3vinQriL+z/NVL7SpWx5hPdfevWPD/jvQNZhj8i9SK4x88FwwVo29PSvApryKW4NvI5aJ+kajj2z71dh0S2vI8PAhcDiR/vYqqc7aWujy6+BdWTknZnrvxC8e2OjWxg0+aK71V1xCkRyEPdmIry7SJbmzswY0DTXDmSVs9STyahi0iG23SW67V/vEdfas7Vbm6uNWttPtkMcs2DsXj5frU1JuTVkd2Ew0MJTlKT1NW71mw0m8eJ0a41CUgny/nCD3rOvL6O5vn80SQyIAyXABVkPrkdq0VNv4Mea3hsY7uW5IdnkO54z6VQ1bxDb31zkWwhZlw0S8j8u1V7NJWbsYTxM5SvpY3tJ8b61Dpwt3mj1K2Qgs4crKPQbup/Gti6+Kd+Yv9F0qRF24O9t2TXD6ZpolmuLlkIW4xiOPhU9627aOGwSVJFYhR1I3BgamNSonvp5lfU6E4qUo2k+i2LM/jrxBqkSpZrFYr/dY5OfWsTSLDUfE2sGDTIpdTvgT5t1ISIYD/L8qseH9HPjLxe+nxs9lo9kga8lXh5M9FB7V7v4ftbLRrI2Gm20dpYLjy1Tqx9WPc1a56mszgxFWnQ9ygtVu/8AI5nwl4KHhN/7RnnOoaoy7ZWCgKin+5XWpayRXkMtjHbJCctMSv7xs9NpqRwZdyDcq/3h1J9KYomMUjxy5Z2GzIA2ev1q/I82cnJ3bNIuuccgnqKAylTt6Zqoz7dqMW3Y+9jrUscilQCwzVWvqZ7Ez88NgelV5AQQVXLL0B7U8uGIwRnsaq3Vx5Q6Fh3IFXHyEVGcvfGNiCBjK1X1mcKyRLwjAqT65plvdQXEoi37n3HPY1Q1sRW6qZpCYIuSDyfzreyi0OOrPF9JCWdzJKoOLbUMfNyDkjrWp4q0uynuLsXETMznMIjHrzn8zWTZOLqPVWhbaGkaQAjjIPFd3Z2TX5trraoiltxhgeBgc5964ZQ5lax9HQqxpp8z6Hi934Xubdw4KyjPKjrjtVCTQb4mQQ2zkLyPWvbrvT4XkO5Ebjhh6dqzxaqGby1xIuM5rmdGzOhRpzXY4HwhaXlndrcKwC2xDtG5K49a6D4lQ2d1cw69bJNaXckgW6t3YZR8Dayj8ua1TpcgeWVz5iMQyxsgJ+mfSj4mWEV3DomtxqGlni8iYkY+73x7f0ranG0WjixMfeiuhiav4yvNS0ZdOv7S0muDhTesmJgOg3ED0q7ayzG3tIbgwL5K7YQoAAHcse5rl4hbB3SNHk83gM59O9aVhuaMxXAUQ4AVD/MfjTTvqx0k4aJ6F/ULVrqJYBMIiDkIBy3vXKanpFxNmO4V8kfIyjqPeu4uBAtqQ4Ie2wWkLfcHbnvWL4vvNVWyRLG2WVhhy8fVl9TSnbc3qNKF2vU4VFvbVfJQptTgZODRWtFcoY1M9viU/eDR85orPm8zlVNW/wCCfTzTQSyIIdjKhEe9l6j0xWU1zc2l7LYpbQW1k8brLMoAY7hj8agvNSOmlkSFJJZDu8lTyB6068tZb1IrqZI8kgne3K177Skj5+EuU8k1fwNdaLKL03CT2krn99BJkjngsO1ZN7azQoSZ2nRf4k6j6+or2DUdOTz1tbmTKuCyFBxJkfdIri9Q8OzaYJms2V4YxmaEt8yr6ivMqYX2a93Y92hi1V0lu/l/TOYspFkheJGVJNgYqOjfQ10GnvPBa+Xcts2r/qxyCPWuYkiezvNrMFtCQ4APJB9K6K3lthHEWmeUbsKuMjPqTXLFcrselGpzpN9PxNTU5yBH5O0KibTnhRkelc5efbIr6G9sJU+0KNu9+cd8it25nE0piliVo/ukdgB6msO0jvNa1ZNL0WINI7YXeeIl6FmPpSm3zK25bnT9nJ1HZFN9SuYdQkN3Obu8uP4lGcj0FdFpngHxPrJF7BZQ2cEnCm5fa2P92vU/CXgjSvDqo6Qpd6iOZLqUZ5/2fQV1e4tksPm9qfslLWTueNUzJxXLRVl+J46fhd4kj+SDUrIZ7hwAKzdU8M+KdGAa+s3urKLq1sfMI9zXu4HG0nGaRdyHOTkjGO1W6UehlDMayerufNnhzxFqXhC6vX0+CO6imIaeKRcO4znkeor13wx4x07xckKaRcxW9wmGks7kbXDd8HuOtaPinwlpGvo0l3bBb1RhLmL5WU+/rXjHivwnqPhe4jkuCDADmDUrc4KH/bpxnKn8WqG/ZYh+57r7H0Jpt29y0wuoBC0TZjYn74+lJcGOG+WdkYKqbSeoB7cV5L4Q+Ikr3dvpXiqbEjALHfJ91x23V6jPfzRm2V4xJayYxIhDBvQ5rdWkrxOKpTlB2kjWDZ27yu4DOaimt45ZS5JR8dQcVif2mI5vKkdyoON4GQD2Bpl4+sM7ODGI15JJwGHqPehRaZnY6KPaFAXt0qnqUzQxbUPzN3rmtQ1e5t1iaMyB2wMHuPQ+lQ3GvPISqrgA4dPvYPqPUVvGn1FqTq5juo5A25AdxA5J/GqnxUuEtfC7yCXZJOREoHU561LBC7NFvdAXcEspxx9K4b4j64ut+IrSwsH32Gnt+8cdHf2+lOvKysjfDw5p3eyMWxiSG1EasphIxj/ax3962tN1G8to7LT5IdtpHuLkDktzgn2rI4tI2RUykpOWPTkda3vDtz5nh+6Z38xhMLcEjqMZFcb2semtKkUbEX+kqZAcM3GMYxUEkLL84IOB09T9asJENqEozFBtBHA59aZPKYcFx5aJwAaj1Otu17MrgHeCkbFyuMN61z3xDvEt77TtCt2aeezjaW5/uguMbRXUCxg/sqTWb+6ktLK2O54kbmUjov4+leZS6n57X+o3hAu7ubeN/VUHRfqQKcnZWZzSn7SVo7L8zOmYLM8yfJHjYU/u49K1LS2eWOKXypJcKSVHO0ep9BXOnN3cNI5VCzZzuxgZ6Vdtb28tWnWOeWKCX5HjiYHeB2zWV1uzWLfwxOht7oSxOrxoqNxhTnI9/epmaGGFlRTEzAHJPG30rNtWSS3Esky+VEAWjHUe1WfMDwO7hDaSDCuDyD6GqTudCdtwkKK5CKhXsRRSQy7IlVQWAHBx1oqDqU4vW7PXovD8CXbXfnNI5bIkPLAemPSr88a25woLM/Iz0FWBboLTZASr9GOc5qYKhRoJTuKr6c17LqdD4ReZzE1xAbGG7uYGWVZMLz0IOM1i64iXaz3FvH/pROCxbhvp61tXsSTLLbOQsRUhe5B9a52H7ZZaBcJLEqxLuXc/3iOzLTWq1N6bs1bc821zYNUtIAGLoSpB+vStVEeGddioYV4dT1Nc7ZsZ/EgW5kYqvJkzz9K6YXMEkyBFBuB823d09q8e93zH0kJaNFzWLp7HRpHV0eLjGB2713nwk8PDS/DS6jMgTUb1vML9xH2FebeMHRtMWAB0csNwxhRntXvGlx+Vp9mvZbeMDH+6K0irts8/H1PdjH5mggRFOMhmOTUoY55IP86rLJnoak3cng4p67HmXTJS/GCSRRuJODnjnNQ5PmZz8o7etOL5OV+nNFhpjuCfmwRWbq2nQahZywXCCSGRSrq3II+lX8jjjimjBYnkg9BQtBqR87+NvDD+H5TBMjvpc7f6PL3iPYMak8K+ONQ8Kothqs8txYhwWi6lk9VJ6V7tr+mQazpF1p90iPHMhHzDo3Y185to8cl7eaLq4cXVm2EcHr6HNZtunK8Op6dFxxUHCfxLbzPYNU8Q+G4bVLy/1EQ2sih44YW3Svn1ArDuPijAYPLg0y/ngHCmUhSR24rzS30uzs5zI0RkuAPlZuefWrpuTG7R3Ugebrv7EYq3Xk/IqGBX2tTv9O+I+hHfBrenXlp54xuYhh+ldEbnQzZJc6Vf2zZG3DMAcV85+INYjumSGLLGM4LdabDeCIBjhUHP4044qS8zF4ak5WUj1vxl4pGw6RYnypj/AK+YH7q99tc/E6WdnEjTiO23ZDEDJPr6msfRZm1BpNSuFHmuPLhB/ix3NSW1lPfayfJU3E8bYVMZjX1NXzOXvPqaqMYx5Y+v/BNwLFJpTtBcCSINu3g7sN6f/Wra8FXVv9n1u0ciNgq3Kgjg4wCRXC21u+ka49nIrRJdZ3Rn5VEg5BFa2lXJmnkt2UmSNSF2DknPKn271N9SHLReTO+srjzbUsjkxs2UI7A9zVqGwOq3kdpM+BEPMaQcgAeprD8N+dLaLGsbMTMUVUHQelT+LNSbQba7s4p4/IK5n2H5i56Rg/zpXVk2dGJnyy5YPVnLfEDXRqt6thA7Q6BZHEbZwbhx1PvXCNFd+INQ8mxRo4EBJc9Fx71PdXe6QyTgMQdsMPQc+lS6JrMWmefpl7avJbO4YhX2vnr1HUVklzO8jKo1SXJHfqZ2iNBHcSx36+dNGSEOeMDqcVsSI7RJPaQoFU/dyQcetZOu+RJrC3FohgidsRg/exjvUonnCPtciIjk8cn0pNW0ClPSzN3eloZCShaYDIB6Gsq7vIrYBY/MyeqE/KKzJbmCJD5khmdl+Yr1A7VSe9Zvkgjb0LP296nzNqmJjFcqNv8AtK7PMeFTsC4FFZ6aXeSKGXT7mQHneFPNFVySOf6y+59VaRqUN3arKrKibejHnA71BqskktjJJHL5bdFbOOK8q8I+IkvZPKlmFtKFG0sflb/ZPsa6S/1ZtRdGWN4oG+SRc8bh6e1exFxl70ep4koOEuWReklSG1V5ZgJB8pkBzmpNZubG50S5t71yxigLhuhb6VDb2rpIqtbgoF3BicgfSquqvbXECrL+6LhkM7fw9abd00OL1R43pL+bcTShXdv4WA5HvXcaRpMVowmMLSTbd7y56/h61yHhiET6re29o6hVY4ZjwBXcX180bQRWZeaUYyVTAYDqQfavHppJczPo+dNJGb4tRzpkOXLKk6nYecV7nauDbW7RkN+5j6Hp8orwfxRdFdPkkRh5ZkG4Y5H1r23T5kOn6e0BCRvChLdm+UVrDeS9Dz8wfws1A4BXb1HanSSuNrKfk/iB6moIj8xB4x0PrUpOcZPyimefclU5GeuOcUu7GeQBVSe4MVs80ULzsoyI0+830p7sWgBQ7QwyQRyPamkO45pvlKhuD6U62kV4xtyVU/lVZ2QRl1wwUdDUOlTKF8suzyPlwT0A9M1fLoFy/cqZYXRSVZhjcOq+9eGfFmzGla1Z3Ns7sHiMUjMOWcep717oTuG459Aa8i+PC406O5VdnkzIu4n7x9qynHmgzpw1T2dVSPPLQyXMKB3cSHgqgySKsWtpdX9lqFpAo86JdwY9QKg0TUJLKd3tUZ5nUqqKm8lSOSKtG1u7SVJMSwySIfm7Mp649a5Y+9ue/wA8aSXL1372OOs1MU4ju7KTaRiV07/StCw0ia8k867jaHTg3yRH77j612tto06QQ4yzTMBEMZ61ua54dudHtY3uZo3354Tsa1jF9UcawtKP2732Rxst1CljcyKywi3GyJB0JPSu/wDAGnnS9DikkAa5uDvZ+vHpXmeuQuYdOgDfupZxnPXr3r2Wwkjt47dIj+5SJVCY712UVeV+x5+JqSs0+piePNOh1zT7zyUcX9mBJEzDGMc4HrXmWga62marb6hvZ0H+tiA5Yjg5/WvYr1/NjlWP92Q3L46D0rwsRKdV1CFCQ4lba3YDPepxEeVqRFCTl7p7YPEGh6ZpU2uaLd7pr0bI7InJifuSPzry/VLp9QnLSsGgiO/Jb/WOepPvWXb2Ty3BWNvLGMvMo6+wrMvZFW/aK7eSK3RQ0UZGQW9655zczrS9i+aWrLXnqdbM0arcxSJtRBzg+lZGrpNp90rXagiYcgH7v0q5aSzedFMvyxQtuxjlj2I9qs3X2W/Km6Vn56DjaazbTVkTyuacno3sUoVEG25kmLqV/d7uce1a2leFNV1uwS7tzm3diFGcfWsjUIUjuIEZQsJ4Cg9BXscX/Eug0+G1Y/ZJbcFBH8u0nBOa2oUlUb5uhjiKnIuWKOS0/wABXJk8uW7tooUGWYcs3tXRWnhXRrNQYT9pnjG8mZuvtjvUrzSC5/eN5kAO50B6f40sus27XDtDCC5GxX24AHpXbGnCJxzqTexrx3rBFHnhOPu8jFFcc+v3odgojYA8FjyaK29r5mHKcJZX0kVwkjgwzJ8wYD5WrrdK8VSCIQx7YATuz95Se9VLjR47mWVwjIVA2+hHtWd/YEv2feg+XkhR97HrXmRlOkes6Uanmej23iW3ltE26qgMZAYOcHHqKyfF3idU0+W3sFdnl+XzScjHtXDWui6g6l0jJA7cdK27DRpblYxqFwwWI4QbeB7Vo8VOUHGxNPCRU1LoWvCVuLTb5gHmyjdJxjntzXTXDojNFI4WF12gp95SfSs22tfKmEltuCj5dj9vU1T1fVFDRWlkrG/upREgKnCn1zWSfKtTsvHa+hTv5obhpbSXfsxtZ+ucdM12nw98Zrp1smieIXKqmBbXJ5VV7Bqi1D4cTxW8b6TfiS5CgzQzjhz3we341xtxaX0NxJHeWlxG4+UhoyRj64rN89OV5BL2GLhaL1/rofRiyBkV12uGAKuvIb3BpzSiRSgbY/QH3r570zxNruiII7C8mWJD/qpFJUfTNa1t4u8WTzMtihlaY5LKhwD6j0rRVovQ8+eBqx17HtNvay29uyeY7yNyWbt/hUi4wQrHJ6+5rxm90PxhZafJr0upsl1Gd7QbiWK+/avQ/BHiA+ItAhvTtW5X5ZkX+9WkHfS1jCdPkV07o3rmXEJj27d3DAd6s24EESqpwoHfvWdOZHmiVVPz/eJ/hqdgv2V4tw2sCM5610aWMbmgHDKS2NoGRivFPjPq8GoPZ6dAVMKN9ods5KkdsV32tauPDGiTXEreZHs224J5LkdPpXnnw78Of8JBqM+taoRJBHJkx/8APST/AAFY1Vf3Fuzrw0Uv3s/hRr/Bjw3PYxy63qEPl3NwNlvG68+X3JB6Zrpn0u1lu59AvUDW8ubqzkxzGe4H6mulJyFycKOMDtWX4hhmmt4rmzYLe2rb4yB95f4l/EVUYKK5UZSrSlPnODsIrjRfFNomoqDHFNtU54II4bFeh63Y2+o2k0Uyhzglc9j6iuP8cXFrf6dp2rRtmGR/KfH3lP8A9Y/yq54S8RfbJG0q/mQ3tuPkk6ecnb8aULL3GddSU6sY11utzyjxSgt4A8W5pbSf548fcIPNelWer29zp1ldtHutZYgysv8Ae7iub1TQ7mfXdVjuEKx3RLRBukh9M+tcfCmveHpZbfT7kRROxBtpRlfoPSppVXSu2tDTE03WacdX5HpWua/Bp+jzX08qbQnyqT989gPWvHNP86RGuWQ+ZcuWZj2BPSrd4L671eKTxC63bxrmK3XhF9OlaE0YeN5y8Qk6NEuQKitV9q+yQYbDuF+bcjgVzG0atmJWwCO/tU8tw1naxRXESS45CbdzA+hNVZLyMbME+bHwABhRVEXHmSz3Er+WADsQn175rG/S51uSvexLcalDJsBtCJsduw7ZFVUaO1ZTap5kjNkb+AD600y3L2oOn2yKQdzSvndJ/wDWqLRL83WvRzakgPlkBkUccGmlqrnLOtzs2dB0NtYuZXvzgL87S44A9BXoEjiRLXDpAsSYjU+nTmszUL6zso5Gknt54XUNbQQHBJ/2vQCuWn8bXEEzgQwSoPl8kf412Jxoo8+V5u52Ii8oTKFxI3Kj1Peqd00QO+GA71HHGVDdzUNl4rt7q3Vb+NrOZlDI45z7GtCS8iWSLNzElrJhsZHIrWMlLUxlzLcjghs5YVkurZBOwy4CnrRUc2o3Pmt5LRmPPynI6UVtePYy94rtOIVZpo3Eh+6vY/8A1qoXN4trciSeQ72G1TGflAqLXXQxoks7nB2hjxWRZ2Nz4h1JbDS1xBGMySkcIO5zXnTk72W56qklG7NR/EkaEjzNhTpjjNXrTWba4aJUnB8zgjpz71tab4O0W0tA0drLqjoD5kzNgf8AARVc+GPD+oW3l2X2i1lBIYscMCemR6U/ZVER9dhJ2Y+/aGO1aWOZo1K885zjtWf4SR9R8Z6ekjBliLShccjFYt6l3o94mm3+JdvMTg5SVfb3rovhmyJ4tlkTc/7k9eq57Vj8VRJ9GdEqqjh5SWt0evxkEsrHk9z1pzHcf3pDqeDuGazpbgIUDZEjHA96h1XUhYQxnAaNj87k/drsm1FczPGT1NM29schrWBh2zGKdApiTZHHFEM8CNcDFZGlavDqETSW7B4lO3cDmtUONuR+lRFqSuhuT2Yt9H9rsLyAHDSxMgZvWvMvhNqq6dqV5o10RHJMx2NnguDyP5V6W0mDkfN7V4x8R9NfRvEbXtsrJBdNvRwcbH9qmpeNprodWHcZJ05Pc9ycnJRmKt0bFZmsXcOnWT3V3KI7eHkMxxkeg9a8mtviTrMNvHEwt5WQY3OvzN9azNR1e+1+6ik1W7BGcrFjEaD6etV9YSXuq5UMHJztN2Q/xf4kk8SXqsoeCxhO2CNj1P8AeNereBUmstD061jtiIXj8x5gerGvGbm2R5kTeGBO7LV6b4H8Z2D6atlqN1HbT2/yLv4DKPepoSu3KW7N8bTdKCpx2R6B5pVmyMIRx6/jSiUbwwYFfY1iDxBpZgd5dRtURTglm6//AFq4vxh490i3tpINKczTsD++U4RfceprpbjFXbPNjGUnoilrd+sf2uzhG6IX3mqB0HBz+tJ4cggfxcL26mEaBA0QPGTXnum+IJJtVQRwkxp0djzknkmupGpG5LAxhcHiXP8ASuO6m+bsexh3anyJ76HrusW1rqemsJ518mI+Z50bZMR9eK82u9SivLO+dFju4rRtqXXRpPeqRhkSGY6ZeSW/nDE6Mcq3/AelVIEgtNLe389ZFY5KAY5oq1G3tY1wuHdNfFcyLeANeMdx2sMFicnJpGETB4PMy8R4H94+tMLD95Lt2NggBT096r6e0UN8jctGV+YE/wAVYJmtWPK7DdXt5zbH7KGDtzJnqfpWLDAXaH9/vgdwrg9VPvXWwSJczSrGWa4PAB+6B7VFPpenlwGJSUjIaM/KTVcieqOWactmP1RbGzhgNlOWYNzg8Ee9YSwma4a+hdYGzhUI5I9anh0+OIujOzqmWAbgEeuKlYwnaRySO/RTVOXMiI0rP3igxm8xtiIrEHJUdRULRxrDtEXzf3/U1pyybSFx8w+82ev0qKZTJjIVVPCkdBWcnfqaRo2VzNkmuIcbW8xQON3ao5LqVkV3woA6nJ/KtKWL5lXaScYBHQ1m3UZZwgwzDg8cD61N5bE1KcYajvtk3/PVvzNFR/2fcNz+8OfReKKq0zDmieiHSX8QaVDci5Ft5kaTbfL343DOM5FdN4Ss08O6aYIQs0kjfvJGXBb+dFFKNaafMnqeXKpKV4t6G/HcrDJ+7iCq38KnAB9abMttdXCTXFsrzoMK+cEUUVaxFTuTYwNc8MRaugMdw1vKrhlfbu2/hkVZ8J+HW0LVLi7N39oMkewr5WzHvnJooqXUk5KV9TVTly8vQ6W9hS/hETmRMHcGRsEH61Wu9O+12JtrqdpINwOMfNj0zRRTdaclZsixa0ixttLt2gs4hHCeQo9fWtFZMDIHI96KKcaklZIBrSYOcc4z1qlrelWms2L297EGDD5W7ofUUUVq6krtAm1qcXH8Myg2/wBr5GeM23IH/fdWIvhxtyx1XcQOP9H/APsqKKxR1fW6y2kOm+HJnJJ1VVbGARa9B/33VWX4YOyhDrXyd/8AReT+O+iimxSxNWWrkV2+EiM5A1lgDx/x7/8A2dSt8KYjEyHVA3GFLW2cf+P0UU1uSq0+4y3+FZtGTydZAXHzj7J9/wD8f4qY/DRkm8yPWCh7AW3A/wDH6KKkuOJqxVky3/whTLbeU2ogtjBfyME/+PVA/gEbgDqTEsvXyf8A7Kiipk7vUuOMrQ+GX5FST4cnYx/tYgn0t/8A7KmSfDMFgrarkkdRbY/9nooqYxVhyxtdu7l+C/yLMfgIxosaamV2nkiDGf8Ax6nf8IR5bbotQ2qP4TBkf+hUUVqmZfWqvcmi8GKXLXF2k0hXEZMGBH743c1jzfDd2BiXWAFzuJ+y5JP/AH3RRTtdakvE1b/EQy/DN3X9/rO/nAP2XB/9DqGH4eGJzH/apYHpm36f+PUUUuVIX1qq9Wyc+AGKMU1Tbt7fZ8/+zUtn8PUgYySagJVHzspgxuP/AH1RRVrRXRnLEVJbsvN4Yfcdt8FHYCHp/wCPUUUVr7Wfcy5mf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a juvenile colonic polyp shows dilated cystic crypts and abundant, mildly inflamed lamina propria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37928=[""].join("\n");
var outline_f37_2_37928=null;
var title_f37_2_37929="Strategies to reduce hospitalizations in patients with heart failure";
var content_f37_2_37929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strategies to reduce hospitalizations in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Leora Horwitz, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Harlan Krumholz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37929/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/2/37929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14824245\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is one of the most common causes of hospitalization and readmission. Approximately six million Americans and 15 million Europeans are living with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 2006, the HF hospitalization rate in the United States was 23 per 1000 for men over age 64 and 20 per 1000 for women over age 64 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/3\">",
"     3",
"    </a>",
"    ], making HF the leading cause of hospitalization in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, about a quarter of those who are hospitalized with HF are readmitted within 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/4\">",
"     4",
"    </a>",
"    ] and 30 percent within 60 to 90 days post-discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/5\">",
"     5",
"    </a>",
"    ]. Despite a decrease in admission rates for HF among Medicare patients between 1998 and 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/6\">",
"     6",
"    </a>",
"    ], rehospitalization rates have not decreased and may even have increased in the same period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/7\">",
"     7",
"    </a>",
"    ]. Data for Medicare patients hospitalized from 2005 to 2008 show that risk-standardized rehospitalization rates and mortality rates were correlated only weakly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/8\">",
"     8",
"    </a>",
"    ]. A majority of readmissions after HF hospitalization are not for HF, as shown in a separate study of Medicare patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies to reduce hospitalizations in patients with HF include optimization of evidence-based drug and device therapies, addressing causes of HF, treating comorbidities, and improved management of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/10\">",
"     10",
"    </a>",
"    ]. Evidence from randomized controlled trials has established the efficacy of certain drug and device therapies in reducing hospitalizations as well as mortality in patients with systolic HF, but treatment in patients with diastolic HF remains empiric since trial data are limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H20200745#H20200745\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Components of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with HF are typically older adults with complex drug regimens for HF, multiple concurrent diagnoses, and resulting polypharmacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/11\">",
"     11",
"    </a>",
"    ]. They are often cared for by many clinicians. Because of these complexities, the care of HF involves more than straightforward medical management of a solitary disease. Moreover, HF patients may have trouble with balance, eyesight, hearing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    executive function that makes self management difficult. The clinician, working with others in a care team, must provide appropriate coordination of care, manage the patient between office visits, ensure adequate patient education to support the acquisition of self-care skills, and create safe transitions of care between settings.",
"   </p>",
"   <p>",
"    This topic will review outpatient- and inpatient-based management strategies aimed at reducing the risk of hospitalization and rehospitalization for patients with HF. Patient self management of HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link\">",
"     \"Heart failure self management\"",
"    </a>",
"    .) The medical management of heart failure and treatment of acute decompensation are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824261\">",
"    <span class=\"h1\">",
"     OUTPATIENT STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824276\">",
"    <span class=\"h2\">",
"     Disease management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease management programs are designed to provide a multidisciplinary, integrated approach to care for patients with a chronic condition. Disease management programs facilitate the development of an individualized care plan, provide patient education and support, and coordinate care among healthcare providers, patients and patients&rsquo; support systems. A clinician acting as a solo caregiver typically has neither the expertise nor time to address all these components of a patient&rsquo;s healthcare needs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18202432\">",
"    <span class=\"h3\">",
"     Definition and essential components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease management programs typically involve a multidisciplinary, integrated approach to care for patients with a chronic condition. A disease management program for HF should include at a minimum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A means of identifying and tracking patients with HF",
"     </li>",
"     <li>",
"      Use of formal evidence-based practice guidelines",
"     </li>",
"     <li>",
"      Multidisciplinary care, including physicians, nurses, care coordinators, social workers, pharmacists, physical therapists, nutritionists,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      others as needed",
"     </li>",
"     <li>",
"      Frequent contact with providers, either by phone or in clinic",
"     </li>",
"     <li>",
"      Comprehensive patient education particularly focused on self care",
"     </li>",
"     <li>",
"      Discharge and early postdischarge support if hospitalized",
"     </li>",
"     <li>",
"      Process and outcomes measurement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in practice, disease management programs may not include all of these essential components. Published studies vary widely in their targeted population, interventions provided, team personnel, and intensity of interaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of disease management on outcomes for patients with HF is uncertain due to the heterogeneous nature of the interventions and the poor quality of most of the trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18202439\">",
"    <span class=\"h3\">",
"     Evidence of effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of disease management programs has been evaluated in a variety of trials. However, the generalizability and validity of this evidence are difficult to ascertain given the wide variety of interventions tried and personnel involved and the fact that the evaluators and developers are often the same. Furthermore, as with all complex interventions of practice improvements, local context is critical for disease management, and the quality of implementation may be as important to success as the strategy itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636329\">",
"    <span class=\"h4\">",
"     Impact on hospitalization and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the publication of large trials, numerous meta-analyses reviewed the effect of smaller studies of disease management for patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]. The validity of combining data from these widely diverse programs has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/23\">",
"     23",
"    </a>",
"    ]. Most of the included studies were small, underpowered, single-site interventions, and most meta-analyses were limited in number of participants (about 2000 patients) and trials (less than 15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/23\">",
"     23",
"    </a>",
"    ]; an exception is the 2012 Cochrane review discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/24\">",
"     24",
"    </a>",
"    ]. The meta-analyses included only one or two randomized trials with more than 1000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. There is a substantial risk of publication bias particularly for small studies such that negative results are often not published, and study quality is generally low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. In addition, the heterogeneity of the interventions used in the trials raises questions about the value of pooling outcomes across studies even for high-quality trials.",
"   </p>",
"   <p>",
"    Meta-analyses have typically divided disease-management programs into three broad categories: those that included in-person multidisciplinary follow-up either in clinic or at home, those that primarily promoted self care, and those restricted to telephone support from a clinician (typically a nurse). However, categorization of studies is difficult since most of the self-management studies included other disease management interventions, and all programs included patient education. Generally speaking, the analyses suggest that programs that promoted self care and those that included multidisciplinary team follow-up were more effective than programs utilizing telephone contact alone (",
"    <a class=\"graphic graphic_table graphicRef61054 \" href=\"mobipreview.htm?15/38/15982\">",
"     table 1",
"    </a>",
"    ). The following conclusions are suggested by meta-analyses, which should be considered exploratory rather than definitive given the quality of the evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/14,16,17,19-21,27\">",
"     14,16,17,19-21,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strategies that incorporated in-person specialized multidisciplinary follow-up either at home or in clinic reduced HF hospitalizations (RR 0.74), all-cause hospitalizations (RR 0.81), and mortality (RR 0.75) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/14\">",
"       14",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Programs that emphasized long-term patient self-care activities with frequent reinforcement reduced HF hospitalizations (RR 0.44-0.66) and all-cause hospitalizations (RR 0.59-0.80) but had no significant effect on mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/14,17,19,21\">",
"       14,17,19,21",
"      </a>",
"      ]. The meta-analysis lacked power for the mortality endpoint.",
"     </li>",
"     <li>",
"      Studies that employed structured telephone support involving direct calls with a clinician to patients reduced HF hospitalizations (RR 0.75-0.78) but not all-cause hospitalization or mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/14,16,19,20\">",
"       14,16,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Outcomes with telemonitoring are discussed below. (See",
"      <a class=\"local\" href=\"#H14824283\">",
"       'Telemonitoring'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar but not directly comparable results were obtained in a 2012 Cochrane review that included 25 RCTs with 5942 subjects but included only one study with &gt;1000 subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/24\">",
"     24",
"    </a>",
"    ]. This review categorized studies into intensive monitoring, clinic intervention, and multidisciplinary intervention groups (although all three groups included multidisciplinary interventions); the meta-analysis specifically excluded pure educational interventions, telemonitoring interventions, and structured telephone support interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive monitoring of patients reduced mortality (OR 0.66), HF hospitalizations (OR 0.47), and all-cause hospitalization (OR 0.75) at 12 months.",
"     </li>",
"     <li>",
"      HF clinic interventions did not significantly reduce mortality or hospitalizations.",
"     </li>",
"     <li>",
"      The two studies categorized as multidisciplinary did not reduce mortality but did reduce HF hospitalization and all-cause hospitalizations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As examples, there have been five RCTs of various types of disease management involving over 1000 patients with HF. Healthcare utilization was reduced in two studies and unchanged in three. Each RCT examined a different approach to disease management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eight Medicare Health Support pilot programs around the United States randomly assigned over 240,000 fee-for-service Medicare patients, most with HF, to usual care or participation in disease management programs sponsored by Medicare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/28\">",
"       28",
"      </a>",
"      ]. These were commercial disease management programs, not directly involved with the patient&rsquo;s clinical practice, and included nurse-led telephone-based chronic care services (symptom monitoring and management, medication counseling, health education, self-care coaching). Approximately 75 to 96 percent of patients in the intervention groups participated in the interventions. However, evaluators identified little improvement in self-care practices in the intervention group. After 18 months, evaluators found no difference between intervention and control groups in hospitalizations, readmissions, emergency department utilization or mortality. Possible reasons for lack of success included the lack of integration of the disease management program into the beneficiary&rsquo;s primary health care team, the infrequency of phone contact (on average less than one contact per month and 80 days between contact), contacts not coinciding with the time of disease flare or hospitalization, and the large number of comorbid illnesses in this patient population. This is the largest study of chronic disease management reported to date.",
"     </li>",
"     <li>",
"      The COACH trial (Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) randomly assigned 1023 Dutch patients with HF to three groups: routine care; nine visits to a specialized nurse; or 18 visits to a specialized nurse as well as two home visits and two pharmacy counseling sessions. This trial found no differences in readmission or mortality between the three groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial of 174,120 patients in the United States assigned patients to telephone-based disease-management support (&ldquo;enhanced support&rdquo;) or usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/30\">",
"       30",
"      </a>",
"      ]. Patients in the enhanced support arm had a 10.1 percent reduction in annual hospital admissions, compared to those in the control group. The study was sponsored and conducted by a for-profit company that owns the intervention and was designed as a quality improvement study rather than a research study, meaning that the decision about publication followed the study rather than preceded it.",
"     </li>",
"     <li>",
"      The DIAL trial (Randomized Trial of Phone Intervention in Chronic Heart Failure) randomly assigned 1518 Argentinean patients with HF to either routine care or an intervention consisting of an explanatory booklet plus periodic telephone contact by a specialized nurse over the course of one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/25\">",
"       25",
"      </a>",
"      ]. The nurse performed telephone evaluation and enforced self-management education, adjusted medications, and recommended nonscheduled medical or emergency visits. The intervention resulted in a lower rate of death or hospitalization for HF compared with usual care at a mean of 16 months (26.3 versus 31 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/25\">",
"       25",
"      </a>",
"      ]; a small benefit was sustained three years after the intervention ended (55.7 versus 57.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/31\">",
"       31",
"      </a>",
"      ]. This benefit was related mostly to a reduction in admission for HF.",
"     </li>",
"     <li>",
"      A randomized trial of 1069 patients assigned two-thirds to an intervention consisting of home scales and a disease manager who provided telephone management over 18 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/26\">",
"       26",
"      </a>",
"      ]. Intervention patients, compared to controls, had increased survival (mean survival of",
"      <sup>",
"      </sup>",
"      526.9 versus 450.5 days), but there was no difference in overall utilization (hospitalizations, outpatient visits, medications and procedures) or costs. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636319\">",
"    <span class=\"h4\">",
"     Other outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality-of-life results are mixed: about half of RCTs studying quality of life in HF patients after self-care education show improvement in perceived quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two RCTs have studied compliance with recommended health behaviors such as daily weights and salt restriction; in both studies, adherence improved with the educational intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. As an example, in one study of 223 patients, intervention patients were more likely to report conducting daily weights (66 versus 51 percent) and not smoking (97 versus 90 percent) and showed a trend toward reducing salt in their diet (32 versus 20 percent, p = 0.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824283\">",
"    <span class=\"h4\">",
"     Telemonitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telemonitoring is a particular form of chronic disease management in which patients are given equipment such as blood pressure monitors and scales to obtain physiologic data at home. These data are remotely transmitted to care providers on a daily or intermittent basis, allowing close monitoring of the patient&rsquo;s clinical status without office or in-home visits by health personnel. Telemonitoring data may be received by a nurse or personnel in a monitoring agency who screen data and only alert physicians of abnormal results, or data may go directly to ordering physicians. Telemonitoring should be distinguished from direct telephone calls with clinicians. Telemonitoring may be a stand-alone intervention or may be combined with other disease-management strategies.",
"   </p>",
"   <p>",
"    Challenges of telemonitoring include ensuring that the data are submitted (strategies include self reporting versus automated data transmission) and that they are appropriately reviewed and addressed.",
"   </p>",
"   <p>",
"    A meta-analysis of 11 RCTs including 2710 patients with HF found that telemonitoring reduced all-cause mortality (RR 0.66, 95% CI 0.54-0.81) and HF-related hospitalizations (RR 0.79, CI 0.67-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/20\">",
"     20",
"    </a>",
"    ]. The trials were generally small and of low to moderate quality. Only one study satisfied more than five of the nine specified quality criteria. Another systematic review, including 12 RCTs and nine observational studies (3082 patients) found similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the publication of the meta-analyses, two large negative trials have been reported. The largest trial to date, Tele-HF, enrolled 1653 patients with HF from 33 sites in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/37\">",
"     37",
"    </a>",
"    ]. Subjects were randomly assigned to telemonitoring using an automated telephone-based system that collected daily information about symptoms and weight, or to usual care. The primary endpoint was readmission for any reason or all-cause mortality at 180 days. Secondary endpoints included hospitalization for HF. There were no significant differences between the two treatment groups for any of the endpoints. Similarly, another large RCT of telemonitoring, TIM-HF which included 710 patients at 165 sites in Germany, and found no difference in mortality (HR 0.97, 95% CI 0.67-1.41) or in the composite secondary endpoint of cardiovascular death and HF hospitalization (HR 0.89, 95% CI 0.67-1.19) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These multicenter trials suggest that telemonitoring in isolation is not likely to be a successful strategy for reducing readmission. However, their findings may not apply to telemonitoring provided in the context of a broader disease management program and are not generalizable to other types of telephone-based support that involve direct communication between clinicians and patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15404312\">",
"    <span class=\"h3\">",
"     Recommendations for disease management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15404215\">",
"    <span class=\"h4\">",
"     Guidelines and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 Heart Failure Society of America (HFSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/27\">",
"     27",
"    </a>",
"    ] and the 2009 focused update of the 2005 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     (AHA/ACC)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/39\">",
"     39",
"    </a>",
"    ] HF guidelines recommend multidisciplinary HF disease-management programs in high-risk patients.",
"   </p>",
"   <p>",
"    As discussed above, very large randomized controlled trials of varying protocols have reached disparate conclusions regarding the efficacy of disease management. If a decision is made to use disease management for outpatients at high risk of hospitalization, it would make sense to use a protocol similar to one of those that demonstrated a benefit in a large randomized trial. Some features of effective programs include a comprehensive approach that includes at a minimum frequent in-person contact with clinicians, and formal self-care education and support. Programs limited to telephone contact or remote data gathering (telemonitoring) are less likely to be successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15404222\">",
"    <span class=\"h4\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HFSA guidelines define high-risk patients to include those with any of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Low output state",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease",
"     </li>",
"     <li>",
"      Persistent New York Heart Association (NYHA) class III or IV symptoms",
"     </li>",
"     <li>",
"      Frequent hospitalization for any cause",
"     </li>",
"     <li>",
"      Multiple active comorbidities",
"     </li>",
"     <li>",
"      History of depression or cognitive impairment",
"     </li>",
"     <li>",
"      Inadequate social support, poor health literacy, or persistent nonadherence to therapeutic regimens",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9965494\">",
"    <span class=\"h3\">",
"     Checklist for multidisciplinary HF care",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest using a checklist for multidisciplinary HF care. The following example is modified from a National Heart Foundation of Australia publication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Define intended recipients of multidisciplinary HF care",
"     </li>",
"     <li>",
"      Recruit target population",
"     </li>",
"     <li>",
"      Define and measure outcome goals (eg, to reduce rates of unplanned rehospitalization)",
"     </li>",
"     <li>",
"      Clinical assessment (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=see_link\">",
"       \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Confirm",
"      <span class=\"nowrap\">",
"       presence/type",
"      </span>",
"      of HF (eg, physical examination and echocardiography)",
"     </li>",
"     <li>",
"      Assess functional capacity (eg, initial and subsequent six-minute walk)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical management (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prescribe and titrate medications according to evidence-based guidelines",
"     </li>",
"     <li>",
"      Develop treatment plan to manage comorbid and related conditions",
"     </li>",
"     <li>",
"      Provide routine preventive care (eg, immunizations, treatment of risk factors, prevention of thromboembolism)",
"     </li>",
"     <li>",
"      Develop personalized treatment plans (eg, personalized exercise program, well-defined medication regimen)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-care education and support (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link\">",
"       \"Heart failure self management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assess patient capacity for self care (eg, formal assessment of patient ability to self care, health literacy, cognitive function, screening for depression)",
"     </li>",
"     <li>",
"      Provide appropriate information and support for self care (eg, ensuring understanding of the causes and consequences of HF, purpose of medicines, medicines to avoid)",
"     </li>",
"     <li>",
"      Develop action plan and provide clear instructions to patients and caretakers (eg, daily weight monitoring and recording in personal diary, personalized actions to take when weight or symptoms change) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link&amp;anchor=H6600128#H6600128\">",
"       \"Heart failure self management\", section on 'Heart failure action plan'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosocial care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Determine individual needs: eg, apply validated tool to assess concurrent depression, social support needs, and caretaker&rsquo;s coping (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Screening tools'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Develop and document a plan personalized to patient&rsquo;s culture and language",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palliative care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Discuss and assess palliative care needs: eg, routine discussion and offering of advance directives and reassessment and documentation of palliative care options, (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=see_link\">",
"       \"Legal aspects of end of life care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link\">",
"       \"End of life considerations for heart failure patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15404119\">",
"    <span class=\"h2\">",
"     Other outpatient care options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other aspects of outpatient care such as a &ldquo;hospital at home&rdquo; model have been reported as a method of increasing the intensity of care available to outpatients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15404375\">",
"    <span class=\"h3\">",
"     Hospital at home",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to avoiding hospitalization even for acutely ill patients is the &ldquo;hospital at home&rdquo; model, which provides patients who would otherwise be admitted to the hospital with acute care-level care at home. An RCT of hospital at home for patients with HF was performed by a group in Italy with a well-established, sophisticated &ldquo;hospital at home&rdquo; program. In this single-blind trial, 101 patients 75 years or older were randomly assigned to receive hospital care or &ldquo;hospital at home&rdquo; care. There was no difference between the two groups in six-month mortality or total hospital readmissions, but the mean time to first additional admission was longer for patients receiving &ldquo;hospital at home&rdquo; care (84.3&nbsp;days versus 69.8&nbsp;days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/41\">",
"     41",
"    </a>",
"    ]. Nonrandomized studies have shown neutral to positive effects on outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unlikely that a &ldquo;hospital at home&rdquo; program could be implemented without substantial resources and experience in this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48533427\">",
"    <span class=\"h1\">",
"     CARE BY A CARDIOLOGIST",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59155827\">",
"    <span class=\"h2\">",
"     Outpatient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported better patient outcomes when a cardiologist participated in outpatient HF management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/44\">",
"     44",
"    </a>",
"    ], particularly when a cardiologist and primary care physician were both involved with care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], compared to management solely by a generalist (general medicine or primary care physician). These studies report an approximately 20 to 40 percent reduction in mortality, or mortality combined with hospitalization, with management by both a cardiologist and a generalist as compared to care solely by a generalist.",
"   </p>",
"   <p>",
"    Improved survival may be due to greater guideline adherence when a cardiologist is involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/44,46-49\">",
"     44,46-49",
"    </a>",
"    ], as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 10,599 HF patients discharged from the emergency department in Ontario, Canada found that patients seen by both cardiologists and primary care physicians versus solely primary care physicians in the first 30 days post-discharge had a lower mortality rate at one year (hazard ratio 0.79; 95% CI 0.64 to 1.00) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/46\">",
"       46",
"      </a>",
"      ]. Mortality was lower among patients who were seen by a primary care physician compared to those who saw no physician at all (hazard ratio 0.75; 95% CI 0.64-0.87) in the first 30 days. There was a nonsignificant trend toward higher mortality with sole cardiology care as compared with combined cardiology and primary care (hazard ratio 1.41; 95% CI 0.98-2.03).",
"      <br/>",
"      <br/>",
"      Patients receiving combined cardiology and primary care were more likely than those receiving solely primary care to undergo assessment of left ventricular function (57 versus 29 percent) and more likely to receive standard HF medications including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      . However, information on left ventricular function was not available so that differences in appropriateness of care for systolic HF were not assessed.",
"     </li>",
"     <li>",
"      In a earlier study of 403 patients with new onset HF from the Kaiser system, cardiology care was an independent predictor of lower risk of death or cardiovascular hospitalization at 24 months (hazard ratio 0.62; 95% CI 0.42-0.93) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/44\">",
"       44",
"      </a>",
"      ]. Patients with a low ejection fraction who were seen by a cardiologist were significantly more likely than those seen only by a primary care physician to have been treated with ACE inhibitors (91 versus 71 percent) or beta blockers (38 versus 21 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the role of differences in patient populations seen by cardiologists and generalists versus by generalists alone is uncertain. Although patients seen by cardiologists have more severe cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/44,46\">",
"     44,46",
"    </a>",
"    ], they also tend to be younger and to have fewer comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. They may also, therefore, have fewer contraindications to medical therapies. It remains uncertain whether the improvement in guideline adherence is due to cardiologist involvement or to a patient cohort with fewer contraindications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59155906\">",
"    <span class=\"h2\">",
"     Inpatient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies have suggested lower mortality for patients cared for by cardiologists while hospitalized for HF, compared with those cared for by internists or family practitioners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. As an example, in a study of 25,869 Medicare beneficiaries hospitalized with HF between 1998 and 1999, patients who were cared for by cardiologists had lower mortality than those cared for by family physicians (8.8 versus 12.0 percent, RR 1.31, 95% CI 1.15-1.49) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/50\">",
"     50",
"    </a>",
"    ]. There was no significant difference between the mortality rate for patients cared for by cardiologist versus general physicians (11.1 percent, RR 1.26, CI 0.99-1.58) or internists (10.0 percent, RR 1.07, CI 0.97-1.19), although a trend was seen. Data for readmissions are not available, and more recent mortality data are also not available.",
"   </p>",
"   <p>",
"    It is unclear is how care differs when delivered by specialists or generalists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824299\">",
"    <span class=\"h1\">",
"     INPATIENT AND TRANSITIONAL CARE STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824313\">",
"    <span class=\"h2\">",
"     Adherence to guideline-based care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence to guideline-based care for inpatients is associated with mortality benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/53\">",
"     53",
"    </a>",
"    ]; however, most studies of individual or composite measures of inpatient clinical care quality do not show a reduction in readmissions for patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. As an example, an observational study of patients hospitalized with HF at 150 hospitals found that one-year cardiovascular readmission risk was not associated with hospital-level process measures including ACE inhibitor or ARB prescription at discharge, beta blocker at discharge, or smoking cessation counseling, although mortality at one year was associated with beta blacker at discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cross-sectional study of 3476 acute care hospitals found that a 10 percentage point increase in average hospital adherence to clinical process measures for HF was associated with a 0.2 percentage point lower 30-day readmission rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/56\">",
"     56",
"    </a>",
"    ]. However, this reduction was closely linked to baseline performance: hospitals already performing well experienced no improvement, while those beginning with scores in the 25 to 50 percentile experienced an average 0.5 percentage point improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824336\">",
"    <span class=\"h2\">",
"     Discharge support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved discharge support, also termed hospital-based case management, includes some or all of the following activities (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=see_link\">",
"     \"Hospital discharge\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medication support, including appropriate medication reconciliation, patient education, and assurance that patients can obtain medications",
"     </li>",
"     <li>",
"      Patient education, including definition of HF, precipitants of worsening disease, warning signs, and home self-care activities (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link\">",
"       \"Heart failure self management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Follow-up planning",
"     </li>",
"     <li>",
"      Coordination of information between settings",
"     </li>",
"     <li>",
"      Prompt postdischarge follow-up",
"     </li>",
"     <li>",
"      Multidisciplinary team-based care, including physicians, nurses, social work, care coordination, pharmacy, physical therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      others as needed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of moderate- to high-quality RCTs have been performed to evaluate the impact of discharge support. A meta-analysis of 18 RCTs of comprehensive discharge planning plus postdischarge support involving 3304 patients found a significant reduction in all-cause readmissions (RR 0.75, 95% CI 0.64-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/57\">",
"     57",
"    </a>",
"    ]. Again, meta-analyses were limited by inclusion of generally small, single-site studies. Some of these interventions may be cost saving. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An RCT of 223 patients with HF compared standard discharge procedure with a one-hour, one-on-one teaching session with a nurse educator prior to discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/34\">",
"       34",
"      </a>",
"      ]. Patients in the intervention group had a lower risk of rehospitalization or death (RR 0.65, 95% CI 0.45-0.93) 180 days after discharge. This intervention was estimated to save $2823 per patient.",
"     </li>",
"     <li>",
"      An RCT involving 142 older adults (&ge;70 years old) with HF or acute coronary syndrome examined the effect of comprehensive inpatient discharge support followed by two post-discharge phone calls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/58\">",
"       58",
"      </a>",
"      ]. The intervention group had a lower readmission rate within the first six weeks than the control group (10 versus 23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a program that reduces readmissions does not necessarily reduce direct costs as illustrated by a prospective study of a nurse-led transitional-care program for patients with HF being discharged from a hospital in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/59\">",
"     59",
"    </a>",
"    ]. Thirty-day readmissions, lengths of stay, and 60-day direct costs were compared with those for HF patients concurrently discharged from other hospitals within the same healthcare system. The program was associated with a 48 percent decrease in 30-day readmissions but had little impact on direct costs to the healthcare system over 60 days, and under the existing Medicare reimbursement system had a negative impact on hospital revenue.",
"   </p>",
"   <p>",
"    Larger trials of discharge support, not limited to HF, have been conducted in the general medical population. For example: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Care Transitions Program&trade; utilizes a &ldquo;transition coach&rdquo; to visit the patient in the hospital prior to discharge and ensure appropriate medication reconciliation, follow-up plans, and education. The coach then visits the patient at home within the first week of discharge and makes at least two telephone calls within the first 30 days to provide post-discharge support. In an RCT of 750 older adults (&ge;65 years old) hospitalized with medical conditions, intervention patients had lower rehospitalization rates at 30 days (8.3 versus 11.9) and at 90 days (16.7 versus 22.5) than control subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/60\">",
"       60",
"      </a>",
"      ]. However, fewer than 20 percent of the patients enrolled in this trial had a discharge diagnosis of HF.",
"     </li>",
"     <li>",
"      Project RED was an RCT conducted at an inner-city hospital that developed low-literacy appropriate patient education materials and utilized a dedicated &ldquo;discharge advocate&rdquo; to coordinate discharge support for adult medical patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/61\">",
"       61",
"      </a>",
"      ]. The 370 patients randomly assigned to the intervention had lower combined hospital and ED utilization than the 368 patients assigned to usual care (incidence rate ratio 0.70, 95% CI 0.52-0.94). This intervention was estimated to save $412 per patient. However, the percentage of patients with discharge diagnosis of HF was not indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, large-scale observational studies of printed discharge instruction content for patients with HF have found no relationship to readmissions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 16,791 patients hospitalized with HF at 150 hospitals found that meeting the discharge instruction requirement set by the Centers for Medicare and Medicaid Services (CMS) had no relationship to one-year cardiovascular readmission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, an observational study of 2222 hospitals found no association between hospital-level performance on the CMS discharge instruction measure and 30-day readmission rates for patients admitted with HF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that discharge support and education must go well beyond a simple discharge instruction sheet to be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824343\">",
"    <span class=\"h2\">",
"     Early follow-up appointment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although prospective data are lacking, observational data suggest that an early follow-up appointment may reduce the risk of HF readmission.",
"   </p>",
"   <p>",
"    An observational study of 30,136 patients with HF found that hospitals in the lowest quartile of early post-discharge physician follow-up (that is, hospitals whose patients were least likely to have follow-up within seven days) had a 3 percent higher 30-day readmission rate than the other 75 percent of hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of an early appointment may depend on the quality of care at the visit which may be affected by the information available to the provider. An appointment may be necessary but not sufficient to reduce risk. Ideally, assessment should take place within one to two weeks after discharge, to reassess fluid status, review and adjust medications, plan additional testing if needed, and provide further patient education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/64\">",
"     64",
"    </a>",
"    ]. Since this strategy might not be feasible for all of the many patients hospitalized for HF, particular focus for early follow-up should be targeted to patients who are at increased risk for early decompensation (eg, low systolic blood pressure, prolonged QRS duration, renal dysfunction, elevated natriuretic peptide level, elevated troponin levels, hyponatremia, or other comorbidities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14824351\">",
"    <span class=\"h2\">",
"     Prompt communication with outpatient clinicians",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have not found an association between prompt communication with outpatient clinicians and reduced readmissions, despite the prima facie value of communication. A multisite observational study of 1078 general medicine patients found no relationship between receipt of a discharge summary within two weeks of discharge and a composite outcome of ED visit, readmission and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/65\">",
"     65",
"    </a>",
"    ]. Also, there was no apparent benefit to direct communication with physicians. Similarly, an observational study comparing 1039 patients rehospitalized within 30 days of discharge with 981 non-rehospitalized patients found no association between transmission of a discharge summary to an outpatient physician and readmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37929/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since these are observational and not randomized controlled studies, however, the question is raised whether timely discharge summaries and physician communication may be more likely for patients with the most complex clinical issues and highest risk of readmission. Additionally, the timeliness of discharge summaries may only be one component of their effectiveness, which might also be affected by the completeness and quality of the content, and the availability of support systems to facilitate appropriate response to issues raised by discharge summaries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15404655\">",
"    <span class=\"h2\">",
"     Recommendations for inpatient and transitional care strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For inpatients with HF, we suggest comprehensive discharge support that should include close follow-up in the immediate postdischarge period. Programs limited to support in the inpatient setting (education, medication reconciliation, and care coordination) are less likely to be successful. Similarly, programs focused on only one aspect of discharge support (eg, only medication reconciliation or only sending discharge summaries to outpatient clinicians) are less likely to be successful. We suggest an inpatient and transitional care strategy for patients hospitalized with HF that incorporates adherence to guideline-based care, discharge support including individualized instruction, and early postdischarge follow-up, whether by phone, at home, or in clinic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9965632\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalization rates for patients with HF may be reduced by approximately 20 to 30 percent through the implementation of comprehensive outpatient and inpatient support programs. However less intensive outpatient and inpatient strategies have been found to be ineffective in improving patient outcomes. (See",
"      <a class=\"local\" href=\"#H18202439\">",
"       'Evidence of effectiveness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14824299\">",
"       'Inpatient and transitional care strategies'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Although evidence on the efficacy of these strategies is not definitive, we suggest the following approaches:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Very large randomized controlled trials of varying protocols have reached disparate conclusions regarding the efficacy of disease management. If a decision is made to use disease management for outpatients at high risk of hospitalization, it would make sense to use a protocol similar to one of those that demonstrated a benefit in a large randomized trial. Some features of effective programs include a comprehensive approach that includes at a minimum frequent in-person contact with clinicians, and formal self-care education and support. Programs limited to telephone contact or remote data gathering (telemonitoring) are less likely to be successful. (See",
"      <a class=\"local\" href=\"#H15404312\">",
"       'Recommendations for disease management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HF who are already hospitalized, we suggest comprehensive discharge support that should include close follow-up in the immediate post-discharge period (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Programs limited to support in the inpatient setting (education, medication reconciliation and care coordination) are less likely to be successful. Similarly, programs focused on only one aspect of discharge support (ie, only medication reconciliation, only sending discharge summaries to outpatient clinicians) are less likely to be successful. (See",
"      <a class=\"local\" href=\"#H15404655\">",
"       'Recommendations for inpatient and transitional care strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At present there is insufficient evidence to recommend &ldquo;hospital at home&rdquo; programs. (See",
"      <a class=\"local\" href=\"#H15404375\">",
"       'Hospital at home'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Observational studies in outpatient and inpatient settings suggest lower mortality rates with cardiology participation in care of HF as compared to care solely by generalists. However differences in patient risk factors and care that may explain these differences in outcomes are not well understood. (See",
"      <a class=\"local\" href=\"#H48533427\">",
"       'Care by a cardiologist'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/1\">",
"      WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/2\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/3\">",
"      Liu L. Changes in cardiovascular hospitalization and comorbidity of heart failure in the United States: findings from the National Hospital Discharge Surveys 1980-2006. Int J Cardiol 2011; 149:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/4\">",
"      Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/5\">",
"      Gheorghiade M, Peterson ED. Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. JAMA 2011; 305:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/6\">",
"      Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 2011; 306:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/7\">",
"      Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010; 303:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/8\">",
"      Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013; 309:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/9\">",
"      Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013; 309:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/10\">",
"      Gheorghiade M, Braunwald E. Hospitalizations for heart failure in the United States--a sign of hope. JAMA 2011; 306:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/11\">",
"      Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011; 124:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/12\">",
"      Krumholz HM, Currie PM, Riegel B, et al. A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation 2006; 114:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/13\">",
"      Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337:a1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/14\">",
"      McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/15\">",
"      Gonseth J, Guallar-Castill&oacute;n P, Banegas JR, Rodr&iacute;guez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J 2004; 25:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/16\">",
"      Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007; 334:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/17\">",
"      Gwadry-Sridhar FH, Flintoft V, Lee DS, et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004; 164:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/18\">",
"      Roccaforte R, Demers C, Baldassarre F, et al. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005; 7:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/19\">",
"      Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005; 91:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/20\">",
"      Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010; :CD007228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/21\">",
"      Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord 2006; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/22\">",
"      Mezger J. [Comments on the contribution by R. Niehues et al]. Internist (Berl) 1992; 33:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/23\">",
"      Clark AM, Savard LA, Thompson DR. What is the strength of evidence for heart failure disease-management programs? J Am Coll Cardiol 2009; 54:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/24\">",
"      Takeda A, Taylor SJ, Taylor RS, et al. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2012; 9:CD002752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/25\">",
"      GESICA Investigators. Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ 2005; 331:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/26\">",
"      Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 2004; 110:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/27\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/28\">",
"      McCall N, Cromwell J. Results of the Medicare Health Support disease-management pilot program. N Engl J Med 2011; 365:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/29\">",
"      Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008; 168:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/30\">",
"      Wennberg DE, Marr A, Lang L, et al. A randomized trial of a telephone care-management strategy. N Engl J Med 2010; 363:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/31\">",
"      Ferrante D, Varini S, Macchia A, et al. Long-term results after a telephone intervention in chronic heart failure: DIAL (Randomized Trial of Phone Intervention in Chronic Heart Failure) follow-up. J Am Coll Cardiol 2010; 56:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/32\">",
"      Ditewig JB, Blok H, Havers J, van Veenendaal H. Effectiveness of self-management interventions on mortality, hospital readmissions, chronic heart failure hospitalization rate and quality of life in patients with chronic heart failure: a systematic review. Patient Educ Couns 2010; 78:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/33\">",
"      Grady KL. Self-care and quality of life outcomes in heart failure patients. J Cardiovasc Nurs 2008; 23:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/34\">",
"      Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005; 111:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/35\">",
"      Ross SE, Moore LA, Earnest MA, et al. Providing a web-based online medical record with electronic communication capabilities to patients with congestive heart failure: randomized trial. J Med Internet Res 2004; 6:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/36\">",
"      Polisena J, Tran K, Cimon K, et al. Home telemonitoring for congestive heart failure: a systematic review and meta-analysis. J Telemed Telecare 2010; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/37\">",
"      Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med 2010; 363:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/38\">",
"      Koehler F, Winkler S, Schieber M, et al. Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail 2010; 12:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/39\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     Multidisciplinary Care for Patients with Chronic Heart Failure: Priniciples and Recommendations for Best Practice. National Heart Foundation of Australia. 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/41\">",
"      Tibaldi V, Isaia G, Scarafiotti C, et al. Hospital at home for elderly patients with acute decompensation of chronic heart failure: a prospective randomized controlled trial. Arch Intern Med 2009; 169:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/42\">",
"      Mendoza Ruiz de Zuazu H, Regalado de los Cobos J, Altuna Basurto E, et al. [Treatment of congestive heart failure in the setting of hospital at home. Study of 158 patients]. Med Clin (Barc) 2003; 120:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/43\">",
"      Leff B, Burton L, Mader SL, et al. Hospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patients. Ann Intern Med 2005; 143:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/44\">",
"      Ansari M, Alexander M, Tutar A, et al. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol 2003; 41:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/45\">",
"      Indridason OS, Coffman CJ, Oddone EZ. Is specialty care associated with improved survival of patients with congestive heart failure? Am Heart J 2003; 145:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/46\">",
"      Lee DS, Stukel TA, Austin PC, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation 2010; 122:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/47\">",
"      Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997; 12:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/48\">",
"      Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997; 30:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/49\">",
"      Go AS, Rao RK, Dauterman KW, Massie BM. A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States. Am J Med 2000; 108:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/50\">",
"      Foody JM, Rathore SS, Wang Y, et al. Physician specialty and mortality among elderly patients hospitalized with heart failure. Am J Med 2005; 118:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/51\">",
"      Jong P, Gong Y, Liu PP, et al. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 2003; 108:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/52\">",
"      Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/53\">",
"      Kfoury AG, French TK, Horne BD, et al. Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. J Card Fail 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/54\">",
"      Patterson ME, Hernandez AF, Hammill BG, et al. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care 2010; 48:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/55\">",
"      Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007; 297:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/56\">",
"      Werner RM, Bradlow ET. Public reporting on hospital process improvements is linked to better patient outcomes. Health Aff (Millwood) 2010; 29:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/57\">",
"      Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004; 291:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/58\">",
"      Naylor M, Brooten D, Jones R, et al. Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med 1994; 120:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/59\">",
"      Stauffer BD, Fullerton C, Fleming N, et al. Effectiveness and cost of a transitional care program for heart failure: a prospective study with concurrent controls. Arch Intern Med 2011; 171:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/60\">",
"      Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a randomized controlled trial. Arch Intern Med 2006; 166:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/61\">",
"      Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 2009; 150:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/62\">",
"      Jha AK, Orav EJ, Epstein AM. Public reporting of discharge planning and rates of readmissions. N Engl J Med 2009; 361:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/63\">",
"      Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/64\">",
"      Metra M, Gheorghiade M, Bonow RO, Dei Cas L. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation 2010; 122:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/65\">",
"      Bell CM, Schnipper JL, Auerbach AD, et al. Association of communication between hospital-based physicians and primary care providers with patient outcomes. J Gen Intern Med 2009; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37929/abstract/66\">",
"      Hansen LO, Strater A, Smith L, et al. Hospital discharge documentation and risk of rehospitalisation. BMJ Qual Saf 2011; 20:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15690 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3B792D9370-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37929=[""].join("\n");
var outline_f37_2_37929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9965632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14824245\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14824261\">",
"      OUTPATIENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14824276\">",
"      Disease management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18202432\">",
"      - Definition and essential components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18202439\">",
"      - Evidence of effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20636329\">",
"      Impact on hospitalization and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20636319\">",
"      Other outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14824283\">",
"      Telemonitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15404312\">",
"      - Recommendations for disease management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15404215\">",
"      Guidelines and recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15404222\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9965494\">",
"      - Checklist for multidisciplinary HF care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15404119\">",
"      Other outpatient care options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15404375\">",
"      - Hospital at home",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48533427\">",
"      CARE BY A CARDIOLOGIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59155827\">",
"      Outpatient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59155906\">",
"      Inpatient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14824299\">",
"      INPATIENT AND TRANSITIONAL CARE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14824313\">",
"      Adherence to guideline-based care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14824336\">",
"      Discharge support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14824343\">",
"      Early follow-up appointment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14824351\">",
"      Prompt communication with outpatient clinicians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15404655\">",
"      Recommendations for inpatient and transitional care strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9965632\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/15690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/15690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/38/15982\" title=\"table 1\">",
"      Summary of meta analyses of heart failure management programs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=related_link\">",
"      Heart failure self management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=related_link\">",
"      Hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_2_37930="Long-term outcome after coronary artery bypass graft surgery";
var content_f37_2_37930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Long-term outcome after coronary artery bypass graft surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Sary Aranki, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/2/37930/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/2/37930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of coronary heart disease (CHD) has evolved significantly over the past several years due in part to improvement in medical, surgical, and percutaneous revascularization techniques. The majority of patients with chronic stable angina are still treated with medical therapy; however, revascularization with either coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) should be considered in several subgroups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term outcome following CABG in patients with stable angina will be reviewed here. The short-term, particularly perioperative complications associated with CABG, the efficacy of CABG in patients with ischemic cardiomyopathy and areas of viable myocardium, and the outcomes with minimally invasive CABG are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF GRAFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients receive both arterial and venous grafts during CABG. This section will compare these and will also compare the different arterial grafts. Graft patency and survival are two of the important long-term outcomes and both outcomes have been shown to be better with arterial grafts, and in particular, the internal thoracic artery (ITA) graft. (See",
"    <a class=\"local\" href=\"#H98316246\">",
"     'Arterial versus vein grafts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Saphenous vein graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greater saphenous vein from the leg had been the choice to connect the aorta with distal portions of narrowed or occluded coronary arteries. The vein grafts are inserted in a",
"    <strong>",
"     reversed",
"    </strong>",
"    position to permit free blood flow through the venous valves.",
"   </p>",
"   <p>",
"    However, only 65 to 80 percent of SVG grafts remain patent five years after the operation, 50 to 60 percent at 7 to 10 years, and 50 percent at 15 years (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"mobipreview.htm?23/28/24013\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61140 \" href=\"mobipreview.htm?11/2/11310\">",
"     movie 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The following findings were noted in two reviews of over 12,000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall graft patency was 61 and 57 percent at 10 years.",
"     </li>",
"     <li>",
"      SVG patency did not vary with the coronary territory grafted, with the exception that one of the studies found a lower rate of graft patency when bypassing the right coronary artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors may predispose to SVG disease, including target vessel diameter less than 2.0 mm, smoking, hypertension, and lipid abnormalities; the role of diabetes is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a report from the BARI trial, the presence of diabetes did not appear to affect the patency of SVGs at four years even though diabetic patients had smaller distal vessels and vessels of poorer quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/7\">",
"     7",
"    </a>",
"    ]. There was also no effect of diabetes on ITA graft patency.",
"   </p>",
"   <p>",
"    Antiplatelet agents (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) and statin therapy are the only modalities with proven efficacy for the prevention of SVG stenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SVG stenosis occurs in three phases: early; intermediate; and late.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Early occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;SVG occlusion occurs prior to hospital discharge in approximately 10 percent of grafts. This complication may be related to small vessel size (&lt;1.5 mm), severity of bypassed proximal stenosis &lt;70 percent, and technical factors, such as kinks from excessive length of the graft or poor distal artery runoff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Intermediate phase occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another 5 to 10 percent of grafts become occluded between one month and one year after surgery. A variety of factors contribute to this process including platelet aggregation, growth factor secretion, endothelial dysfunction due to reduced endothelial production of nitric oxide and prostacyclin, decreased local fibrinolytic potential resulting from upregulation of plasminogen activator inhibitor-1, luminal foam cell accumulation, and marked intimal hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. At least some of these changes are more pronounced in venous compared to arterial grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important modulator of these events is thrombin, and functional thrombin receptors have been demonstrated on the endothelium and smooth muscle cells of the ITA and saphenous vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/14\">",
"     14",
"    </a>",
"    ]. While these receptors mediate vasodilation in the ITA, they result in contraction and smooth muscle cell proliferation in the saphenous vein.",
"   </p>",
"   <p>",
"    Intravascular ultrasound has confirmed that even angiographically normal SVGs have a significant increase in intimal thickness at one year compared to the first month after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/15\">",
"     15",
"    </a>",
"    ]. Exposure of the vein to arterial pressure is presumably at least in part responsible for this change; one effect of such a hemodynamic change is rapid downregulation of thrombomodulin which is responsible for the sequestration of thrombin and activation of protein C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Late occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The late phase occurs after the first year when the areas of intimal hyperplasia develop lipid deposition and finally an atherosclerotic plaque. From the end of year one to year six, SVGs close at the rate of approximately 2 percent per year; the subsequent closure rate rises to 4 to 5 percent per year. In such grafts, there is no focal compensatory enlargement in the stenotic segments (compared to normal graft segments) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/17\">",
"     17",
"    </a>",
"    ]. This is in contrast to what has been seen in native atherosclerotic arteries in which the development of an atherosclerotic plaque is associated with enlargement of the vessel and preservation of the lumen area until plaque progression exceeds the compensatory mechanism of the vessel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late stenoses in SVGs appear to have a worse prognosis than late stenoses in the native coronary vessels. In one report, for example, patients with stenotic SVGs to the left anterior descending (LAD) artery had two and five year survival rates of 70 and 50 percent compared to 97 and 80 percent for patients with native LAD stenoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictors of late occlusion have been evaluated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To establish factors that predict three-year graft patency, data from 266 patients with 656 grafts that were patent seven to ten days after surgery were analyzed by the Veterans Affairs Cooperative Study Group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/20\">",
"       20",
"      </a>",
"      ]. With a multivariate analysis, the only factors that were predictive were vein preservation solution temperature &le;5&ordm;C, serum cholesterol, the number of proximal anastomoses &le;2, and recipient artery diameter &gt;5 mm. Thus, predictors of three-year graft patency are most closely related to operative techniques and the underlying disease.",
"     </li>",
"     <li>",
"      To establish factors that predict the late progression of SVG atherosclerosis, 1248 patients in the Postcoronary Artery Bypass Graft (Post CABG) trial underwent angiography at baseline (1 to 11 years after CABG) and 4.3 years later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/21\">",
"       21",
"      </a>",
"      ]. Factors independently associated with the progression of disease, in order of importance, were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maximum stenosis of the graft at baseline angiography",
"     </li>",
"     <li>",
"      Years after CABG",
"     </li>",
"     <li>",
"      Moderate therapy to lower LDL cholesterol",
"     </li>",
"     <li>",
"      Prior MI",
"     </li>",
"     <li>",
"      High triglyceride levels",
"     </li>",
"     <li>",
"      Small minimum graft diameter",
"     </li>",
"     <li>",
"      Low HDL concentration",
"     </li>",
"     <li>",
"      High LDL concentration",
"     </li>",
"     <li>",
"      High mean arterial pressure",
"     </li>",
"     <li>",
"      Low left ventricular ejection fraction",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Current cigarette smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4121335\">",
"    <span class=\"h4\">",
"     Endoscopic vein-graft harvesting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic vein-graft harvesting is preferred to an open technique due to a lower incidence of wound (leg) complications, better cosmetic appearance, and less pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H19#H19\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Leg wound complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there have been concerns about long-term outcomes such as vein-graft failure rate or mortality after the endoscopic technique. Earlier observational studies of relatively small size came to differing conclusions, with one showing worse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/22\">",
"     22",
"    </a>",
"    ], one showing improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/23\">",
"     23",
"    </a>",
"    ], and one showing no difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/24\">",
"     24",
"    </a>",
"    ] in outcomes.",
"   </p>",
"   <p>",
"    The best evidence regarding long-term outcomes comes from a 2012 study of 235,294 patients in the United States Society of Thoracic Surgeons national database who underwent isolated CABG between 2003 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/25\">",
"     25",
"    </a>",
"    ]. In this report, 52 percent of patients received endoscopic vein-graft harvesting. After propensity score adjustment, there was no difference between endoscopic or open harvesting in long-term mortality (13.2 versus 13.4 percent, respectively; hazard ratio 1.00, 95% CI 0.97-1.04) or a composite of death, myocardial infarction, and revascularization (19.5 versus 19.7 percent, hazard ratio 1.00, 95% CI 0.98-1.05) during a median follow-up of three years.",
"   </p>",
"   <p>",
"    The potential role of chronic kidney disease in late graft occlusion is discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Chronic kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157947738\">",
"    <span class=\"h3\">",
"     Single versus multiple distal anastomoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a vein graft can be used for single or distal anastomoses, concerns have been raised about the possibility of worse outcomes when performed for the latter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/26\">",
"     26",
"    </a>",
"    ]. These concerns are based on a greater likelihood of technical failure and their more frequent use with poor distal coronary targets. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Early occlusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The issue of whether long-term outcomes differ with single or multiple distal anastomoses using SVGs was evaluated in a post-hoc, substudy of the PREVENT IV trial, which randomly assigned 3014 patients undergoing first CABG with at least two planned SVGs to either a novel agent used to prevent neointimal hyperplasia or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/27\">",
"     27",
"    </a>",
"    ]. The use of SVG conduits with multiple distal anastomoses was associated with a significantly higher rate of SVG failure (defined as a &ge;75 percent angiographic stenosis) at one year (adjusted odds ratio 1.24, 95% CI 1.03-1.48) and a trend toward a higher rate of the adjusted composite of death, MI, or revascularization at five years (hazard ratio 1.15, 95% CI 1.00-1.31).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15134962\">",
"    <span class=\"h2\">",
"     Internal mammary versus saphenous vein grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a consequence of higher long-term graft patency and survival, an internal thoracic artery graft, as opposed to a saphenous vein graft, has become the conduit of choice for initial surgery and at reoperation for SVG stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80757869\">",
"    <span class=\"h3\">",
"     Patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early patency of a left ITA (LITA) anastomosed to the LAD is almost 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/30\">",
"     30",
"    </a>",
"    ] and approximately 94 percent for a right ITA anastomosed to major branches of the left circumflex artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/31\">",
"     31",
"    </a>",
"    ]. There are infrequent cases in which the ITA graft develops a stenosis or becomes occluded; this usually occurs within three months of surgery. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment of ITA graft stenosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Long-term graft patency is much higher with ITA than venous grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. There are a number of anatomic and physiologic differences between saphenous veins and internal thoracic arteries that may contribute to this difference (",
"    <a class=\"graphic graphic_table graphicRef61252 \" href=\"mobipreview.htm?4/15/4349\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In initial studies, long-term graft patency in left ITA grafts was 85 to 90 percent (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"mobipreview.htm?23/28/24013\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. However, better outcomes have been described in later reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. This was illustrated in a review of over 2127 arterial to coronary grafts from the Royal Melbourne Hospital of 2127 arterial conduits, which found that patency was influenced by the type of conduit, the coronary territory grafted, and the severity of target vessel stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ITA graft patency was 98 percent at five years, 95 percent at 10 years, and 88 percent at 15 years. Overall patency was significantly higher with grafts to the left anterior descending artery compared to the circumflex marginal artery and when grafted to a native coronary artery with more than 60 percent compared to less than 60 percent stenosis (97 versus 92 percent for both comparisons). The worse outcomes with circumflex grafts may reflect greater technical difficulty, stretching of the left ITA pedicle, or smaller less optimal target vessels.",
"     </li>",
"     <li>",
"      Right ITA graft patency was 96 percent at five years, 81 percent at 10 years, and 88 percent at 15 years. Graft patency varied with the territory grafted, ranging from 95 percent to the left anterior descending artery to 90 percent to the circumflex marginal artery to 83 percent to the right coronary or posterior descending artery. The higher rate of patency when grafted to the left anterior descending may reflect shorter graft length, less difficulty surgery, and better runoff. Graft patency also varied with the severity of target vessel stenosis, ranging from 91 percent with more than 60 percent stenosis to 65 percent in the many fewer cases with less than 60 percent.",
"     </li>",
"     <li>",
"      SVG graft patency was lower at 61 percent and did not vary with the coronary territory grafted or the severity of target vessel stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even higher rates of long-term ITA graft patency were also noted in a review of 2121 ITA grafts from the Cleveland Clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At ten years, patency rates were 98 to 99 percent for ITA grafts to the left descending, diagonals, circumflex, and posterior descending arteries.",
"     </li>",
"     <li>",
"      In contrast, the ten year patency rate was only 83 percent to right coronary arteries but, similar to the previous study, the outcomes were better when the target vessel had &ge;70 percent stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increase in graft patency with ITA grafts has translated into improvements in patient survival. (See",
"    <a class=\"local\" href=\"#H98316246\">",
"     'Arterial versus vein grafts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There has been some concern that the long-term benefit of ITA grafts should be balanced against short-term perioperative risk of graft harvest in higher risk patients. However, this concern may not be warranted. This was suggested in a review from the Clinical Outcomes Assessment Program in the state of Washington in which left ITA grafts accounted for 82 percent of CABG procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/33\">",
"     33",
"    </a>",
"    ]. Left ITA grafting was associated with a significant reduction in perioperative mortality (1.6 versus 3.7 percent when the left ITA was not used) as well as a reduction in morbid events such as ventricular arrhythmias, ventilator dependence, and the need for postoperative dialysis. These outcomes were seen in all subgroups patients over age 75, women, and those with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80757599\">",
"    <span class=\"h3\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of higher long-term patency with arterial compared to saphenous vein grafts described above (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"mobipreview.htm?23/28/24013\">",
"     figure 1",
"    </a>",
"    ) translates into improved long-term survival (",
"    <a class=\"graphic graphic_figure graphicRef69211 \" href=\"mobipreview.htm?20/46/21229\">",
"     figure 2",
"    </a>",
"    ). This was illustrated in a study of almost 6000 patients, which compared the 10-year survival of patients who had one ITA to LAD graft alone or combined with one or more SVGs to those who had only SVGs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/1\">",
"     1",
"    </a>",
"    ]. The following significant 10-year survival benefits for arterial grafting were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One vessel disease &mdash; 93 versus 88 percent for SVGs",
"     </li>",
"     <li>",
"      Two vessel disease &mdash; 90 versus 80 percent",
"     </li>",
"     <li>",
"      Three vessel disease &mdash; 83 versus 71 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After adjustment for clinical and demographic differences, patients receiving a venous graft had, at 10 years, a 1.61 times greater risk of death and a 1.41 times greater risk of late MI compared to those with arterial grafts.",
"   </p>",
"   <p>",
"    Two other series have shown that these mortality benefits persist at 15 and 20 year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A report from the Coronary Artery Surgery Study compared 749 arterial grafts to 4888 saphenous vein grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/34\">",
"     34",
"    </a>",
"    ]. Fifteen-year patient survival was significantly higher with arterial grafts: 64 versus 53 percent (",
"    <a class=\"graphic graphic_figure graphicRef69211 \" href=\"mobipreview.htm?20/46/21229\">",
"     figure 2",
"    </a>",
"    ). The difference increased with time, suggesting that initial selection of an arterial graft had a more important influence on survival than progressive atherosclerosis in vessels that were not bypassed or were distal to the anastomosis. Patients with arterial grafts also tend to have fewer reoperations and a lower rate of MI or recurrent angina compared to those with SVGs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these and other data conclusively demonstrating a survival advantage and minimal if any excess morbidity, a left ITA to the LAD is now considered a clinical standard in all patient groups (including elderly patients, diabetic patients, and women). The discussion has shifted from the benefit of a single ITA graft to the potential benefits of more complete arterial revascularization. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Total arterial revascularization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment of ITA graft stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic ITA graft stenosis can occur at any time, ranging from soon after surgery to years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/36\">",
"     36",
"    </a>",
"    ]. The stenotic lesion is most commonly located at the site of anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. One possible cause is excessive neointimal proliferation resulting from extensive damage to the arterial wall during grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of early (within 30 days) and late ischemia after CABG are discussed separately. Late ischemia may be due to either graft problems or progression of native vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=see_link\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     LIMA plus another arterial graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of arterial graft patency have led to the use of combinations of arterial grafts, including bilateral ITA grafts, left ITA and radial artery grafts, and \"total arterial revascularization.\" However, improved outcomes with two, as opposed to one, arterial graft have not been conclusively demonstrated. This is potentially the explanation for why a 2010 report from the (United States) Society of Thoracic Surgeons found that less than 15 percent of patients undergoing a CABG receive more than one arterial graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bilateral ITA grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral internal thoracic artery grafting, using both the left and right ITAs, has been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. In a series of 2001 patients undergoing bilateral ITA grafts, with or without additional SVG grafts, the in-hospital mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/44\">",
"     44",
"    </a>",
"    ] was 0.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/41\">",
"     41",
"    </a>",
"    ]. Complications such as stroke, myocardial infarction (MI), sternal infection, and reoperation for hemorrhage each occurred in 0.7 to 1.1 percent of patients. Similar findings were noted in a review of 867 patients with bilateral ITA grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term results from randomized trials of single versus bilateral ITA grafting are not available. Short terms results from the ten year Arterial Revascularization Trial (ART), in which 3102 patients were randomly assigned to single or bilateral ITA grafting, have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/44\">",
"     44",
"    </a>",
"    ]. Mortality at 30 days and at one year was similar in both groups (1.2 and 2.3 versus 2.5 percent respectively). There was a small but significant increase in the rate of sternal wound reconstruction in those who received bilateral ITA grafts (1.9 versus 0.6 percent).",
"   </p>",
"   <p>",
"    Observational studies support the use of bilateral ITA grafting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two retrospective reports have assessed the in-hospital outcome of bilateral compared to single ITA grafts, with or without additional SVG grafts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. There were no differences in in-hospital mortality, the number of complications, or the length of hospitalization. One of these two series also evaluated long-term survival, which was better with bilateral ITA grafting at 10 years (81 versus 78 percent) and at 20 years (50 versus 37 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study evaluated 1131 patients undergoing elective primary multiple CABG for multivessel disease: 443 patients underwent bilateral ITA grafting and 688 underwent single ITA grafting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/43\">",
"       43",
"      </a>",
"      ]. In-hospital mortality was 0.9 percent in both groups. At six to seven years, patients receiving bilateral ITA grafts had significant increases in graft patency (97.3 versus 94.3 percent) in repeat CABG-free rate (99.5 versus 97 percent) and a trend toward a lower incidence of new MI; there was no difference in survival.",
"     </li>",
"     <li>",
"      A meta-analysis evaluated 15,962 patients from nine well-designed cohort studies comparing bilateral and single ITA grafts in patients who were followed for at least four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/46\">",
"       46",
"      </a>",
"      ]. Patient survival was better with bilateral grafts (hazard ratio 0.81, 95 percent CI 0.70-0.94).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, the main setting in which bilateral ITA grafting should be considered is in young patients in whom long-term graft survival and freedom from reintervention is particularly important. However, this approach may increase the risk of poor mediastinal healing, possibly leading to mediastinitis, especially in patients with diabetes, chronic obstructive pulmonary disease, or obesity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another procedure, bilateral skeletonized ITA grafting in which both internal thoracic arteries are dissected from their neurovascular bundles, preserves sternal collateral blood supply, thereby enabling rapid sternal healing with less risk of deep sternal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A retrospective cohort study of 1515 patients, many of whom were elderly or had diabetes, suggests that this technique is associated with low perioperative morbidity and comparable long-term survival relative to patients who receive a single ITA graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80756716\">",
"    <span class=\"h3\">",
"     Free arterial grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because ITA grafts enjoy a higher patency rate than vein grafts, the use of other arteries for coronary grafting has been investigated. With free arterial grafts, an arterial segment is excised and anastomosed from the aorta to the coronary artery or, to avoid aortic manipulation, as a T side graft from another pedicled ITA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80756723\">",
"    <span class=\"h4\">",
"     Radial artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of radial artery grafting as part of CABG continues to evolve.",
"   </p>",
"   <p>",
"    There is increasing use of the radial artery, which requires an evaluation for adequate ulnar artery flow to prevent the loss of hand function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/32,49,50\">",
"     32,49,50",
"    </a>",
"    ]. There are usually only minimal changes in hand function after CABG, manifested by a small amount of forearm numbness and tingling, but no change in motor function or tolerance to temperature or pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/51\">",
"     51",
"    </a>",
"    ]. These symptoms are self-limited in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One drawback with the use of the radial artery is the development of spasm of the graft, which has been reported to occur in 4 to 10 percent of radial grafts immediately after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The radial artery is particularly prone to spasm, possibly because of its large medial cross-sectional area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/55\">",
"     55",
"    </a>",
"    ]. A variety of vasodilator agents, most commonly calcium channel blockers, have been used to prevent spasm of radial grafts after implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term outcome with radial artery grafts has been excellent in most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2,50,57-59\">",
"     2,50,57-59",
"    </a>",
"    ] but not all observational series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/60\">",
"     60",
"    </a>",
"    ], with patency rates as high as 96 percent at one year and 89 percent at four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of radial artery patency is higher when grafted to a native coronary artery with more than 80 percent stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2,61\">",
"     2,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three randomized trials with at least one year of follow-up have compared the long-term patency of radial artery and saphenous vein bypass grafts in patients with multivessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RAPS included 561 patients with a left ventricular ejection fraction greater than 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/62\">",
"       62",
"      </a>",
"      ]. All patients received an ITA graft to the left anterior descending coronary (LAD) artery. Patients were then randomly assigned to receive an SVG to the left circumflex and a radial artery graft to the right coronary artery, or the reverse. At one year angiographic follow-up in 440 patients, the incidence of complete occlusion was significantly greater with SVGs than with radial artery grafts (13.6 versus 8.2 percent).",
"     </li>",
"     <li>",
"      In the RSVP trial, 142 patients were randomly assigned to receive either a free radial artery or saphenous vein graft to a branch of the circumflex artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/63\">",
"       63",
"      </a>",
"      ]. At five year angiographic follow-up, the primary endpoint of angiographic patency was significantly higher in those patients who received a radial artery graft (98 versus 86 percent).",
"     </li>",
"     <li>",
"      In a study of 733 patients undergoing first time CABG, the left internal thoracic artery was grafted to the LAD when possible. Patients were then randomly assigned to either a radial artery or a saphenous vein graft in the best remaining recipient vessel. At one year angiographic follow-up, there was no significant difference in the rate of graft patency (89 versus 86 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If possible, radial artery grafts should be avoided in patients with chronic renal disease who are at risk for requiring dialysis. Harvesting of a radial artery in such patients precludes use of the ipsilateral arm for vascular access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80756750\">",
"    <span class=\"h4\">",
"     Gastroepiploic artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another artery that has been successfully used is the right gastroepiploic artery, when the luminal diameter is &gt;2 mm. This vessel may be grafted to a single coronary artery or sequentially to several coronary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. It may be particularly useful in reoperations with limited conduits in patients with a posterior descending or posterior lateral artery target.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80757121\">",
"    <span class=\"h3\">",
"     Right ITA versus radial artery as a second arterial graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;An attempt is made to perform left internal thoracic artery grafting in all patients undergoing CABG. The issue of whether the right internal thoracic or the radial artery is a better second arterial graft was evaluated in an observational study of 1001 patients undergoing first nonemergent CABG and who were receiving one of these two in addition to a LITA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/67\">",
"     67",
"    </a>",
"    ]. SVGs were used as needed. The primary outcome was long-term overall survival and major adverse cardiac and cerebrovascular events (MACCE): free survival, with the latter defined as a combined end point including myocardial infarction, stroke, cardiac-related death, and repeat revascularization. After propensity-score matching, the following findings comparing bilateral ITA to LITA plus radial artery were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of perioperative MACCE was lower (1.4 versus 7.6 percent).",
"     </li>",
"     <li>",
"      After a median follow-up of about 58 months, overall survival and MACCE-free survival were significantly better with bilateral ITA (hazard ratio 0.23, 95% CI 0.066-0.81 and 0.18, 95% CI 0.08-0.42, respectively).",
"     </li>",
"     <li>",
"      The rate of sternal dehiscence was similar (3.2 versus 3.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Total arterial revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of all arterial grafts for CABG markedly reduces the risk of stenosis or occlusion associated with SVG grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2,32,68-71\">",
"     2,32,68-71",
"    </a>",
"    ]. However, this approach is technically demanding and takes longer to perform than other types of CABG.",
"   </p>",
"   <p>",
"    In a review of 3220 patients undergoing total arterial coronary revascularization at the Royal Melbourne Hospital, the operative mortality was 0.7 percent, and angiographic graft patency was 97 and 89 percent at five years for left and right ITA grafts and 91 percent at one year for radial artery grafts (only 65 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of total arterial revascularization was also noted in a report from 27 centers in the United Kingdom included 71,470 patients who underwent CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/71\">",
"     71",
"    </a>",
"    ]. Total arterial revascularization was performed in 5401 (7.6 percent); the frequency increased over time from 3.2 in 1992 to 11.7 percent in 2001, with variability among centers. Propensity analysis revealed a nonsignificant small increase in in-hospital mortality with total arterial revascularization (1.74 versus 1.51 percent for one artery and veins).",
"   </p>",
"   <p>",
"    Total arterial revascularization also reduces the incidence of early cardiac events compared to standard CABG that includes SVGs. This was illustrated in a trial of 200 patients who were randomly assigned to either total arterial or standard CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/68\">",
"     68",
"    </a>",
"    ]. At one year, the total arterial group had significantly lower rates of recurrent angina (2 versus 13 percent for standard CABG) and percutaneous coronary intervention (0 versus 8 percent), and a significantly higher actuarial rate of freedom from death, MI, angina recurrence, graft occlusion, or percutaneous coronary intervention (96 versus 67 percent).",
"   </p>",
"   <p>",
"    The longest term comparative data comes from a retrospective comparison of 612 patients who received all arterial grafts and 4131 patients who received a single internal thoracic artery with one or more saphenous vein bypass grafts []. The 12 year survival was significantly better for patients who received all arterial conduits (86.1 versus 70.6 percent, adjusted risk ratio 0.60, 95% CI 0.48-0.75). However, the benefit was limited to patients with three vessel disease and not seen in patients with two vessel disease.",
"   </p>",
"   <p>",
"    The role of total arterial revascularization compared to single arterial grafts in all patients remains uncertain. However, current available data strongly suggest that more complete arterial revascularization (at least two arterial grafts to the left side of the heart) should be considered in all patients less than 70 years of age. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Incomplete revascularization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review the data on long-term survival after CABG. There is significantly more data about short-term outcomes, particularly perioperative outcomes, than there is about long-term outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many studies of late outcomes after CABG were carried out before current risk factor reduction recommendations in patients with coronary heart disease, such as aggressive reduction of LDL-cholesterol with statin. Thus, past estimates of long-term patient outcomes after CABG are of uncertain applicability to current practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'General medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another issue related to current practice is the comparison of outcomes after CABG with those after percutaneous coronary intervention (PCI). In initial trials, the main advantage with CABG was a much lower rate of target vessel revascularization. However, this difference has narrowed markedly with the availability of drug-eluting stents and PCI in now being performed in patients with unprotected left main disease or total chronic occlusion, lesions that in the past were only treated by CABG. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link&amp;anchor=H6#H6\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Drug-eluting stents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Survival rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality benefit from CABG is most evident in the first decade after surgery and then falls off. It is critically important to understand that survival rates vary with the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/34,72,73\">",
"     34,72,73",
"    </a>",
"    ]. In addition, as mentioned above, survival has improved over the years due both to improvements in perioperative care as well as long-term interventions aimed at reducing overall cardiovascular risk. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'General medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The best available data on long-term survival after CABG comes from 2012 reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ASCERT study linked data from the Society or Thoracic Surgeons Adult Cardiac Surgery Data base and the Centers for Medicare and Medicaid Services (United States) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/74\">",
"       74",
"      </a>",
"      ]. This study included nearly 350,000 isolated CABG patients aged &ge;65 years who were discharged between January 1, 2002 and December 31, 2007. Kaplan-Meier estimated mortality was 3.2 percent at 30 days, 6.4 percent at 180 days, 8.1 percent at one year, 11.3 percent at two years, and 23.3 percent at three years of follow up.",
"     </li>",
"     <li>",
"      In a report from the New York State Cardiac Surgery Reporting System database, the one-, three-, five-, and seven-year mortality rates of 8597 patients who underwent isolated CABG were 6.2, 11.2, 17.6, and 24.2 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5075872\">",
"       'Long-term risk prediction models'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Predictors of mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of the use of arterial grafts, advancement of disease in other vessels, and comorbid conditions appear to be major predictors of long-term outcome, particularly in patients aged &ge;65 years. The ASCERT study (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Survival rates'",
"    </a>",
"    above) made the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors such as emergency status, shock, and reoperation are strong predictors of short-term outcome, but become nonsignificant within two years.",
"     </li>",
"     <li>",
"      Other risk factors such as dialysis-dependent renal failure, insulin-dependent diabetes mellitus, and smoking become more important with time.",
"     </li>",
"     <li>",
"      Age (increment of 10), chronic lung disease (&ge;moderate), and creatinine 1.5-2.5 predict poor outcomes both short- and long-term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98316246\">",
"    <span class=\"h3\">",
"     Arterial versus vein grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left internal thoracic artery graft leads to improved survival compared to the saphenous vein graft. This is discussed in detail above. (See",
"    <a class=\"local\" href=\"#H80757599\">",
"     'Survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Incomplete revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;While complete revascularization (CR) has been the usual goal for CABG, the evidence to support superiority of CR compared to incomplete revascularization (IR) is not consistent, with more recent studies suggesting that incomplete revascularization (IR) may be equally safe and effective.",
"   </p>",
"   <p>",
"    Multiple older studies support CR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. The following are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the CASS registry of patients who underwent CABG for three vessel disease, placing grafts to three or more vessels was independently associated with improved survival at five years (87 to 90 percent versus 78 percent with a graft to only one vessel) and event-free survival at six years (30 versus 23 percent with a graft to only one vessel) in patients with severe but not mild to moderate angina [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The long-term impact of IR was examined in a review of 2067 patients seen between 1971 and 1997 who had isolated grafting of the LITA to the LAD; two or three vessel disease was present in 26 and 13 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/78\">",
"       78",
"      </a>",
"      ]. Compared to patients with only LAD disease, the 20 year survival was significantly lower in those who also had proximal left circumflex or any left main coronary artery disease or proximal right coronary artery disease (44 and 42 versus 75 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The applicability of these older studies to the current era is uncertain and the effect of other confounding high-risk factors is difficult to control. The following studies do not support an advantage to CR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review from the BARI trial comparing CABG to PCI with bare metal stents, there was no independent survival advantage from CR compared to IR, and more than one anastomosis to the non-LAD system conferred no long-term advantage and may have been deleterious [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in the ARTS I trial comparing CABG to bare metal stents in patients with multivessel disease, there was no difference in mortality out to five years in the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/80\">",
"       80",
"      </a>",
"      ], despite a higher rate of CR with CABG (84 versus 71 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/81\">",
"       81",
"      </a>",
"      ]. However, stented patients with IR were more significantly more likely to require CABG at one year (10 versus 2 percent of stented patients with CR). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H13#H13\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'ARTS I trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A single-center registry report of 514 patients undergoing CABG for multivessel CAD compared outcomes between those who received CR (67 percent) and those who received IR (33 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/82\">",
"       82",
"      </a>",
"      ]. Multiple analyses using differing definitions of IR (applied to the diagnostic angiogram prior to revascularization) found no significant difference in the adjusted rates of five year death or the composite of death, MI, or stroke between those with CR and those with IR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be kept in mind that the above studies were not randomized trials of CR versus IR and thus even well constructed analyses may be unable to adjust for all relevant variables. In addition variable definitions of IR prevent direct comparison of some studies. Lastly, not bypassing a stenosed vessel that supplies infarcted tissue may not have the same consequences as not bypassing a vessel that supplies a large territory of infarcted myocardium.",
"   </p>",
"   <p>",
"    Thus, we believe that the goal for surgical revascularization should remain CR (with arterial grafts), whenever possible and safe. However, the above findings suggest that not all patients who undergo CABG require CR. In the setting of a left internal thoracic artery conduit to the left anterior descending artery (LAD), IR may be appropriate for non-LAD vessels that are small or to vessels that supply only a small amount of viable myocardium. In addition IR, as part of a strategy to simplify the surgical procedure in order to reduce operation-related complications, may be reasonable. This may be a situation in which a combined (staged) revascularization approach, with both CABG and percutaneous coronary intervention, may be reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98316636\">",
"    <span class=\"h3\">",
"     Perioperative MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative MI, defined as new Q waves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevations in CK-MB",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    troponins, are associated with postoperative complications and increases in short-term and long-term mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link&amp;anchor=H3#H3\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Perioperative MI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138528813\">",
"    <span class=\"h3\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is an independent predictor of both short- and long-term mortality after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. The following two studies are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 3460 adults, the in-hospital mortality rate increased progressively with greater reductions in estimated glomerular filtration rate (1.0, 10, 29, and 39 percent for patients with reductions in estimated glomerular filtration rate of &le;25 percent, &gt;25 percent or dialysis, &gt;50 percent or dialysis, or &gt;75 percent or dialysis, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort analysis of nearly 30,000 individuals, the magnitude of creatinine increase after CABG was associated in a graded manner with a significant increase in mortality at three months and five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/88\">",
"       88",
"      </a>",
"      ]. For example, the hazard ratios for death at three months were 1.4, 1.9, 2.8, and 5.0 in patients with 1-24, 25-49, 50-99, and &ge;100 percent rise in postoperative serum creatinine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease with a reduced glomerular filtration rate (GFR), even if mild, is associated with increased perioperative mortality after CABG. The mechanisms by which this occurs are not completely understood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H22#H22\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The baseline GFR is also a predictor of long-term mortality after CABG. This was illustrated in a series of 2607 consecutive patients undergoing CABG in whom the baseline serum creatinine was used to estimate the glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/89\">",
"     89",
"    </a>",
"    ]. At 2.3 years, the estimated GFR was an independent predictor of mortality in models with other univariable predictors and in the EuroSCORE cardiac operative risk evaluation (hazard ratio 0.80 to 0.88 per 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 increase in estimated GFR compared to a hazard ratio of 0.71 without adjustment).",
"   </p>",
"   <p>",
"    Multiple methods are available to estimate GFR. This topic and our recommendations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One mechanism by which chronic kidney disease might lead to a lower survival is by causing a lower rate of bypass graft patency. This issue was evaluated in the PREVENT IV trial, in which there was no significant difference between saphenous vein or internal thoracic artery graft failure rates in patients with or without preoperative renal dysfunction at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'General medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98316738\">",
"    <span class=\"h3\">",
"     Cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other variables affecting long-term outcome have been described in several reports and consist mostly of the known coronary risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/73,91-93\">",
"     73,91-93",
"    </a>",
"    ]. In the CASS registry, factors impacting negatively upon late survival, other than the use of SVGs alone, were heavier weight, MI, diabetes, smoking, and left main and left anterior descending disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/73\">",
"     73",
"    </a>",
"    ]. This issue was also addressed in a study of 3559 patients who underwent CABG at a single center and were followed for &ge;25 years; the following predictors of survival were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/91\">",
"     91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age - relative risk 1.54 for each decade",
"     </li>",
"     <li>",
"      Total cholesterol - relative risk 1.11 for each 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      increase",
"     </li>",
"     <li>",
"      Diabetes mellitus - relative risk 1.45",
"     </li>",
"     <li>",
"      Systemic hypertension - relative risk 1.28",
"     </li>",
"     <li>",
"      Cigarette smoking - relative risk 1.33",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described below, chronic kidney disease is now recognized as an important adverse predictor of survival after CABG.",
"   </p>",
"   <p>",
"    In a retrospective review of 6428 patients who were followed for a median of eight years after CABG, over 90 percent of those who died had at least one of these risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/92\">",
"     92",
"    </a>",
"    ]. The hazard ratio increased from 1.64 when one factor was present to 3.95 when all four risk factors were present. Women with this quartet had a poorer outcome than men (hazard ratio 13.4 versus 2.6).",
"   </p>",
"   <p>",
"    Some patients have a cluster of metabolic factors, like diabetes mellitus, hypertension, obesity, and hypertriglyceridemia, that is associated with insulin resistance. This syndrome, which has been called the metabolic syndrome, \"deadly quartet,\" or syndrome X, is associated with cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with diabetes mellitus, both observational studies and a randomized trial have shown improved in-hospital and long-term outcomes with strict glycemic control (using a continuous insulin infusion) during the perioperative period. Thus, maintenance of the serum glucose concentration below 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with a continuous insulin infusion should be a standard part of care of such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link&amp;anchor=H23#H23\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Perioperative glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation, both preoperative and postoperative, has been associated with increased long-term mortality. Although this effect persisted after adjusting for increased comorbidities in these patients, there are no data showing that preventing AF in such patients would prevent the increase in mortality. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H11#H11\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Adverse outcomes following AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is a common problem after CABG and is associated with an adverse effect on patient outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25528?source=see_link&amp;anchor=H9#H9\">",
"     \"Psychosocial factors in coronary and cerebral vascular disease\", section on 'Outcome after CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Preoperative Hemoglobin level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower preoperative hemoglobin (as a continuous variable) and anemia (defined as &lt;13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for men and &lt;12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for women) were independent predictors of higher late mortality (after 30 days) in a study of over 10,000 patients undergoing isolated CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5075872\">",
"    <span class=\"h2\">",
"     Long-term risk prediction models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The New York State Cardiac Surgery Reporting System database was linked to United States National Data Index to evaluate long-term mortality in nearly 8600 patients who underwent isolated CABG between July and December of 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/75\">",
"     75",
"    </a>",
"    ]. The significant predictors of death were similar to the individual factors presented above and included age, body mass index, ejection fraction, unstable hemodynamic state or shock, left main coronary artery disease, cerebrovascular or peripheral artery disease, heart failure, malignant ventricular arrhythmia, chronic obstructive pulmonary disease, diabetes, renal failure, and history of open heart surgery. Using these risk factors, a risk model to predict death at one, three, five, and seven years was developed and the statistical performance of the model was robust (C-statistic between 0.768 and 0.783). The survival rates are discussed above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Survival rates'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This New York state model is one of a few such long-term risk prediction models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. These models have not been widely integrated into clinical practice, although some have suggested that in the future they may play a role in the informed consent process or as part of quality assurance programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECURRENT ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of recurrent stable or unstable angina after CABG varies with the time after surgery when symptoms are first noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent angina during the postoperative period is usually due to a technical problem with a graft or with early graft closure. It is an indication for prompt coronary angiography with catheter revascularization, if feasible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent angina after the first few months is caused by both graft disease and by progression of atherosclerosis in non-bypassed vessels. Progression of native disease is the more likely cause after internal thoracic artery grafts, whereas graft disease is more likely after SVGs. Issues related to late recurrent angina are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=see_link\">",
"       \"Late recurrent angina pectoris after coronary artery bypass graft surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GENERAL MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive risk factor reduction is recommended in all patients with CHD. This includes low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , reaching treatment goals for hypertension and serum lipids, avoidance of smoking, and, in patients with diabetes, controlling the serum glucose. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential importance of risk factor intervention was illustrated in a report from the BARI trial cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/97\">",
"     97",
"    </a>",
"    ]. Among patients undergoing CABG or PCI, progression of disease in previously untreated vessels accounted for two-thirds of the increase in myocardium at risk at five years.",
"   </p>",
"   <p>",
"    A 2005 review found that there were few randomized controlled trials that examined the role of medical therapy in post-CABG patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/98\">",
"     98",
"    </a>",
"    ]. It was concluded that the data provide evidence supporting the routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and lipid-lowering drugs (particularly a statin), do not support the routine use of beta blockers, calcium channel blockers, or nitrates, and that more data were needed on the role of angiotensin converting enzyme (ACE) inhibitors. However, many of these patients require beta blockers and ACE inhibitors for preexistent heart failure or myocardial infarction according to American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guideline recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of underutilization of preventive medical therapies after CABG was evaluated in a follow-up study of 2970 patients enrolled in the PREVENT IV trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/101\">",
"     101",
"    </a>",
"    ]. Patients were assessed for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, ACE inhibitors or angiotensin receptor blockers, and lipid lowering agents after hospital discharge and at one year, and then categorized based upon their percentage use of indicated medications. Patients taking 50 percent or less compared with those taking all indicated medications after CABG had a significantly higher two-year rate of death or myocardial infarction (8 versus 4.2 percent, adjusted hazard ratio 1.69, 95% CI 1.12-2.55). Whether these data reflect the favorable prognostic benefits of compliance with recommend therapies noted in other studies, or to the actions of the drugs is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , are given within 48 hours of CABG to improve both short- and long-term cardiovascular outcomes, including the reduction in the incidence of early and late graft occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual recommendation in patients undergoing elective CABG has been to discontinue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    three to five days and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    five to seven days before surgery. However, with increasing experience, some surgeons recommend continuation of aspirin throughout the preoperative period. The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI recommended that aspirin should",
"    <strong>",
"     not",
"    </strong>",
"    be withheld before either elective or nonelective CABG after ST elevation MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/100\">",
"     100",
"    </a>",
"    ]. This recommendation was not changed in the 2009 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H26#H26\">",
"     \"Perioperative medication management\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the recommendations from the 2008 American College of Chest Physicians (ACCP) guideline on the primary and secondary prevention of coronary artery disease that patients who undergo CABG, including those who receive internal thoracic artery bypass grafting, should be started on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    six hours after surgery and continued indefinitely. If there is postoperative bleeding, it should be started as soon as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/104\">",
"     104",
"    </a>",
"    ]. That document recommends a dose of 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but we are more comfortable recommending 75 to 162",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as an acceptable range.",
"   </p>",
"   <p>",
"    We also suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 9 to 12 months, in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , in those patients who have undergone CABG following myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/104\">",
"     104",
"    </a>",
"    ]. The evidence to support this recommendation is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H19#H19\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are allergic to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (300 mg loading six hours after surgery, followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is recommended. Clopidogrel may actually be superior to aspirin, as observed in a subset analysis of 1480 patients with a prior CABG in the CAPRIE trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/105\">",
"     105",
"    </a>",
"    ]. The yearly rate of vascular death, MI, stroke, or rehospitalization for ischemia or bleeding was significantly lower with clopidogrel than aspirin (16 versus 22 percent). The long-term safety of continuing clopidogrel after CABG requires additional study and should be weighed against potential risks of this therapy.",
"   </p>",
"   <p>",
"    Oral anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) is recommended only if such therapy is indicated for other reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Lipid lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have shown that statin therapy is beneficial in almost all patients with coronary heart disease, including those who have undergone CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/106-111\">",
"     106-111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition aggressive lipid lowering therapy with a statin is associated with better outcomes than less aggressive therapy when started after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. In the Post Coronary Artery Bypass Graft trial, 1351 patients with serum LDL-cholesterol concentrations between 130 and 175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 to 4.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were randomly assigned to receive either aggressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    and, if needed,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , to reduce LDL-cholesterol to less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or to moderate therapy, which resulted in LDL-cholesterol concentrations of approximately 134",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/109\">",
"     109",
"    </a>",
"    ]. Compared to moderate therapy, aggressive therapy was associated with a delay in the progression of graft disease at angiography after an average of 4.3 years (",
"    <a class=\"graphic graphic_figure graphicRef72758 \" href=\"mobipreview.htm?19/19/19774\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. In addition a 30 percent reduction in revascularization procedures and a 24 percent reduction in the composite endpoint of cardiovascular death, MI, stroke, CABG, or angioplasty (",
"    <a class=\"graphic graphic_figure graphicRef74401 \" href=\"mobipreview.htm?21/39/22142\">",
"     figure 4",
"    </a>",
"    ) was seen after clinical follow-up of 7.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence supporting aggressive lipid lowering in CABG patients comes from a post hoc analysis from the TNT trial of patients with stable CAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/108\">",
"     108",
"    </a>",
"    ]. In the 4654 (out of 10,000) patients with previous CABG, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (80 mg daily) was significantly more effective than low dose (10 mg daily) at lowering the rate of a combined cardiovascular endpoint at a median follow-up of 4.9 years (9.7 versus 13.0 percent; hazard ratio 0.73, 95% CI 0.62-0.87). Repeat revascularization with either CABG or PCI was also significantly less frequent in patients with the higher dose (11.3 versus 15.9 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H5#H5\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Trials not showing mortality benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated low serum HDL-cholesterol is also a risk factor for the development of coronary artery disease and may contribute to the development of SVG disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/112\">",
"     112",
"    </a>",
"    ]. The approach to patients with low serum HDL-cholesterol is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interesting, but unexplained finding in the Post Coronary Artery Bypass Graft trial was a benefit from random assignment to low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (1 to 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    during the extended 7.5 year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/111\">",
"     111",
"    </a>",
"    ]. Compared to placebo, warfarin reduced deaths by 35 percent; deaths or MI by 31 percent; and the composite clinical endpoint of death, MI, stroke, CABG, or angioplasty by 17 percent. In contrast, warfarin was not effective in a smaller randomized trial of patients who developed unstable angina or non-ST elevation MI after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link\">",
"     \"Chronic anticoagulation after acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further studies are needed to assess the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from both the APRES and QUO VADIS trials suggested a specific benefit from ACE inhibition in patients who undergo CABG. The APRES trial evaluated the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    in 159 patients with chronic stable angina, an LVEF between 30 and 50 percent, and no clinical HF who underwent CABG or angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/114\">",
"     114",
"    </a>",
"    ]. At a 33 month follow-up, ramipril significantly reduced the composite endpoint of cardiac death, acute MI, or clinical HF compared to placebo (10 versus 23 percent for placebo, risk reduction 58 percent, 95% CI 7 to 80 percent) (",
"    <a class=\"graphic graphic_figure graphicRef53107 \" href=\"mobipreview.htm?12/45/13021\">",
"     figure 5",
"    </a>",
"    ). The benefit of ramipril was independent of the LVEF and the method of revascularization (bypass surgery or angioplasty). The incidence of recurrent angina was not reduced with ramipril.",
"   </p>",
"   <p>",
"    Similar benefits were noted in the placebo-controlled QUO VADIS trial in which left ventricular dysfunction was not an entry criterion and in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/29/24024?source=see_link\">",
"     quinapril",
"    </a>",
"    was begun four weeks prior to elective CABG and then continued after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these findings cannot be used to support a specific benefit from ACE inhibitors or angiotensin II receptor blockers (ARBs) since the blood pressure was also significantly lower in the ACE inhibitor group (eg,",
"    <span class=\"nowrap\">",
"     128/75",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     136/81",
"    </span>",
"    mmHg with placebo at one year in the APRES trial). In a number of other trials that have evaluated ACE inhibitors or ARBs compared to placebo or other antihypertensive in high-risk groups, the intervention that was associated with the lowest blood pressure consistently produced the better best. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, individuals at low risk of cardiovascular events after CABG may not derive specific benefit from angiotensin inhibition. This issue was addressed in the IMAGINE trial in which 2553 low-risk patients following CABG were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (target dose 40 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/2/37930/abstract/116\">",
"     116",
"    </a>",
"    ]. Low-risk was defined as stable patients with LVEF &ge;40 percent and no other clear indication such as uncontrolled hypertension, diabetes with microalbuminuria or insulin dependency. After a median follow-up of almost three years, there was no significant difference between the two groups in the combined primary endpoint (cardiovascular death, resuscitated cardiac arrest, nonfatal myocardial infarction, coronary revascularization, unstable angina or heart failure requiring hospitalization, documented angina, or stroke).",
"   </p>",
"   <p>",
"    These findings do not preclude the use of ACE inhibitors or ARBs nor do they minimize the utility of these drugs as first-line therapy in all CABG patients who have specific indications for their use, such as left ventricular systolic dysfunction or proteinuric chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H18#H18\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41023269\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term graft patency is typical with internal thoracic artery (ITA) bypass grafts, while saphenous vein graft (SVG) patency declines significantly starting at the time of surgery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Choice of graft'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ten-year survival of ITA grafts greater than 90 percent in most series.",
"     </li>",
"     <li>",
"      SVG occlusion occurs prior to hospital discharge in approximately 10 percent of grafts.",
"     </li>",
"     <li>",
"      From the end of year one to year six, SVGs close at the rate of approximately 2 percent per year; the subsequent closure rate rises to 4 to 5 percent per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ITA grafts have also been associated with improved patient survival. (See",
"      <a class=\"local\" href=\"#H98316246\">",
"       'Arterial versus vein grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term outcome with radial artery grafts has been excellent in most but not all observational series, with patency rates as high as 96 percent at one year and 89 percent at four years. (See",
"      <a class=\"local\" href=\"#H80756723\">",
"       'Radial artery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients receive at least one arterial graft, usually an ITA. Some patients are treated with bilateral ITA or total arterial revascularization. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'LIMA plus another arterial graft'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive risk factor reduction is recommended in all patients with coronary heart disease, including those who have undergone coronary artery bypass graft surgery. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'General medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/1\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/2\">",
"      Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg 2004; 77:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/3\">",
"      Sabik JF 3rd, Lytle BW, Blackstone EH, et al. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system. Ann Thorac Surg 2005; 79:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/4\">",
"      Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/5\">",
"      Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004; 44:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/6\">",
"      Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/7\">",
"      Schwartz L, Kip KE, Frye RL, et al. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/8\">",
"      Shi Y, O'Brien JE Jr, Mannion JD, et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997; 95:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/9\">",
"      Yang Z, Oemar BS, Carrel T, et al. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 1998; 97:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/10\">",
"      Chello M, Mastroroberto P, Perticone F, et al. Nitric oxide modulation of neutrophil-endothelium interaction: difference between arterial and venous coronary bypass grafts. J Am Coll Cardiol 1998; 31:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/11\">",
"      L&uuml;scher TF, Diederich D, Siebenmann R, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988; 319:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/12\">",
"      Kauhanen P, Sir&eacute;n V, Carp&eacute;n O, et al. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation 1997; 96:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/13\">",
"      Kockx MM, De Meyer GR, Bortier H, et al. Luminal foam cell accumulation is associated with smooth muscle cell death in the intimal thickening of human saphenous vein grafts. Circulation 1996; 94:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/14\">",
"      Yang Z, Ruschitzka F, Rabelink TJ, et al. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation 1997; 95:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/15\">",
"      Hozumi T, Yoshikawa J, Yoshida K, et al. Use of intravascular ultrasound for in vivo assessment of changes in intimal thickness of angiographically normal saphenous vein grafts one year after aortocoronary bypass surgery. Heart 1996; 76:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/16\">",
"      Gosling M, Golledge J, Turner RJ, Powell JT. Arterial flow conditions downregulate thrombomodulin on saphenous vein endothelium. Circulation 1999; 99:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/17\">",
"      Nishioka T, Luo H, Berglund H, et al. Absence of focal compensatory enlargement or constriction in diseased human coronary saphenous vein bypass grafts. An intravascular ultrasound study. Circulation 1996; 93:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/18\">",
"      Hermiller JB, Tenaglia AN, Kisslo KB, et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol 1993; 71:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/19\">",
"      Lytle BW, Loop FD, Taylor PC, et al. Vein graft disease: the clinical impact of stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 1992; 103:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/20\">",
"      Goldman S, Zadina K, Krasnicka B, et al. Predictors of graft patency 3 years after coronary artery bypass graft surgery. Department of Veterans Affairs Cooperative Study Group No. 297. J Am Coll Cardiol 1997; 29:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/21\">",
"      Domanski MJ, Borkowf CB, Campeau L, et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol 2000; 36:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/22\">",
"      Lopes RD, Hafley GE, Allen KB, et al. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med 2009; 361:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/23\">",
"      Dacey LJ, Braxton JH Jr, Kramer RS, et al. Long-term outcomes of endoscopic vein harvesting after coronary artery bypass grafting. Circulation 2011; 123:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/24\">",
"      Zenati MA, Shroyer AL, Collins JF, et al. Impact of endoscopic versus open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. J Thorac Cardiovasc Surg 2011; 141:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/25\">",
"      Williams JB, Peterson ED, Brennan JM, et al. Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA 2012; 308:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/26\">",
"      Sabik JF 3rd. Understanding saphenous vein graft patency. Circulation 2011; 124:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/27\">",
"      Mehta RH, Ferguson TB, Lopes RD, et al. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. Circulation 2011; 124:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/28\">",
"      Ferguson TB Jr, Coombs LP, Peterson ED. Internal thoracic artery grafting in the elderly patient undergoing coronary artery bypass grafting: room for process improvement? J Thorac Cardiovasc Surg 2002; 123:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/29\">",
"      Leavitt BJ, O'Connor GT, Olmstead EM, et al. Use of the internal mammary artery graft and in-hospital mortality and other adverse outcomes associated with coronary artery bypass surgery. Circulation 2001; 103:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/30\">",
"      Berger PB, Alderman EL, Nadel A, Schaff HV. Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass. Circulation 1999; 100:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/31\">",
"      Ura M, Sakata R, Nakayama Y, et al. Analysis by early angiography of right internal thoracic artery grafting via the transverse sinus : predictors of graft failure. Circulation 2000; 101:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/32\">",
"      Tatoulis J, Buxton BF, Fuller JA, Royse AG. Total arterial coronary revascularization: techniques and results in 3,220 patients. Ann Thorac Surg 1999; 68:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/33\">",
"      Dabal RJ, Goss JR, Maynard C, Aldea GS. The effect of left internal mammary artery utilization on short-term outcomes after coronary revascularization. Ann Thorac Surg 2003; 76:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/34\">",
"      Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period. N Engl J Med 1996; 334:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/35\">",
"      Cameron AA, Green GE, Brogno DA, Thornton J. Internal thoracic artery grafts: 20-year clinical follow-up. J Am Coll Cardiol 1995; 25:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/36\">",
"      Najm HK, Leddy D, Hendry PJ, et al. Postoperative symptomatic internal thoracic artery stenosis and successful treatment with PTCA. Ann Thorac Surg 1995; 59:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/37\">",
"      Gruberg L, Dangas G, Mehran R, et al. Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. J Am Coll Cardiol 2000; 35:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/38\">",
"      Hosono M, Ueda M, Suehiro S, et al. Neointimal formation at the sites of anastomosis of the internal thoracic artery grafts after coronary artery bypass grafting in human subjects: an immunohistochemical analysis. J Thorac Cardiovasc Surg 2000; 120:319.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.sts.org/documents.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/40\">",
"      Galbut DL, Traad EA, Dorman MJ, et al. Seventeen-year experience with bilateral internal mammary artery grafts. Ann Thorac Surg 1990; 49:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/41\">",
"      Lytle BW, Blackstone EH, Loop FD, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 1999; 117:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/42\">",
"      Ioannidis JP, Galanos O, Katritsis D, et al. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. J Am Coll Cardiol 2001; 37:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/43\">",
"      Endo M, Nishida H, Tomizawa Y, Kasanuki H. Benefit of bilateral over single internal mammary artery grafts for multiple coronary artery bypass grafting. Circulation 2001; 104:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/44\">",
"      Taggart DP, Altman DG, Gray AM, et al. Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J 2010; 31:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/45\">",
"      Lytle BW, Blackstone EH, Sabik JF, et al. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg 2004; 78:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/46\">",
"      Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 2001; 358:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/47\">",
"      Pevni D, Mohr R, Lev-Run O, et al. Influence of bilateral skeletonized harvesting on occurrence of deep sternal wound infection in 1,000 consecutive patients undergoing bilateral internal thoracic artery grafting. Ann Surg 2003; 237:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/48\">",
"      Pevni D, Uretzky G, Mohr A, et al. Routine use of bilateral skeletonized internal thoracic artery grafting: long-term results. Circulation 2008; 118:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/49\">",
"      Manasse E, Sperti G, Suma H, et al. Use of the radial artery for myocardial revascularization. Ann Thorac Surg 1996; 62:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/50\">",
"      Acar C, Ramsheyi A, Pagny JY, et al. The radial artery for coronary artery bypass grafting: clinical and angiographic results at five years. J Thorac Cardiovasc Surg 1998; 116:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/51\">",
"      Dumanian GA, Segalman K, Mispireta LA, et al. Radial artery use in bypass grafting does not change digital blood flow or hand function. Ann Thorac Surg 1998; 65:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/52\">",
"      Anyanwu AC, Saeed I, Bustami M, et al. Does routine use of the radial artery increase complexity or morbidity of coronary bypass surgery? Ann Thorac Surg 2001; 71:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/53\">",
"      Possati G, Gaudino M, Alessandrini F, et al. Midterm clinical and angiographic results of radial artery grafts used for myocardial revascularization. J Thorac Cardiovasc Surg 1998; 116:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/54\">",
"      Tatoulis J, Royse AG, Buxton BF, et al. The radial artery in coronary surgery: a 5-year experience--clinical and angiographic results. Ann Thorac Surg 2002; 73:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/55\">",
"      Acar C, Jebara VA, Portogh&egrave;se M, et al. Comparative anatomy and histology of the radial artery and the internal thoracic artery. Implication for coronary artery bypass. Surg Radiol Anat 1991; 13:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/56\">",
"      He GW, Yang CQ. Comparative study on calcium channel antagonists in the human radial artery: clinical implications. J Thorac Cardiovasc Surg 2000; 119:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/57\">",
"      Zacharias A, Habib RH, Schwann TA, et al. Improved survival with radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to left anterior descending artery grafting. Circulation 2004; 109:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/58\">",
"      Weinschelbaum EE, Macchia A, Caramutti VM, et al. Myocardial revascularization with radial and mammary arteries: initial and mid-term results. Ann Thorac Surg 2000; 70:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/59\">",
"      Iac&ograve; AL, Teodori G, Di Giammarco G, et al. Radial artery for myocardial revascularization: long-term clinical and angiographic results. Ann Thorac Surg 2001; 72:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/60\">",
"      Khot UN, Friedman DT, Pettersson G, et al. Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation 2004; 109:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/61\">",
"      Maniar HS, Sundt TM, Barner HB, et al. Effect of target stenosis and location on radial artery graft patency. J Thorac Cardiovasc Surg 2002; 123:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/62\">",
"      Desai ND, Cohen EA, Naylor CD, et al. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 2004; 351:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/63\">",
"      Collins P, Webb CM, Chong CF, et al. Radial artery versus saphenous vein patency randomized trial: five-year angiographic follow-up. Circulation 2008; 117:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/64\">",
"      Goldman S, Sethi GK, Holman W, et al. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA 2011; 305:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/65\">",
"      Albertini A, Lochegnies A, El Khoury G, et al. Use of the right gastroepiploic artery as a coronary artery bypass graft in 307 patients. Cardiovasc Surg 1998; 6:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/66\">",
"      Ochi M, Bessho R, Saji Y, et al. Sequential grafting of the right gastroepiploic artery in coronary artery bypass surgery. Ann Thorac Surg 2001; 71:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/67\">",
"      Ruttmann E, Fischler N, Sakic A, et al. Second internal thoracic artery versus radial artery in coronary artery bypass grafting: a long-term, propensity score-matched follow-up study. Circulation 2011; 124:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/68\">",
"      Muneretto C, Negri A, Manfredi J, et al. Safety and usefulness of composite grafts for total arterial myocardial revascularization: a prospective randomized evaluation. J Thorac Cardiovasc Surg 2003; 125:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/69\">",
"      Sundt TM 3rd, Barner HB, Camillo CJ, Gay WA Jr. Total arterial revascularization with an internal thoracic artery and radial artery T graft. Ann Thorac Surg 1999; 68:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/70\">",
"      Muneretto C, Bisleri G, Negri A, et al. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. Circulation 2003; 108 Suppl 1:II29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/71\">",
"      Baskett RJ, Cafferty FH, Powell SJ, et al. Total arterial revascularization is safe: multicenter ten-year analysis of 71,470 coronary procedures. Ann Thorac Surg 2006; 81:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/72\">",
"      Kirklin JW, Naftel CD, Blackstone EH, Pohost GM. Summary of a consensus concerning death and ischemic events after coronary artery bypass grafting. Circulation 1989; 79:I81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/73\">",
"      Myers WO, Blackstone EH, Davis K, et al. CASS Registry long term surgical survival. Coronary Artery Surgery Study. J Am Coll Cardiol 1999; 33:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/74\">",
"      Shahian DM, O'Brien SM, Sheng S, et al. Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). Circulation 2012; 125:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/75\">",
"      Wu C, Camacho FT, Wechsler AS, et al. Risk score for predicting long-term mortality after coronary artery bypass graft surgery. Circulation 2012; 125:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/76\">",
"      Bell MR, Gersh BJ, Schaff HV, et al. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Circulation 1992; 86:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/77\">",
"      Jones EL, Weintraub WS. The importance of completeness of revascularization during long-term follow-up after coronary artery operations. J Thorac Cardiovasc Surg 1996; 112:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/78\">",
"      Scott R, Blackstone EH, McCarthy PM, et al. Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery: late consequences of incomplete revascularization. J Thorac Cardiovasc Surg 2000; 120:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/79\">",
"      Vander Salm TJ, Kip KE, Jones RH, et al. What constitutes optimal surgical revascularization? Answers from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2002; 39:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/80\">",
"      Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/81\">",
"      van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/82\">",
"      Kim YH, Park DW, Lee JY, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation 2011; 123:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/83\">",
"      Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol 2001; 38:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/84\">",
"      Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001; 104:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/85\">",
"      Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation 1997; 95:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/86\">",
"      Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009; 119:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/87\">",
"      Thakar CV, Worley S, Arrigain S, et al. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 2005; 67:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/88\">",
"      Ishani A, Nelson D, Clothier B, et al. The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med 2011; 171:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/89\">",
"      Hillis GS, Croal BL, Buchan KG, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006; 113:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/90\">",
"      Mehta RH, Hafley GE, Gibson CM, et al. Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2008; 136:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/91\">",
"      DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000; 85:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/92\">",
"      Sprecher DL, Pearce GL. How deadly is the \"deadly quartet\"? A post-CABG evaluation. J Am Coll Cardiol 2000; 36:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/93\">",
"      Weintraub WS, Clements SD Jr, Crisco LV, et al. Twenty-year survival after coronary artery surgery: an institutional perspective from Emory University. Circulation 2003; 107:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/94\">",
"      van Straten AH, Hamad MA, van Zundert AJ, et al. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population. Circulation 2009; 120:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/95\">",
"      Gao D, Grunwald GK, Rumsfeld JS, et al. Time-varying risk factors for long-term mortality after coronary artery bypass graft surgery. Ann Thorac Surg 2006; 81:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/96\">",
"      MacKenzie TA, Malenka DJ, Olmstead EM, et al. Prediction of survival after coronary revascularization: modeling short-term, mid-term, and long-term survival. Ann Thorac Surg 2009; 87:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/97\">",
"      Alderman EL, Kip KE, Whitlow PL, et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2004; 44:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/98\">",
"      Okrainec K, Platt R, Pilote L, Eisenberg MJ. Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 2005; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/99\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/101\">",
"      Goyal A, Alexander JH, Hafley GE, et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg 2007; 83:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/102\">",
"      Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/103\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/104\">",
"      Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:776S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/105\">",
"      Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/106\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/107\">",
"      Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/108\">",
"      Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 2008; 51:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/109\">",
"      The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/110\">",
"      Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 1999; 99:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/111\">",
"      Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/112\">",
"      Chen L, Th&eacute;roux P, Lesp&eacute;rance J, et al. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996; 28:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/113\">",
"      Huynh T, Th&eacute;roux P, Bogaty P, et al. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/114\">",
"      Kj&oslash;ller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000; 35:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/115\">",
"      Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001; 87:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/2/37930/abstract/116\">",
"      Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008; 117:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1554 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37930=[""].join("\n");
var outline_f37_2_37930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41023269\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF GRAFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Saphenous vein graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Early occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Intermediate phase occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Late occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4121335\">",
"      Endoscopic vein-graft harvesting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H157947738\">",
"      - Single versus multiple distal anastomoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15134962\">",
"      Internal mammary versus saphenous vein grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80757869\">",
"      - Patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80757599\">",
"      - Survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment of ITA graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LIMA plus another arterial graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bilateral ITA grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80756716\">",
"      - Free arterial grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H80756723\">",
"      Radial artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H80756750\">",
"      Gastroepiploic artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80757121\">",
"      - Right ITA versus radial artery as a second arterial graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Total arterial revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DETERMINANTS OF SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Survival rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Predictors of mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98316246\">",
"      - Arterial versus vein grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Incomplete revascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98316636\">",
"      - Perioperative MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1138528813\">",
"      - Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98316738\">",
"      - Cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Preoperative Hemoglobin level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5075872\">",
"      Long-term risk prediction models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECURRENT ANGINA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GENERAL MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Lipid lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41023269\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1554|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/28/24013\" title=\"figure 1\">",
"      IMA versus vein graft patency after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/46/21229\" title=\"figure 2\">",
"      Survival advantage of arterial coronary bypass grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/19/19774\" title=\"figure 3\">",
"      Control of lipids decreases the progression of SVG disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/39/22142\" title=\"figure 4\">",
"      Lipid lowering improves outcome after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/45/13021\" title=\"figure 5\">",
"      Ramipril post revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1554|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?11/2/11310\" title=\"movie 1\">",
"      Restenosis within a saphenous vein graft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/15/4349\" title=\"table 1\">",
"      Compare venous arterial grafts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=related_link\">",
"      Late recurrent angina pectoris after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25528?source=related_link\">",
"      Psychosocial factors in coronary and cerebral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_2_37931="Frequency of oral clefts in relatives by proband phenotype";
var content_f37_2_37931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of oral clefts in relatives based on the proband's phenotype",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Relative",
"      </td>",
"      <td class=\"subtitle1\">",
"       CL (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       CL/P (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       CP (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sibling",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       3.9",
"      </td>",
"      <td>",
"       3.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Half sibling",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parent",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       2.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Offspring",
"      </td>",
"      <td>",
"       3.5",
"      </td>",
"      <td>",
"       4.1",
"      </td>",
"      <td>",
"       4.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Niece/nephew",
"      </td>",
"      <td>",
"       0.9",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       1.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aunt/uncle",
"      </td>",
"      <td>",
"       0.6",
"      </td>",
"      <td>",
"       1.1",
"      </td>",
"      <td>",
"       0.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       First cousin",
"      </td>",
"      <td>",
"       0.3",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CL: cleft lip, CP: cleft palate, CL/P: cleft lip with or without cleft palate",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Grosen, D, Chavrier, C, Skytthe, A, et al. A cohort study of recurrence patterns among more than 54,000 relatives of oral cleft cases in Denmark: support for the multifactorial threshold model of inheritance. J Med Genet 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37931=[""].join("\n");
var outline_f37_2_37931=null;
var title_f37_2_37932="Comparison PD solutions";
var content_f37_2_37932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of different peritoneal dialysis solutions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Dextrose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Amino acid",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Icodextrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Low Ca++",
"       </td>",
"       <td class=\"subtitle2\">",
"        High Ca++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osmolality (mOsm/kg)",
"       </td>",
"       <td>",
"        346, 396 and 485",
"       </td>",
"       <td>",
"        346, 396 and 485",
"       </td>",
"       <td>",
"        365",
"       </td>",
"       <td>",
"        282",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular Weight (Dalton)",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        100-200",
"       </td>",
"       <td>",
"        20,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advantages",
"       </td>",
"       <td>",
"        <p>",
"         Well studied",
"        </p>",
"        <p>",
"         Most commonly used for a long time",
"        </p>",
"        <p>",
"         Side effect profile well known to most of the nephrologists",
"        </p>",
"        <p>",
"         Allow the use of oral calcium containing phosphate binders",
"        </p>",
"       </td>",
"       <td>",
"        Same as low calcium solutions except it may help bringing up serum calcium in patients with low calcium levels",
"       </td>",
"       <td>",
"        Can improve nutritional status in malnourished diabetic and/or patients with recurrent peritonitis",
"       </td>",
"       <td>",
"        <p>",
"         Sustained ultrafiltration for many hours",
"        </p>",
"        <p>",
"         Decreased solute absorption",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disadvantages",
"       </td>",
"       <td>",
"        <p>",
"         Short lived ultrafiltration",
"        </p>",
"        <p>",
"         Metabolic complications like hyperinsulinemia, hyperglycemia, hyperlipidemia, and weight gain",
"        </p>",
"        <p>",
"         Can lead to low serum calcium and bone disease",
"        </p>",
"       </td>",
"       <td>",
"        Same as low calcium except it can limit the use of calcium containing oral phosphate binders",
"       </td>",
"       <td>",
"        <p>",
"         Expensive",
"        </p>",
"        <p>",
"         May increase nitrogen waste product in blood",
"        </p>",
"        <p>",
"         May cause/worsen acidosis",
"        </p>",
"       </td>",
"       <td>",
"        Increases serum levels of maltose, maltotriose, and oligopolysacharides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indications",
"       </td>",
"       <td>",
"        <p>",
"         Commonly used, first line peritoneal dialysis solution in all patients unless special circumstances exist",
"        </p>",
"        <p>",
"         High serum phosphorus and normal to high serum calcium",
"        </p>",
"       </td>",
"       <td>",
"        Used in patients who have low calcium levels with low calcium containing dialysis solutions",
"       </td>",
"       <td>",
"        <p>",
"         Malnourished diabetic patients or",
"        </p>",
"        <p>",
"         Malnourished patients with recurrent peritonitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Patients who lose ultrafiltration",
"        </p>",
"        <p>",
"         In patients with automated PD situation during the dry day to achieve sustained UF and increased solute and fluid removal",
"        </p>",
"        <p>",
"         In diabetic patients",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dinesh Chatoth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37932=[""].join("\n");
var outline_f37_2_37932=null;
var title_f37_2_37933="Inflammatory markers in CKD";
var content_f37_2_37933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inflammatory markers that have been studied in CKD patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Marker (and commonly used abbreviation)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Evidence for outcome predictability in CKD*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Short pentraxins",
"      </td>",
"      <td>",
"       C-reactive protein (CRP)",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum amyloid P (SAP)",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Long pentraxins",
"      </td>",
"      <td>",
"       Pentraxin-3 (PTX3)",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuronal pentraxins",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"7\">",
"       Pro-inflammatory cytokines",
"      </td>",
"      <td>",
"       Interleukin-6 (IL-6)",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interleukin-1 beta (IL-1",
"       <sub>",
"        &beta;",
"       </sub>",
"       )",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tumor necrosis factor alpha (TNF-&alpha;)",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interleukin-8 (IL-8)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interleukin-18 (IL-18)",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interleukin-12 (IL-12)",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interferon gamma (IFN",
"       <sub>",
"        &Gamma;",
"       </sub>",
"       )",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"4\">",
"       Anti-inflammatory cytokines",
"      </td>",
"      <td>",
"       Interleukin-10 (IL-10)",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-1 receptor antagonist (IL-1ra)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interleukin-4 (IL-4)",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transforming growth factor beta (TGF-",
"       <sub>",
"        &beta;",
"       </sub>",
"       )",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"5\">",
"       Adipokines and related compounds",
"      </td>",
"      <td>",
"       Adiponectin",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Visfatin",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Resistin",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leptin",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD163",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       Adhesion molecules and endothelial markers",
"      </td>",
"      <td>",
"       Intercellular adhesion molecule-1 (ICAM-1)",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vascular cell adhesion molecule-1 (VCAM-1)",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       E-selectin",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"5\">",
"       Coagulation markers",
"      </td>",
"      <td>",
"       Fibrinogen",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tissue plasminogen activator (t-PA)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plasminogen activator inhibitor-1 [PAI-1])",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       von Willebrand factor (vWF) &amp; factor VII",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibrin D-dimer",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"4\">",
"       Inflammatory molecules with negative acute phase reaction",
"      </td>",
"      <td>",
"       Albumin (negative)",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transferrin or TIBC",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Iron",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fetuin",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Inflammatory lipoproteins",
"      </td>",
"      <td>",
"       HDL inflammatory index (HII)",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxidized LDL (oxLDL)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Inflammatory enzymes",
"      </td>",
"      <td>",
"       Myeloperoxidase (MPO)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Matrix metalloproteinase (MMP-9)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Pro-inflammatory transcription factors",
"      </td>",
"      <td>",
"       Activator protein-1 (AP-1)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nuclear factor-kappa B (NF-&kappa;B)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"7\">",
"       Other inflammatory markers",
"      </td>",
"      <td>",
"       Serum ferritin",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum amyloid A (SAA)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neopterin (monocyte/macrophage activator)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Platelet count",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       WBC count",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neutrophil count",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Erythrocyte sedimentation rate (ESR)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Evidence for CKD outcome predictability pertains to CKD progression or patient survival.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kalantar-Zadeh, K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2:872. Copyright &copy;2007 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37933=[""].join("\n");
var outline_f37_2_37933=null;
var title_f37_2_37934="Pill esophagitis II CPC Endosc";
var content_f37_2_37934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medication-induced esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy revealed superficial ulcerations with bleeding localized in the proximal esophagus at the level of the aortic arch. The mid and distal esophageal mucosa appeared normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37934=[""].join("\n");
var outline_f37_2_37934=null;
var title_f37_2_37935="Ischemic ulceration Endosc";
var content_f37_2_37935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ischemic airway ulceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopic images demonstrating ischemic ulceration of the vocal cords (left) and trachea (right) following endotracheal intubation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_2_37935=[""].join("\n");
var outline_f37_2_37935=null;
